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Preface 
This PhD Thesis deals with the synthesis of carbohydrates derivatives as analogues of 
natural compounds and their biological evaluation as tools for the study of biochemical 
regulatory pathways. 
Carbohydrates, together with proteins, nucleic acids and lipids, are the building blocks 
on which complex living systems are based. This spectacular class of compounds acts 
as energetic sources, signaling regulators and components of cell surface. So, they are 
involved in many biological processes essential for the living cells, as immune 
response, inflammation, cell growth, cell-cell adhesion and so forth. The possibility to 
develop biochemical tools based on carbohydrates structures could be used to explain 
their functional role in many of these mechanisms and how to intervene to conceive 
new drugs systems for the treatment of several pathologies like cancers and bacterial 
infections, generally due to altered carbohydrate-mediated interactions. 
The topic of this PhD thesis can be divided into two parts. The first one, composed by 
Chapter 1, 2 and 3, deals with the synthesis of glycosylglycerols ligands of Akt, a 
protein kinase overexpressed in many cancer cells, while the second part, resumed in 
Chapter 4, is oriented to the study of the opportunity to employ gold nanoparticles as 
alternative carriers for saccharide antigens in the vaccinology field. 
Chapter 1 is a general overview on protein kinase B, also known as Akt, which recently 
has attracted great attention because of its involvement in many crucial cellular 
process like proliferation, differentiation and apoptosis. Specifically, hyperactived Akt 
is responsible of tumor formation, progression and invasion. So, the research of an 
effective method to prevent its activation could be a way to locate novel anticancer 
drugs.  
Chapter 2 describes the advancements leaded by our research group in the 
investigation on new Akt inhibitors based on -glucosylglycerol. Starting from the 
synthetic analogues of a class of natural compounds, the 
sulfoquinovosyldiacylglycerols (SQDGs), which have showed good inhibiting properties 
with Akt, a novel category of potential Akt inhibitors has been developed. The 
synthesis of these novel compounds, related to the natural glucuronosyldiacylglycerols 
   
  
(GlcADGs), is described in this chapter. Furthermore, the evaluation of their inhibitory 
activity on the isolated enzyme (Akt) and on cell systems, performed in collaboration 
with the Università di Milano Bicocca and the Istituto dei tumori di Milano,  is also 
reported.  
In Chapter 3 the importance of fluorescent dye in biochemistry is reported. In 
particular, the most active compound reported in Chapter 2 has been functionalized 
with a fluorescent probe in order to study its cell distribution and shed some light on 
its action mechanism. In this chapter the novel straightforward synthetic methodology 
to obtain fluorescent derivatives functionalized on the glycerol moiety is illustrated, 
while their biological evaluation is underway. 
Chapter 4 reports the potential application of gold nanoparticles as carriers for 
saccharide antigens related to Streptococcus pneumoniae, work achieved thanks to the 
collaboration with Prof. Soledad Penadés and Dr. Marco Marradi. In this chapter, the 
carbohydrate's world and that of nanotechology combine together seeking to improve 
the development of fully synthetic carbohydrate vaccines. The trisaccharide repeating 
unit of Streptococcus pneumoniae serotype 19F, which I had previously synthesized in 
our laboratory, was properly functionalyzed during the six months spent in the 
Laboratory of GlycoNanotechnology of CIC biomaGUNE center (San Sebastián-Spain) as 
a Guest PhD student and conjugated to gold nanoparticles alone or together with the 
tetrasaccharide related to S. pneumoniae serotype 14 in order to develop 
multiantigenic systems. New different gold glyconanoparticles have been prepared and 
their immunological properties carried out by Dr. Dodi Safari at Eijkman Institute for 
Molecular Biology in Jakarta, are also reported in this chapter. 















Protein Kinase B (Akt) as potential antitumoral target  
Among the most important proteins of the whole human genome, protein kinases are 
one of the largest families of genes in eukaryotes.1 They are enzymes that catalyse the 
transfer of the terminal phosphate group from adenosine triphosphate ATP to protein 
substrates, specifically to the hydroxyl group of tyrosine (Tyr kinase) or the hydroxyl 
group of serine/threonine (Ser/Thr kinase). Since protein kinases represent key players 
in many crucial cellular processes like proliferation, differentiation and apoptosis ,2,3 
the discovery of molecule kinase inhibitors has attracted growing interest for novel 
drug research and development as well as the identification of experimental tools for 
the understanding of the biological roles of this class of protein.   
 
Figure 1.1: Structure of inactive PKB/Akt. Taken from Ref.4 
The serine/threonine protein kinase B (PKB), also known as Akt (Figure 1.1), has 
recently garnered a great deal of attention as a promising molecular target for cancer 
therapy due to its critical role as a regulator of the cell’s apoptotic machinery.5 Akt is a 
57-kDa soluble cytosolic protein with three structurally conserved domains namely an 
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N-terminal pleckstrin homology (PH) domain, a central kinase domain and a C-terminal 
regulatory domain, mainly consisting of hydrophobic aminoacids (HM).4 
In the human genome have been identified genes coding for three highly homologous 
PKB isoforms, PKB/Akt1, PKB/Akt2 and PKB/Akt3 (Figure 1.2). Despite of the high 
structural homology, the physiological functions of the three isoforms are not 
superimposed.6 In fact, PKB/Akt1, ubiquitously expressed, is involved in cell survival 
pathways and growth control, PKB/Akt2, which is highly expressed in muscle and 
adipocytes, has been shown to be relevant for glucose metabolism, whereas the role 
of PKB/Akt3, expressed predominantly in the brain, is unclear.  
 
Figure 1.2: Three different PKB/Akt isoforms. Taken from Ref.7  
 
1.1 Akt activation 
The protein kinase B plays a key role as a component of the phosphoinositide 3-kinase 
(PI3K)-Akt-mTOR axis in tumor cell survival. In fact, hyperactivation of Akt is a common 
feature of tumor cells that has been linked to increased survival, invasion and drug 
resistance, and rapidly it became evident that this pathway could be an effective 
target for antineoplastic therapies. It has been shown that Akt is activated in a 
phosphatidylinositol-3-kinase (PI3K)-dependent manner (Figure 1.3). Akt is normally 
maintained in an inactive state through an intramolecular interaction between the P H 
domain and and kinase domain. The stimulation of PI3K by growth factors and 
cytokines generates, by means of the phosphorylation of position 3 of the 
phosphatidylinositol 4,5 diphosphate [PtdIn(4,5)P2 or PIP2], the key second 
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phosphatidylinositol 3,4,5 triphosphate [PtdIn (3,4,5)P3 or PIP3] in the plasma 
membrane, able to bind the PH domain of inactive Akt.8 In consequence of the linkage 
between the phosphate in position 3 of the phosphoinositide and specific basic 
residues in the protein as salt bridges, a conformational change of protein kinase 
occurs, leading to the exposure of two phosphorylation sites that mediate activity.7 
 
Figure 1.3: Activation and regulation of Akt. The phosphorylation of phosphatidylinositol 4,5 diphosphate 
PIP2 leads to the  generation of phosphatidylinositol 3,4,5 triphosphate PIP3 able to bind the PH domain 
of an inactive Akt and to induce a conformational change resulting in the exposure of two 
phosphorylation sites. Their phosphorylation active the Akt which dissociates from the pl asma 
membrane and phosphorylates substrates in the cytoplasm and in the nucleus. 
Specifically, threonine 308 in the catalytic site is phosphorylated by phosphoinositide-
dependent kinase 1 (PDK-1) while serine 473 in the C-terminal hydrophobic motif is 
phosphorylated by an unidentified S473 kinase.9 In particular, the phosphorylation of 
the serine is considered a crucial step in the Akt activation because its stabilizes the 
kinase domain in an active conformation state.10 Once activated, Akt dissociates from 
the plasma membrane and can phosphorylate substrates in the cytoplasm and in the 
nucleus, as several signaling proteins. Another key regulator able to inhibit this 
activation cascade of the Akt is the phosphatase and tensin homologue PTEN, which 
possesses 3-phosphainositide phosphatase activity. It is the second most frequently 
mutated tumor suppressor gene, again underscoring the medical relevance of the Akt 
pathway. When the function of PTEN is attenuated, PIP3 levels increase and promote 
oncogenic process.11 
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1.2 Regulation of cellular processes by Akt 
Akt regulates many cellular processes including metabolism, proliferation, cell survival, 
growth and angiogenesis. For this reason, inappropriate activation of the PI3K/Akt 
pathway is cause of different human diseases. 
One of the key roles of Akt is the regulation of glucose uptake into muscle and fat cells 
by the translocation of insulin regulated GLUT-4 (glucose transporter-4) from 
intracellular compartments to the plasma membrane, thus explaining as the Akt 
deregulation is implicated in diabetes.  
It has been already largely proved the involvement of Akt in the cell-cycle regulation at 
different stage (Figure 1.4). Akt is able to promote G1/S transition through 
phosphorylation of several substrates, as inhibitors of cyclin-dependent kinase12,13 
(CDK) p21WAF1 and p27kip1. Also, Akt promotes progression from S to G2 phase by 
phosphorylation of CDK2 leading to its cytoplasmatic localization, necessary for cell-
cycle progression.14 Kandel reported that constitutively activated Akt overcomes a 
G2/M cell-cycle checkpoint induced by DNA damage causing a continuous cellular 
division in the presence of mutagens. This could explain the frequent upregulation and 
overactivation of Akt in human cancer.15 
Finally, Akt causes the cytoplasmatic accumulation of a dual-specific phosphatase, the 
cell division cell CDC25B, as a consequence of phosphorylative events, promoting 
mitotic entry.16 Moreover, Akt is demonstrated to mediate cell survival inhibiting 
apoptosis process by the phosphorylation of downstream mediators, such as Bad , an 
associated death protein, GSK-3 (Glycogen Synthase Kinase 3), pro-caspase9, IKB 
kinase (IKK), Yes-associated protein (YAP)17,18 and through the phosphorylation of 
different family members of forkhead transcription factors FOXO, which results in their 
exclusion from the nucleus and a lower transcriptional activity that is required to 
promote apoptosis. Increased Akt activity has been shown inducing cellular oncogenic 
transformation and tumor formation in breast, prostate, ovary and pancreas. 19 Akt 
hyperactivation is also considered a negative prognostic marker cancer20 because it is 
more frequently found in poorly differentiated tumors, that generally are more 
invasive. For instance, several groups have proved Akt hyperactivation in human 
primary thyroid cancers,21,22 which are generally employed for in vivo cellular studies.  
Also, the PI3K-Akt-mTor axis is strongly involved in many events that control  the tumor 
progression and invasion, as cell mobility, metastasis and cell adhesion properties. 23,24 
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The angiogenesis event, essential for tumor growth and metastasis,25 is promoted by 
Akt modulating the activity of several downstream targets as FOXO, NOS (nitric oxide 
synthase) and GSK-326 These factors increase the hypoxia-inducible factor 1 alpha 
(HIF-1) expression, an activator of the vascular endothelial growth factor (VEGF), 
demonstrating once again the involvement of Akt in tumor events. 
Finally, many evidences support the role of Akt in the mechanisms of resistance to 
therapies based on cytotoxic agents, hormones, biological agents and radiation, 
making tumor cells resistant to antitumor agent.27  
 
Figure 1.4: Akt and cell-cycle regulation with the main regulators involved. 
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1.3 Main inhibitor categories 
In the last years, the search of potential inhibitors of the Akt has gained great 
attention. Among the strategies to inhibit this enzyme, compounds able to bind the 
ATP site, allosteric inhibitors binding a site adjacent to the ATP pocket and inhibitors of 
PIP3 binding, have been developed over the years. 
1.3.1 ATP-competitive protein kinase inhibitors 
A potential class of Akt inhibitors is focused on the ATP-binding site. Small molecules 
included isoquinolone-5-sulfonamides,28 indazole,29 aminofurazan analogues30 and 
pyrazole31 have been reported as ATP-binding site inhibitors. However, the highly 
conserved ATP-binding domain in kinases, makes difficult their application due to low 
selectivity. For instance, compound GSK690693 1,32 a potent inhibitor of Akt1, 2 and 3 
developed by GlaxoSmithKline, is able to inhibit the growth of ovarian, breast and 
prostate tumors in mice, but it inhibits also other kinases. Also an indazole-pyridine 
based compound A-443654 2,33 identified by Abbott, is resulted active in blocking the 
growth of pancreatic and prostate tumors, but also in this case, without selectivity for 
Akt (Figure 1.5). 
 
Figure 1.5: ATP-competitive inhibitors 1, developed by GlaxoSmithKlin, and 2, identified by Abbott, both 
not having selectivity for Akt. 
1.3.2 Allosteric inhibitors 
An allosteric inhibitor is a compound which binds the enzyme, in a site called allosteric, 
inducing a conformational change and reducing its affinity for the natural ligand. Using 
this effect, different allosteric inhibitors for Akt have been proposed, among that the 
fungal metabolite wortmannin 334 and the flavonoid derivative LY294002 435 (Figure 
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1.6). Nevertheless, because of their toxicity and the low stability, together with the 
instability of 3 in water and the insolubility of 4, their potential pharmaceutical 
applications are limited. 
 
Figure 1.6: Allosteric inhibitors wortmannin 3 and flavonoid derivative LY294002 4. 
A deep study devoted to seek better allosteric inhibitors was carried out by Lindsley 
and co-worker36 which identified through a high throughput screening 2,3-
diphenylquinoxaline 5 (Figure 1.7) as lead compound able of inhibiting specifically Akt.  
Particularly, in assays with Akt mutants lacking the PH domain, this compound 
displayed no inhibition; moreover, Akt inhibition was not competitive with ATP, 
suggesting an allosteric binding site. Based on this lead compound, these authors have 
developed a library of allosteric inhibitors by introducing structural chemical 
modification addressed to delete gem-dimethyl function and to replace the primary 
amine with several functionalized amines. Introducing these structural modifications, 
compound 6, 10-fold more potent than 5, was synthesized, even if it results poor 
soluble and lacking of cell activity. Proceeding toward the study of these lead 
compounds, these same authors have discovered a novel series of potent allosteric Akt 
kinase inhibitors based on a 2,3,5-trisubstituted pyridine core 7 with improved 
aqueous solubility, cell permeability and reduced molecular weight relative to the 
previously reported inhibitors37 and, at a later stage, their further optimization to give 
8a,b.38 
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Figure 1.7: Allosteric inhibitors developed by Lindsley and co-workers. 
Another 2,3-diphenylquinoxaline derivative, the MK-2206 9,39 which inhibits the 
growth of several tumors, has been reported by Merck & Co. (Figure 1.8). This 
compound has recently entered a Phase I clinical trial in patients with solid tumors 
where it results tolerated. However, further developments of this promising 
compound are on hold. Thanks to their good selectivity for Akt, allosteric inhibitors 
have progressed quickly into clinical development.  
 
Figure 1.8: Compound MK-2206 9 developed by Merc & Co. in phase I clinical trials. 
1.3.3 Inhibitors of PIP3 binding 
An alternative to look for selective Akt inhibitor is targeting the pleckstrin homology 
PH domain. It is present in a relatively small number of kinases,40 as phospholipase C- 
(PLC), Bruton’s tyrosine kinase (BTK) and Akt. In particular, PH domain is answerable 
to bind phospholipids derivatives, playing a key role in the regulation of several 
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intracellular signalling, i.e. cell-cycle regulation, apoptosis and tumor progression in 
the case of Akt. Specifically, blocking the interaction between Akt PH domain and its 
natural phosphatidylinositol ligands, it is possible to interfere with the conformational 
change of the Akt preventing the exposure of the phosphorylation sites that mediate 
the activity. In this way, the kinase remains in the inactive state unable to 
phosphorylates signalling proteins in the cytoplasm and in the nucleus . This 
mechanism of inhibition can represent a promising approach in cancer drug discovery.  
So, new inhibitors targeting the PH domain have been designed and proposed as 
analogues of natural phosphatidylinositols. The structure of the phosphatidylinositol 
3,4,5 triphosphate PIP3 10, (Figure 1.9), is composed by an inositol ring with the 
phosphate group in position 3, accountable for the salt bridge with an arginine residue 
of the PH domain, and a 1,2-diacyl diacyl glycerol moiety with long lipophilic chains, 
necessary for the anchorage to the plasma membrane,40 linked to the position 1 
through a phosphate ester bridge. 
 
Figure 1.9: Chemical formula of phosphatidylinositol 3,4,5 triphosphate PIP3 10, natural ligand of Akt PH 
domain, with palmitate (C16:0) on the sn-1 position and arachinoid acid (C20:4) on the sn-2 position of 
the glycerol moiety. 
In order to obtain synthetic analogues of the natural PIP 3, different chemical structural 
modification have been taken into account.41 To overcome drawbacks of stability, the 
labile phosphate ester linkage between the inositol ring and the diacylglycerol moiety 
has been substituted by carbonates or ether linkage instead of ester in the glycerol 
function was introduced and, finally, the same inositol ring has been replaced by 
similar scaffold. These new classes of inhibitors targeting the PH domain as analogues 
of natural phosphatidylinositols include phosphoinositide analogues, 
alkylphospholipids and inositol phosphates. 
The first example of the use of phosphatidylinositol analogue as possible inhibitors 
was reported by Kozikowski.42,43 The D-3-deoxy-phosphatidyl-myo-inositol 11 (DPI, 
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Figure 1.10) showed inhibition of Akt in vitro at low concentration, but resulted only a 
weak inhibitor in vivo in the different cellular system tested. The low inhibition of 11 
could be explain by the hydrolysis of the ester lipids in the glycerol moiety by means of 
phospholipases. Hence the idea of introducing the more metabolically stable ether 
lipid chains. Also this new class of analogues, the D-3-deoxy-phosphatidyl-myo-inositol 
ether lipid 12 (DPIEL, Figure 1.10) was found to inhibit the Akt.44 Nevertheless, its 
clinical use was severely limited because of its acid lability if orally administered, while 
the intravenously administration causes the induction of a massive hemolysis. Another 
structural modification focused to increase the stability of PIP3 analogues, consists in 
the replacement of the phosphate bridge with a carbonate45 (DCIEL, Figure 1.10). 
However, compound 13 does not result a good inhibitor of Akt/PI3K pathway in all 
cells lines tested. Molecular modeling and docking of these three classes, showed that 
DPIEL binds much more strongly to the Akt PH domain than DPI and DCIEL. Despite 
this, the inhibitory activity in vivo is hindered by physiological presence of natural 
substrates myo-inositol. Therefore, their toxicity and lower solubility have limited their 
development as potential drug candidates.  
 
Figure 1.10: Phosphatidylinositol analogues. 
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Another class of compounds deeply studied are the inositolphosphate-based inhibitors 
(Figure 1.11). Besides their well-known role of second messengers, variously 
phosphorylated inositols 14a, 14b and 14c, have attracted great attention as 
therapeutic molecules.  
 
Figure 1.11: Inositolphosphate inhibitors. 
Falasca46,47 have proposed a competitive mechanism for these compounds against the 
natural ligand PIP3 in the binding PH domain, probably preventing the translocation of 
Akt to the plasma membrane. Different inositol polyphosphates were evaluated and 
compound 1,3,4,5,6-pentakisposphate 14b [Ins(1,3,4,5,6)P5] resulted able to inhibit 
Akt activation in vivo at very low concentration. 
In particular, compound 14b promotes also apoptosis in human lung, ovarian and 
breast cancers characterized by an high Akt activity. 
An innovative category of potential Akt kinase inhibitors are the more recent glucose-
based inositol analogues48 (Figure 1.12). In derivatives 15, the inositol ring of the 
natural PIP3 has been substituted by a glucose scaffold, in which the pyranosidic 
oxygen replaces the hydroxyl group in position 2 of the inositol, while the diacyl 
glycerol moiety is replaced by a more stable phosphoramidate group -linked to the 
anomeric position of the sugar and carrying two acyl chains. Moreover, instead of the 
phosphate group in position 3 of the inositol ring, corresponding to the position 6 of 
the glucose, a carboxyl group was inserted in derivatives 16. The long acyl chains have 
been also substituted by shorter ones, assuming that the long lipophilic chains are not 
needed for biological activity, but only for the anchorage to the membrane. 40 
 Chapter 1 
21 
 
Figure 1.12: Glucose-based inositol analogues as inhibitors of Akt. 
The inhibition power of these compounds against Akt activation, employing an in vitro 
Kinase Assay Kit, was evaluated. The results show that compounds 16 are more active 
than 15, underlining the importance of a negative charge. 
Research studies regarding these different classes of potential inhibitors developed 
over the years laid the foundation and, at the same time, paved the way towards the 
search for new classes of compounds to the aim of improving the knowledge about 





Synthetic analogues of natural compounds as 
potential inhibitors targeting Akt for anticancer drugs 
2.1 Introduction 
The many biological processes in which Akt is involved, above all cell -cycle regulation 
and the various aspects of tumor cells like proliferation and differentiation, as well as 
the lacking of an adequate class of inhibitors already discussed in Chapter 1, make still 
now this protein kinase subject matter of research in order to find novel alternative 
inhibitors and promote the discovery of new anticancer drugs. In particular, 
compounds that interfere with the activation of Akt by preventing the binding of PH 
domain with the natural ligand phosphatidylinositol triphosphate PIP3 could be 
desirable because of their potential higher selectivity. 
Nature is often largely exploited as source of compounds characterized by potential 
therapeutic properties. For instance, the sulfoquinovosylacylglycerols 17 (SQDG) in 
which sulfoquinovose (6-deoxy-6-sulfoglucose), with a negative charge in position 6 of 
the sugar, is -linked to the sn-3 position of an acylglycerol49 are a class of natural 
glycoconjugates evaluated as promising compounds in different therapeutic areas 
including anti-cancer therapy. This class of compounds shows structural features 
common to PIP3 10, the natural ligand of the PH domain highlighted in Figure 2.1, such 
as the glycerol motif bearing long acyl chains and a negative head.  
Our research group headed by Professor Fiamma Ronchetti has developed over the 
years a synthetic procedure aimed to synthesize sulfoquinovosyldiacylglycerols 
analogues 18a-c and the corresponding monoacylglycerol derivatives 19a-c showed in 
Figure 2.2, based on the same 2-O--D-glucosylglycerol scaffold. 
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Figure 2.1: Natural sulfoquinovosylacylglycerols SQDG 17 and common features with the natural PIP3 10, 
natural ligand of Akt. 
These compounds were synthesized and tested as anti-tumor promoters in cancer 
prevention studies.50 As the natural SQDG, they possess the key features needed for 
interaction with the PH domain, as an acyl glycerol portion and a negative head. These 
likeness prompted us to evaluate the Akt inhibitory activity of our sulfolipids 18a-c and 
19a-c together with others simplified compounds which were also synthesized. These 
last ones were the sulfoquinovosyl-2-O--D-glycerol 20 which do not bear acyl chains 
on the glycerol moiety, the glucoglycerolipid 2150 lacking the characteristic sulfonate 
group to evaluate the influence of the negative charge, the methyl and octyl--D-
sulfoquinovosides 22 and 23, in which the glycerol moiety is replaced by a lipophilic 
chain directly linked to the anomeric position and, finally, compound 24 where the 
anionic carboxyl group is replaced by the cationic amino group. 
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Figure 2.2: Sulfoquinovosyldiacylglycerols 18a-c, the corresponding monoacylglycerol derivatives 19a-c 
and simplified analogues 20-24. 
First of all, the synthesized compounds 18-24 were assayed in vitro using a cell-free 
assay, at fixed concentration of 100 M, employing a commercial Kinase Assay Kit. 
The results of ELISA test, represented in Figure 2.3, show that compounds 18a with 
sulfonate group and diacylglycerol with long chains, the corresponding 
monoacylglycerol 19a and octyl sulfoquinovopyranoside 23 are the most active Akt 
inhibitors, which show as common features the longest alkyl chain and the anionic 
group in position 6 of the glucose scaffold.  On the other hand, compound 20 missing of 
the acyl chains on the glycerol and the amino derivate 24, with a positive charge, are 
the less active ones as further proof of the need of lipophilic moiety, which mimics the 
diacylglycerol group of PIP3, and of a negative charge for the interaction with basic 
residues in the PH domain since a positive charge is not accepted by the enzymatic 
pocket for the presence of a repulsive cationic residues. Moreover, the length of the 
alkyl chain influences the potency of the sulfonate derivates, indeed compounds with 
longer chains show higher activity, while the number of acyl chains seems to be not 
important (series 18 vs 19).  
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The Akt1/2 kinase allosteric inhibitor (1,3-Dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g] 
quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one trifluoroacetate 
salt hydrate, indicated as A6730 from Sigma), included in ELISA studies as reference 
compound, showed 75% inhibition of Akt, demonstrating the strength of the test.   
 
Figure 2.3: Inhibitory activity of compounds 18-24 against Akt. Akt activity was assayed through a 
specific ELISA test. Compounds were added at a concentration of 100µM and the data represent the 
mean of three independent experiments.  
The most active in vitro compounds, with the exception of 18a, which resulted 
insoluble in DMSO, together with compound 24 as negative control have been tested 
for their antiproliferative activity on three papillary thyroid carcinomas PTC cell lines 
characterized by constitutive activation of Akt pathway functionally related to 
RET/PTC-1 rearrangement (TPC-1 cells), to PI3KCA gene E542K mutation (K1 cells) and 
to decreased expression of the dual-specificity phosphatase PTEN (Nim-1 cells). 
Despite a comparable inhibitory efficacy of compounds 19a and 23 in the Akt kinase 
assays only 19a exhibited a biological effect being favored in the cel lular tests (Figure 
2.4a).  
Next, the efficacy of the sulfoglycolipids compounds was assessed on the ovarian 
carcinoma cell line. To facilitate drug uptake and interaction with the target, cells were 
treated in the absence of serum. In this model, compound 19a effectively reduced cell 
growth in a concentration-dependent manner, whereas compound 24 slightly affected 
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cell proliferation and compound 23 was substantially inactive up to 50 µM (Figure 2.4). 
Again, despite a comparable inhibitory efficacy of compounds 19a and 23 in the ELISA 
Akt kinase assay (Figure 2.3) only 19a exhibited a biological effect being favored in the 
cellular tests.  
 
Figure 2.4: (A) Effect of selected sulfoglycolipids on papillary thyroid carcinoma and (B) ovarian 
carcinoma cell proliferation. Cells were exposed to vehicle or to different concentrations of the indicated 
compounds in complete medium for 72h (A) or for 24h (B). Cells were counted by a Coulter counter 72h 
after the beginning of the treatment. Mean dose-curves from data obtained in two independent 
experiments are reported. * p<0.05; ** p<0.001; ***p<0.0001 versus vehicle-treated cells. (C) Inhibition 
of GSK-3α and -3β phosphorylation in IGROV-1 cells exposed to compound 19a and to known inhibitor 
(A6730) as reference compound. Cells were exposed to vehicle (-) or the indicated drug concentrations 
for 24h. Whole cell lysates were analyzed by Western blotting. 
These preliminary results achieved with the synthetic analogues of SQDG prompted us 
towards the search of other potential inhibitors of Akt based on carbohydrate 
structure bearing a glycerol moiety properly functionalized and a different negative 
charge. 
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2.2 Aim of the work 
Following our ongoing interest in the search of potential inhibitors binding the Akt PH 
domain and basing on the results previously obtained with the synthetic analogues of 
SQDG, we planned to prepare a new class of potential inhibitors, replacing the 
solfonate group in position 6 of the glucose scaffold with a different negative charge , 
selecting the carboxylate group. This choice was motivated by a precedent 
investigation reported by Cipolla48 in which synthethic compounds based on the 
glucose-scaffold and characterized by the presence of a carboxyl group in position 6 of 
the sugar, were evaluated as Akt inhibitors. The substitution of the solfonate group in 
our synthetic SQDG with the carboxylate group led to the generation of new 
compounds that could be referred to another class on natural compounds, the  
glucuronosyldiacylglycerols 25 (GlcADG, Figure 2.5). 
 
Figure 2.5: Natural sulfoquivonosyldiacylglycerol 17 (SQDG) and the corresponding natural 
glucuronosyldiacylglycerol 25 (GlcADG). 
Natural GlcADGs have been found in bacteria,51 fungi,52 algae53 and in some higher 
plants such as rice.54 They share with the SQDG some biosynthetic pathways in 
chloropasts. Indeed, in condition of phosphate deprivation, SQDG and GlcADG, 
produced by the same synthase (Figure 2.6), replace the phospholipids in the 
membrane lipid remodelling promoting the remobilization of the phosphorus. 55,56,57 
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Figure 2.6: The biosynthesis of SQDG in chloroplast involves three different enzymes, the  UGP-3, the 
SQD1 and the SQD2. The last one is also responsible of GlcADG in case of P-deficient conditions. Taken 
from Ref.54  
Due to the strict structural resemblance of SQDG, GlcADG and PIP3, the natural 
activator of Akt, and relying to the results previously achieved for our synthetic 
sulfolipids, part of my PhD project was devoted to the preparation of a small library of 
synthetic analogues of GlcADG to test for Akt inhibition. Specifically, 2-O--D-
glucuronosyldiacylglycerols 26a and b and the corresponding monoacyl 27a and b in 
which the glucose is -linked to the position 2 of the glycerol, as well as glucuronides 
28a,b as simplified anionic models, showed in Figure 2.7, have been synthesized. 
The common scaffold for all of them remain a D-glucose -linked to an acylglycerol 
with acyl chains of different length or directly connected to a lipophilic chain. The 
choice of the length of the chains was based on the results previously discussed that 
showed an higher activity for the longest chains.  
All the compounds obtained (Figure 2.7) have been evaluated for their inhibitory 
activity on Akt, both in an isolated enzyme system and in an ovarian carcinoma cell 
line. 
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Figure 2.7: Structures of the GlcADGs analogues synthesized. 
2.3 Results and discussion  
2.3.1 Synthesis of diesters 26a,b 
Compounds 26a,b were prepared starting from the known 2-O-(2’,3’,4’,6’-tetra-O-
acetyl--D-glucopyranosyl)-sn-glycerol 29, synthesized following a reported procedure 
developed by our research group58 using glucose pentaacetate and 1,3-
dibenzylglycerol, both commercially available. The following synthetic scheme was 
based on that already used for the synthesis of  the sulfoquivonosil analogues 18a-c50 
with the exception of the last oxidation step necessary to obtain the final compounds 
26a,b. Thus, the acetates on the sugar of compound 30 were removed with a Zemplén 
reaction and replaced with monochloroacetates as temporary protective groups by 
chloroacetic anhydride treatment in a dichloromethane/pyridine mixture at 0°C. The 
glycerol benzyl groups of compound 31 were removed by hydrogenolysis on 10% Pd/C 
in methanol to yield 32 that was functionalized on the free hydroxyl groups with the 
appropriate acid chloride achieving 33a or b. The known 1,3-di-O-octadecanoyl-2-O--
D-glucopyranosyl-sn-glycerol 34a50 and the corresponding didecanoyl 34b were 
obtained via hydrazinolysis by means of hydrazine acetate treatment in a mixture of 
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methanol and ethyl acetate 1:1 at room temperature. A final oxidation step to obtain 
compounds 26a,b was carried out by means of 2,2,6,6,-tetramethyl-1-piperidinyl-oxy 
(TEMPO), a selective oxidant of primary alcohols, in the presence of NaClO 15% and 
NaClO2 20% aq solutions. A biphasic acetonitrile/sodium phospate buffer pH 6.7 
system was used and after stirring overnight at room temperature a water solution 0.5 
M of sodium thiosulfate Na2S2O3 and a few drops of acid chloride concentrated to set 
pH to 2 were added. Finally, the extraction with diethyl ether allows to achieve the 
products as acid (Scheme 2.1). 
 
Scheme 2.1: a) CH3ONa, CH3OH, rt, 90%; b) Chloroacetic Anhydride, Py dry, CH2Cl2 dry, 0°C, 93%; c) H2 
Pd/C (10%), CH3OH, 80%; d) Specific acid chloride, CH2Cl2/Py, -10°C, 60-70%; e) Hydrazine Acetate, 
AcOEt/CH3OH, rt, 42-43%; f) TEMPO, NaClO/NaClO2, CH3CN, 0.67M phosphate buffer (pH 6.7), rt, 43-
80%. 
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2.3.2 Attempt to reduce the synthetic steps to synthesize compounds 26a,b  
In order to reduce the synthetic steps to obtain compound 26a or b, we have sketched 
the different synthetic scheme showed below (Scheme 2.2). 
In this new strategy we performed the hydrogenolysis on the known 29 to give the 
tetraacetate 35 which was subsequently acylated the free hydroxyl groups of glycerol 
by acid chloride treatment achieving 36a or b. At this point, following a recently 
reported procedure,59 we used hydrazine hydrate in aqueous ethanol 85% at 45 °C to 
selectively remove the acetate groups from the sugar to obtain compound 34. 
 
Scheme 2.2: a) H2, Pd/C (10%), CH3OH, rt, 90%; b) Specific acid chloride, CH2Cl2/Py, -10°C, 35-40%; c) 
Hydrazine hydrate, EtOH aq. 85%, 45°C, 40%; d) TEMPO, NaClO/NaClO2, CH3CN, 0.67M phosphate buffer 
(pH 6.7), rt, 40-80%. 
However, this reaction suffered from low reproducibility in our hands showing 
unexpected drawbacks. Very important seemed to be the reaction temperature. 
Working at room temperature, a white precipitate, probably due at the poor solubility 
of starting material, encumbered the advancement of the reaction, while at 30-35°C 
the reaction solution was clear, but checking through TLC none progress of reaction 
was evident. Also protracting the reaction time the result did not improve. On the 
other hand, raising the temperature at 55-60°C an high amount of by-products was 
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obtained in a short time. So, the best value of temperature of 45°C, adequate to take 
in solution the starting material and the reactive, was finally used to obtain 
compounds 34a and b. Also, purification procedure was difficult. The removal of the 
solvent under vacuum in the presence of the unreacted hydrazine reactive due to high 
equivalents of reactive initially used (10 eq.) hampered the progress of the reaction 
causing the increase of the amount of by-products. To solve this drawback, the amount 
of reactive was reduced to 5 eq. and after 6h of magnetic stirring, the solvent was 
evaporated under stream of nitrogen. The crude thus recovered was subsequently 
purified by repeated flash chromatography with dichloromethane and methanol 9/1, 
giving as best result the 40% of yield. 
Overcame this setback, the next step was based on the selective oxidation of the 
glucose primary hydroxyl group with TEMPO given 26a,b with quantitative yield.  
In conclusion, the reaction steps have been reduced to four against the seven steps 
required with the precedent strategy, but the inconvenients encountered in this new 
scheme have lengthened the time to achieve the same final product with an overall 
comparable yield.  
2.3.3 Synthesis of monoesters 27a,b  
In an attempt to prepare the monoesters derivatives 27a and b through a 
chemoenzymatic approach and avoiding the use of hydrazine because of low 
reproducibility, the fully protected compound 29 was converted with a classical 
Zemplén transesterification in the deacetylated 37, which was efficiently oxidized by 
treatment with TEMPO in acetonitrile and buffer phosphate to yield compound 38. The 
following hydrogenolysis provided compound 39 which could be selectively acylated at 
the sn-1 position of glycerol58 by Pesudomonas cepacia lipase (LPS) catalized 
transesterification reaction in organic solvent, yielding in just four steps the desired 
products 27a and b (Scheme 2.3). 
However, when transesterification was carried out in the usual conditions, i.e. LPS in 
pyridine at 40°C employing 2,2,2-trifluoroethyl (TFE) esters as acyl carriers, the check 
of reaction progress by TLC showed a spot attributable to the product, but it was 
completely degradated after the work up.  
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Scheme 2.3: a) CH3ONa, CH3OH, rt, 90%; b) TEMPO, NaClO/NaClO2, CH3CN, 0.67M phosphate buffer (pH 
6.7), rt, 90%; c) H2 Pd/C (10%), CH3OH, rt, 80%; d) Pseudomonas cepacia lipase (Amano PS), Py, TFE-
octadecanoate or -decanoate, 45°C. 
The inability to recover the product through this via compelled us to change strategy 
planning a different synthetic procedure (Scheme 2.4). 
So, transesterification by means of LPS was performed on compound 35 and in this 
case the products 40a or b were easily recovered by filtration on pad of celite, as 
already reported.60 To protect the remaining primary free hydroxyl group of the 
glycerol moiety, from the following oxidation step, a conventional tritylation was 
performed using trityl chloride in pyridine at 100 °C. The obtained fully protected 
glucosylglycerols 41a,b were converted into the deacetylated compound 42a,b by 
hydrazine hydrate treatment in aqueous ethanol at 45°C for the selective removal of 
the sugar acetyls59 using 10 eq. of hydrazine hydrate. Following TEMPO oxidation 
afforded the compound 43 while the removing of the trityl by giving the final 
compounds 27a,b was carried out in dichloromethane exploiting the acidic resin 
MARATHON C, previously activated, which assured also the presence of the acid 
function in position 6 of the sugar. 
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Scheme 2.4: a) Pseudomonas cepacia lipase (Amano PS), Py, TFE-octadecanoate or -decanoate, 45°C, 74-
82%; b) CPh3Cl, Py, 100°C, 96-70%; c) Hydrazine hydrate, EtOH aq., 45°C, 45-56%; d) TEMPO, 
NaClO/NaClO2, CH3CN, 0.67M phosphate buffer (pH 6.7), rt, 97-98%; e) DOWEX H+, CH2Cl2, rt, 76-81%.  
Furthermore, to be sure about the formation of the correct stereoisomer, the 
derivative 40a obtained from the enzymatic trasfesterification, was transformed into 
the 3-O-acetylderivative 44 by acetic anhydride/pyridine treatment (Scheme 2.5). The 
1H NMR spectrum of the obtained compound 44 resulted identical to that of the 
known 1-O-octadecanoyl-3-O-acetyl-2-O-(2’,3’,4’,6’-tetra-O-acetyl--D-
glucopyranosyl)-sn-glycerol,58 confirming the 2S configuration of compound 40a.  
 
Scheme 2.5: acetylation of compound 40a, by means of acetic anhydride in pyridine gives the known 
compound 44. 
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As the enzymatic transesterifications employed to obtain the monoesters 40a and 40b 
differed just in the acyl carrier used, only the configuration of compound 40a was 
assigned, assuming the same 2S configuration also for compound 40b. 
2.3.4 Synthesis of glucuronides 28a,b 
To synthesize the simplified glucuronides 28a, commercial glucose pentaacetate 45 
was used as starting material. The alkyl chain was introduced in Fisher conditions, 
using the corresponding alcohol 46 and boron trifluoride diethyl etherate BF3·Et2O as 
Lewis acid. The known decyl -D-glucopyranoside 4761 was deacetylated with a 
classical Zemplén reaction and the free primary hydroxyl group of 48a was converted 
in the carboxyl group of the product 28a62 in good yields by regioselective TEMPO 
oxidation (Scheme 2.6). 
 
Scheme 2.6: a) BF3·Et2O, rt, 36%; b) CH3ONa/CH3OH, rt, 94%; c) TEMPO, NaClO/NaClO2, CH3CN, 0.67M 
phosphate buffer (pH 6.7), rt, 53%. 
Instead, the final compound 28b was easily obtained in a single step by TEMPO 
oxidation of the commercial octyl -D-glucopyranoside 48b (Scheme 2.7). 
 
Scheme 2.7: a) TEMPO, NaClO/NaClO2, CH3CN, 0.67M phosphate buffer (pH 6.7), rt, 62%. 
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2.4 Cell free evaluation of Akt inhibition 
Thanks to a collaboration with Dr. Barbara Costa of the University of Milano-Bicocca, 
the synthesized compounds, with the exception of compound 26a that was not soluble 
in DMSO, were tested for their inhibitory activity against Akt (Akt1), using an in vitro 
ELISA kinase assay. 
As shown in Figure 2.8, the effect of compounds 26b, 27a-b and 28a-b tested at five 
different concentrations (1, 10, 50, 100 and 500 µM) were compared to the 
alkylphospholipids (ALPs) miltefosine, a general inhibitor of the PI3K/Akt pathway, the 
perifosine, that is an Akt inhibitor targeting the PH domain,63 and the surfactant 
sodium dodecyl sulfate (SDS). The results show that the Akt1 activity is poorly 
influenced by compound 28b, while the other compounds showed a concentration-
dependent inhibitory effect, 27a and 26b being the most potent inhibitors of Akt1 
activity (IC50 19.71 µM and 30.75 µM respectively, Table 2.1).  
 
Table 2.1: Compound concentration producing 50% inhibition of PKB1 activity. 
Compounds 27b and 28a elicited a concentration-dependent inhibition of Akt1, 
however they displayed only slight efficacy, even at the maximum concentration: 24% 
and 39%, respectively. The IC50 values (Table 2.1) and the maximal efficacy indicated 
that the effect is higher for long than for short acyl chains (27a vs 27b and 28a vs 28b, 
Table 2.1) and for the presence of a second acyl chain (27b vs 26b, Table 2.1), in 
agreement with other data already reported.64 The data obtained (Table 2.1 and Figure 
2.8) for Miltefosine as well as SDS did not exhibit any significant inhibition of Akt in the 
ELISA test, but only a very weak inhibition was observed at very high concentrations, 
i.e. 500 µM. On the contrary, Perifosine displayed a significant inhibition with an IC 50 
Compound IC50 (M) 95% Confidence Intervals 
Compound 27a 19.71 13.85-28.04 
Compound 27b >100  
Compound 26b 30.75 22.91-41.26 
Compound 28a >100  
Compound 28b >100  
Miltefosine >100  
Perifosine 43.35 22.65-83.17 
SDS >100  
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value of about 40 µM, thus suggesting a specificity for the effect induced by 
glucuronides 27a and 26b and a potency that is comparable with that of Perifosine. 
 
Figure 2.8: In vitro Akt1 Kinase Assay (ELISA) of compounds 26b, 27a-b and 28a-b, Miltefosine, Perifosine 
and SDS at the indicated concentrations. Concentration-response (%inhibition) analysis. 
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2.5 Cellular studies 
The same compounds assayed for Akt inhibition were also tested in cellular system by 
Dr. Paola Perego of the Isituto dei Tumori-Milano. Specifically, the antiproliferative 
activity was examined in the IGROV-1 ovarian carcinoma cell line which is 
characterized by heterozygous mutation (Hetc.955_958delACTT) of the dual -specificity 
phosphatase PTEN, a negative regulator of Akt. A 72 h exposure to the compounds  
resulted in a concentration-dependent inhibition of IGROV-1 cell growth for three of 
the novel glucuronides, i.e. 26b and 27a-b (Figure 2.9). The inhibitory effect was 
evident for compound 26b and 27a with IC50 values (±SD) of 156.7±23.0 and 49.0±7.6 
(SD) μM, respectively (Table 2.2). The 28a and 28b compounds induced a slight 
inhibition of IGROV-1 cell growth after 72 h exposure only when a concentration of  
300 μM was used. A modest inhibition of proliferation was also  observed when cells 
were exposed to the 27b compound, the IC50 value being around 300 μM.  
Since the 28a and 28b compounds do not contain glycerol in their structure, the 
present data suggest that the presence of glycerol might facilitate growth inhibition 
(27b vs 28a). Moreover, long chains seem to enhance the activity because the 27a 
compound carries a longer chain than 27b.  
 
Figure 2.9: Cell sensitivity of human ovarian carcinoma cells (IGROV-1) as evaluated by growth inhibition 
assays. Cells were seeded and 24 h later they were exposed to the novel compounds for 72 h. At the end 
of incubation with the compounds, cells were counted with a cell counter. Results from a repr esentative 
experiment are shown. 
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Further effort is required to optimize the growth inhibition properties of this class of 
compounds. Indeed, an analysis of inhibition of cell growth in cells exposed to 24 h to 
the studied compounds in serum-free medium indicated an increased potency for the 
two active compounds. Under these conditions, the IC50 values (±SD) of compound 27a 
and 26b were 3.35±0.35 and 9.40±5.0 μM, respectively (Table 2.2). This evidence 
raises the possibility that binding of the compounds to serum components can reduce 
their cellular uptake. 
 
Table 2.2: Inhibition effect of compounds 27a and 26b towards IGROV-1 ovarian carcinoma cells in the 
presence of serum or in serum-free medium. When cells were exposed to 24 h to the tested compounds 
in serum-free medium an increased potency was showed. 
To confirm the influence of serum presence in medium on cellular sensitivity to Akt 
inhibitors, we also tested the sensitivity of IGROV-1 cells to Perifosine in the presence 
or absence of serum in the medium (Table 2.3). Under our experimental conditions, we 
found that the growth inhibitory effect of the compound was favored in serum-free 
medium, thus implying that serum affects the stability of Perifosine. However, whereas 
for Perifosine a 2.8 fold increase in the anti-proliferative activity was observed upon 
incubation in serum-free medium, the fold-change for the novel compounds was 
higher, implying that they might be less stable or less prone to accumulate in the cells 
than Perifosine in the presence of serum.  
 
Table 2.3: Sensitivity of IGROV-1 ovarian carcinoma cells to perifosine in the presence of serum or in 
serum-free medium. a Cell sensitivity was assessed by growth inhibition assays in which cells were 
exposed to perifosine for 72 h in serum (FBS)-containing medium or for 24 h in serum-free medium. Cells 
were counted 72 h after treatment start. IC50 represents the perifosine concentration producing 50% 
inhibition of cell growth. The reported values are the mean ± standard deviation of 3 independent 
experiments. 
Compound IC50 (M)±SD 
Compound 26b with serum medium 156.7±23.0 
Compound 26b serum free medium 9.40±5.0 
Compound 27a with serum medium 49.0±7.6 
Compound 27a serum free medium 3.35±0.35 
FBS IC50 (M)±SD 
+ 2.21±0.69 
- 0.80±0.29 
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2.6 Conclusions 
In conclusion, a synthetic procedure for the obtainment of new 
glucuronosylacylglycerols was presented in this chapter. Their inhibitory activity 
against Akt, both in an isolated enzyme system and in an ovarian carcinoma cell line, 
has been also reported. The two compounds exhibiting the best target inhibition 
activity in cell-free assay, i.e. compounds 26b and 27a, were found to be endowed 
with antiproliferative activity in ovarian carcinoma cells. Although inhibition of 
proliferation was observed, further efforts are needed to increase the potency of the 
compounds in in vitro cultured cells. Overall these data, by showing a clear modulation 
of Akt inhibition in relation to chain length and number, and also to the presence of 
glycerol in cell experiments, provide insights into the understanding of the structural 
features needed to achieve Akt inhibition. 
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2.7 Experimental section 
2.7.1 General methods 
Chemical: Pseudomonas cepacia lipase (LPS, lipase PS, specific activity 30.5 triacetin 
units/mg solid), from Amano Pharmaceutical Co. (Mitsubishi Italia), was supported on 
celite.60 2-O-(2’,3’,4’,6’-Tetra-O-acetyl--D-glucopyranosyl)-sn-glycerol 2958,65 2-O-
(2’,3’,4’,6’-tetra-O-chloroacetyl--D-glucopyranosyl)-sn-glycerol 3266 and the acyl 
carriers60 trifluoroethyldecanoate and -octadecanoate were synthesized according to 
literature procedures.  
All reagents and solvents used were purchased from Sigma-Aldrich as reagent grade 
and were purified before use by standard methods. Dry solvents and liquid reagents 
were distilled prior to use or dried on 4 Å molecular sieves. Air- and moisture sensitive 
liquids and solutions were transferred via oven-dried syringe through septa. 
The acidic Dowex® Marathon™ C sodium form resin was activated by washing it with 
1M HCl and with distilled water prior to use.  Column chromatography was carried out 
on flash silica gel (Aldrich 230–400 mesh) or by a Biotage IsoleraTM Prime flash 
purification system (Biotage-Uppsala, Sweden). Thin-layer chromatography (TLC) 
analysis was carried out on silica gel plate (Merck 60F254) with visualization under UV 
(254 nm) and/or developing with anisaldehyde based reagent [anisaldehyde (9.3 mL), 
H2SO4 (12.5 mL), EtOH (340 mL), and CH3COOH (3.8 mL)]. Evaporation under reduced 
pressure was always effected with a bath temperature at 40°C.  
The structures of all the new synthesized compounds were confirmed through full 1H 
and 13C NMR characterization and mass spectroscopy, which confirmed purity and 
identity of all synthesized compounds. 
1H NMR analysis were performed at 500 MHz with a Bruker FT-NMR AVANCE™ DRX500 
spectrometer using a 5 mm z-PFG (pulsed field gradient) broadband reverse probe at 
298 K unless otherwise stated, and 13C NMR spectra at 125.76 MHz were done for all 
the new compounds. The signals were unambiguously assigned by 2D COSY and HSQC 
experiments (standard Bruker pulse program). Chemical shifts are reported as  (ppm) 
relative to residual CHCl3, CH3OD or pyridine fixed at 7.26, 3.30 ppm and 7.19 ppm 
(higher field signal), respectively, for 1H NMR spectra and relative to CDCl3 fixed at 
77.0 ppm (central line), CD3OD at 49.0 ppm (central line) or pyridine at 123.0 ppm 
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(higher field signal, central line) for 13C NMR spectra. Scalar coupling constants (J) are 
reported in hertz (Hz). Splitting patterns are described by using the following 
abbreviations: br, broad; s, singlet; d, doublet; t, triplet; m, multiplet; dd, doublet of 
doublet; ddd, doublet of doublet of doublet. 
Mass spectra were recorded in negative or positive-ion electrospray (ESI) mode on a 
Thermo Quest Finnigan LCQ DECA™ ion trap mass spectrometer. The mass 
spectrometer was equipped with a Finningan ESI interface. Sample solutions were 
injected with a ionization spray voltage of 4.5 kV or 5.0 kV (positive and negative-ion 
mode, respectively), a capillary voltage of 32 V or -15 V (positive and negative-ion 
mode, respectively), and capillary temperature of 250 °C. Data were processed by 
Finnigan Xcalibur software system.  
Optical rotations were determined on a Perkin–Elmer 241 polarimeter at 20 °C, in a 1 
dm cell. Melting points were recorded on a Büchi 510 capillary melting point apparatus 
and were uncorrected.  
Biochemical: Miltefosine, Perifosine and Sodium Dodecyl Sulfate (SDS) were purchased 
from Sigma. ELISA kit employed to screen inhibitors of Akt was the CycLex AKT/PKB 
kinase Assay/Inhibitor Screening Kit (CycLex, Eppendorf, Milano, Italy).  Plates were 
pre-coated with “AKTide-2T”. Stausporine, used as “inhibitor control”, was purchase 
from Sigma-Aldric, Milano, Italy. 
Human ovarian carcinoma IGROV-1 cell line, characterized by heterozygous mutation 
(Hetc. 995_958delACTT), was used for in vivo assays. Cells were counted with Coulter 
Counter Z1, Beckman Coulter.  
2.7.2 Synthesis of diester derivatives 26a,b 
General procedure for the synthesis of monochloroacetyl protected 33a,b 
2-O-(2’,3’,4’,6’-Tetra-O-chloroacetyl--D-glucopyranosyl)-sn-glycerol 3266 was dissolved 
in dry CH2Cl2 (0.1M) and cooled at -10 °C. The proper acyl chloride (3 eq.) as a 15% 
(v/v) CH2Cl2 solution and pyridine (6 eq.) as a 10% (v/v) CH2Cl2 solution were added and 
the mixture stirred under Ar atmosphere. The reaction was monitored by TLC 
(Petroleum ether/AcOEt 7:3 and CH2Cl2/CH3OH 95:5) and stopped after 30 minutes 
diluting with CH2Cl2 (15ml). The solution was washed with HCl 1M (10 ml), water (10 
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ml), NaHCO3 saturated solution (10 ml) and finally water again (2×10ml). The collected 
aqueous phases were re-extracted with CH2Cl2 (2×20ml), dried with anhydrous Na2SO4, 
filtered and evaporated. The crude obtained was purified  by silica gel flash 
chromatography (petroleum ether/AcOEt 8:2) affording 33a or b. 
Application of the general procedure to 
compound 32 (212 mg, 0.378 mmol) with 
stearoyl chloride (343 mg, 1.134 mmol) 
afforded compound 1,3-di-O-octadecanoyl-2-
O-(2’,3’,4’,6’-tetra-O-acetyl--D-
glucopyranosyl)-sn-glycerol 33a as a white 
solid (249 mg, 0.228 mmol, 60% yield). 
For characterization see Ref.50  
Application of the general procedure to 
compound 32 (265 mg, 0.473 mmol) with 
decanoyl chloride (270 mg, 1.419 mmol) 
afforded compound 1,3-di-O-decanoyl-2-O-
(2’,3’,4’,6’-tetra-O-acetyl--D-glucopyranosyl)-
sn-glycerol 33b as an oil (294 mg, 0.338 mmol, 
70% yield).  
[] 20D :3.3 (CHCl3, c 1.0);  
1H-NMR (CDCl3): 0.85-0.90 (m, 6H, 2 CH3), 1.20-1.34 (m, 24H, 12 CH2), 1.56-1.64 
(m, 4H, 2 CH2), 2.27-2.33 (m, 4H, 2 CH2), 3.83 (ddd, 1H, J5’,6’a=2.5 Hz, J5’,6’b=5.1 Hz, 
J4’,5’=10.0 Hz, H-5’), 3.98 (s, 2H, ClCH2), 4.01 (m, 2H, ClCH2), 4.04 (m, 2H, ClCH2), 4.05-
4.27 (m, 5H, H-1a, H-1b, H-3a, H-3b and H-2), 4.14 (s, 2H, ClCH2), 4.29 (dd, 1H, 
J6’a,5’=2.5 Hz, J6’a,6’b=12.3 Hz, H-6’a), 4.36 (dd, 1H, J6’b,5’=5.1 Hz, H-6’b), 4.72 (d, 1H, 
J1’,2’=7.9 Hz, H-1’), 5.05 (dd, 1H, J2’,3’=9.6 Hz, H-2’), 5.14 (dd, 1H, J3’,4’=9.6 Hz, H-4’), 4.32 
(dd, 1H, H-3’);  
13C-NMR (CDCl3): 14.1 (2 CH3), 22.6 (2 CH2), 24.8 (2 CH2), 29.1-29.4 (8 CH2), 31.8 (2 
CH2), 34.0 (CH2), 34.1 (CH2), 40.1, 40.2, 40.3 and 40.5 (4 CH2Cl), 62.7 (C1 and C3), 63.1 
(C6’), 69.6 (C4’), 71.3 (C5’), 72.2 (C2’), 73.7 (C3’), 75.9 (C2), 100.2 (C1’), 165.9, 166.2, 
166.9, 167.0 (4 CO), 173.4 (2 CO);  
ESI-MS (CH3OH, negative-ion mode): m/z 867.1 [M-1]
-, Calcd for C37H58Cl4O14, m/z 
868.25 [M]. 
General procedure for the synthesis of compounds 34a,b 
The fully protected 33a66 or b was dissolved in a mixture of AcOEt/CH3OH 1:1 (~ 0.035 
M) and hydrazine acetate (15 eq.) was added. The reaction was stirred under Ar 
 Chapter 2 
44 
atmosphere at room temperature for 18h. Then, the solvent was evaporated under 
reduced pressure and the crude residue subjected to repeated ﬂash column 
chromatography (CH2Cl2/CH3OH, from 95:5 to 90:10) yielding pure 
dyacylglucosylglycerols 34a,b. 
Application of the general procedure to 
compound 33a (200 mg, 0.183 mmol) with 
hydrazine acetate (253 mg, 2.745 mmol) afforded 
compound 1,3-di-O-octadecanoyl-2-O--D-
glucopyranosyl-sn-glycerol 34a as a white solid 
(60 mg, 0.076 mmol, 42% yield).  
For characterization see Ref.50  
Application of the general procedure to compound 
33b (230 mg, 0.265 mmol) with hydrazine acetate 
(366 mg, 3.975 mmol) afforded compound 1,3-di-
O-decanoyl-2-O--D-glucopyranosyl-sn-glycerol 
34b as a white solid (60 mg, 0.076 mmol, 43% 
yield). 
Mp: 85.1-85.9°C;  
[] 20D :8.2 (CHCl3, c 1.0);  
1H-NMR (CDCl3): 0.86-0.91 (m, 6H, 2 CH3), 1.19-1.35 (m, 24H, 12 CH2), 1.56-1.65 (m, 
4H, 2 CH2), 2.28-2.37 (m, 4H, 2 CH2), 3.32-3.44 (m, 2H, H-2’ and H-5’), 3.51-3.58 (m, 2H, 
H-3’ and H-4’), 3.78 (m, 1H, H-6’a), 3.89 (m, 1H, H-6’b), 4.04 (m, 1H, H-2), 4.14-4.22 (m, 
2H, H-1a and H-3a), 4.27 (dd, 1H, J1b/3b,2=5.0 Hz, J1b/3b,1a/3a=11.5 Hz, H-1b or H-3b), 4.35 
(dd, 1H, J1b/3b,2=3.8 Hz, J1b/3b,1a/3a=11.8 Hz, H-1b or H-3b), 4.41 (d, 1H, J1’,2’=7.7 Hz, H-1’);  
13C-NMR (CDCl3): 14.1 (2 CH3), 22.7 (2 CH2), 24.8 (2 CH2), 29.1-29.4 (8 CH2),  31.8 (2 
CH2), 34.1 (CH2), 34.2 (CH2), 62.3 (C6’), 63.1 (C1 and C3), 70.1 (C3’ or C4’), 73.5 (C2’), 
75.8 (C5’), 76.0 (C2), 76.2 (C3’ or C4’), 103.3 (C1’), 173.7 (CO), 174.1 (CO); 
 ESI-MS (CH3OH, positive-ion mode): m/z 585.4 [M+Na]
+, calcd for C29H54O10, m/z 
562.37 [M]. 
General procedure of oxidation to obtain the final products 26a,b  
Compound 34a50 or 34b were suspended in a 55:45 mixture of CH3CN and 0.67M 
phosphate sodium buffer at pH 6.7 (0.1 M). TEMPO (0.21 eq.), NaClO2 (20% aqueous 
solution, 3 eq.) and NaClO (15% aqueous solution, 0.15 eq.) were added. After stirring 
overnight at room temperature (TLC, CH2Cl2/CH3OH 90:10), Na2S2O3 0.5 M was added 
and the aqueous phase was acidified with a few drops of HCl 12 M and extracted with 
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Et2O. The organic layers were assembled, dried over anhydrous Na 2SO4, filtered and 
evaporated under reduced pressure to give final products 26a or b.  
Application of the general procedure to 
compound 34a (55 mg, 0.07 mmol) with TEMPO 
(2.5 mg, 0.015 mmol), NaClO2 (100 l of 20% 
aqueous solution, 0.21 mmol) and NaClO (5l 
of 15% aqueous solution, 0.011 mmol) afforded 
compound 1,3-di-O-octadecanoyl-2-O--D-
glucuronopyranosyl-sn-glycerol 26a as a white solid (24 mg, 0.03 mmol, 43% yield). 
The lower yield was due to the low solubility of the starting material in the reaction 
conditions.  
Mp: 158-159°C; 
[] 20D : the product 26a was scarcely soluble making impossible the measurement of the 
optical rotation;  
1H-NMR (CDCl3:CD3OD:D2O, 65:35:6, 315 K): 0.82-0.87 (m, 6H, 2 CH3), 1.18-1.31 (m, 
56H, 28 CH2), 1.53-1.61 (m, 4H, 2 CH2), 2.27-2.32 (m, 4H, 2 CH2), 3.24 (dd, 1H, J1’,2’=7.8 
Hz, J2’,3’=9.1 Hz, H-2’), 3.42 (dd, 1H, J3’,4’=9.0 Hz, H-3’), 3.45 (dd, 1H, J4’,5’=9.5 Hz, H-4’), 
3.56 (d, 1H, H-5’), 4.17-4.23 (m, 4H, H-2, H-1a, H-3a, and H-1b or H-3b), 4.30 (m, 1H, H-
1b or H-3b), 4.41 (d, 1H, H-1’);  
13C-NMR (CDCl3:CD3OD:D2O, 65:35:6, 315 K): 14.3 (2 CH3), 23.1 (2 CH2), 25.3 (2 CH2), 
29.5-30.2 (24 CH2), 32.4 (2 CH2), 34.6 (2 CH2), 63.2 (C1 or C3), 64.0 (C1 or C3), 72.5 
(C4’), 73.8 (C2’), 75.2 (C2), 75.6 (C5’), 76.6 (C3’), 103.2 (C1’), 174.8 (2 CO); 
ESI-MS (CH3OH, negative-ion mode): m/z 799.7 [M-1]
-, Calcd for C45H84O11, m/z 800.60 
[M].  
Application of the general procedure to 
compound 34b (40 mg, 0.07 mmol) with TEMPO 
(2.5 mg, 0.015 mmol), NaClO2 (100 l of 20% 
aqueous solution, 0.21 mmol) and NaClO (5l of 
15% aqueous solution, 0.011 mmol) afforded 
compound 1,3-di-O-decanoyl-2-O--D-
glucuronopyranosyl-sn-glycerol 26b as an oil (36 mg, 0.06 mmol, 88% yield).  
[] 20D :18.9 (CH3OH, c 1.0);  
1H-NMR (CD3OD): 0.85-0.92 (m, 6H, 2 CH3), 1.22-1.36 (m, 24H, 12 CH2), 1.54-1.64 
(m, 4H, 2 CH2), 2.29-2.37 (m, 4H, 2 CH2), 3.32 (dd, 1H, J1’,2’=8.0 Hz, J2’,3’=8.5 Hz, H-2’), 
3.41 (dd, 1H, J3’,4’=9.0 Hz, H-3’), 3.47 (dd, 1H, J4’,5’=9.0 Hz, H-4’), 3.65 (br d, 1H, H-5’), 
4.19-4.26 (m, 4H, H-2, H-1a, H-3a, and H-1b or H-3b), 4.31 (m, 1H, H-1b or H-3b), 4.46 
(d, 1H, H-1’);  
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13C-NMR (CD3OD): 14.5 (2 CH3), 23.7 (2 CH2), 26.0 (2 CH2), 30.2-30.6 (8 CH2), 33.1 (2 
CH2), 34.9 (2 CH2), 63.9 (C1 or C3), 64.7 (C1 or C3), 73.5 (C4’), 74.8 (C2’), 75.9 (C2), 76.4 
(C5’), 77.6 (C3’), 104.3 (C1’), 175.1 (CO), 175.2 (CO), 176.9 (br s, CO);  
ESI-MS (CH3OH, negative-ion mode): m/z 575.3 [M-1]
-, Calcd for C29H52O11, m/z 576.35 
[M]. 
2.7.3 Synthesis of monoester derivatives 27a,b 
General procedure for the enzymatic synthesis of monoesters 40a or b  
Compound 2-O-(2’,3’,4’,6’-tetra-O-acetyl--D-glucopyranosyl)-sn-glycerol 3558,65 was 
dissolved in dry pyridine (0.1 M) and the appropriate trifluoroethyl ester (6 eq.) and 
LPS (5 times the weight of starting material 35) were added. The suspension was 
stirred at 45 °C and monitored by TLC (CH2Cl2/CH3OH 95:5). After 18 h the reaction was 
stopped and filtered to remove the enzyme which was washed with pyridine and 
methanol. The solvent was evaporated under vacuum and the crude purified by 
automated flash chromatography (Hexane/AcOEt) yielding 40a or b. 
Application of the general procedure to 
compound 35 (500 mg, 1.184 mmol) with 
trifluoroethyl octadecanoate (2.60 g, 7.10 mmol) 
and LPS (2.5 g) afforded compound 1-O-
octadecanoyl-2-O-(2’,3’,4’,6’-tetra-O-acetyl-D-
glucopyranosyl)-sn-glycerol 40a as an 
amorphous solid (600 mg, 0.87 mmol, 74% yield) after purification by flash column 
chromatography (Hexane/AcOEt from 9:1 to 2:8).  
Mp: 95.1-95.4 °C; 
[] 20D :4.7 (CHCl3, c 0.5);  
1H NMR (CDCl3): 0.87 (t, 3H, J=7.0 Hz, CH3), 1.19-1.34 (m, 28H, 14 CH2), 1.61 (m, 2H, 
CH2), 2.00 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 2.05 (s, 3H, COCH3), 2.09 (s, 3H, COCH3), 
2.30 (t, 2H, J=7.6 Hz, CH2), 3.58-3.69 (m, 2H, H-3a and H-3b), 3.76 (ddd, 1H, J5’,6’a=5.6 
Hz, J5’,6’b=2.6 Hz, J4’,5’=9.7 Hz, H-5’), 3.88 (m, 1H, H-2), 4.05-4.11 (m, 2H, H-1a and H-1b), 
4.16 (dd, 1H, J6’a,6’b=12.2 Hz, H-6’a), 4.21 (dd, 1H, H-6’b), 4.61 (d, 1H, J1’,2’=8.0 Hz, H-1’), 
5.01 (dd, 1H, J2’,3’=9.7 Hz, H-2’), 5.05 (dd, 1H, J3’,4’=9.7 Hz, H-4’), 5.22 (dd, 1H, H-3’);  
13C-NMR (CDCl3): 14.1 (CH3), 20.5-20.07 (4 COCH3), 22.7 (CH2), 24.9 (CH2), 28.9-30.0 
(12 CH2), 31.9 (CH2), 34.1 (CH2), 61.9 (C6’), 62.8 (C3), 63.1 (C1), 68.4 (C4’), 71.2 (C2’), 
72.0 (C5’), 72.5 (C3’), 81.5 (C2), 101.2 (C1’), 169.2, 169.4, 170.2, 170.6 and 173.4 (5 
CO);  
ESI-MS (CH3OH, positive-ion mode): m/z 711.3 [M+Na]
+, calcd for C35H60O13, m/z 
688.40 [M]. 
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Application of the general procedure to compound 35 (500 mg, 1.184 mmol) with 
trifluoroethyl decanoate (1.8 g, 7.10 mmol) and 
LPS (2.5 g) afforded compound 1-O-decanoyl-2-
O-(2’,3’,4’,6’-tetra-O-acetyl-D-
glucopyranosyl)-sn-glycerol 40b as an oil (560 
mg, 0.97 mmol, 82% yield) after purification by 
flash column chromatography (Hexane/AcOEt 
from 7:3 to 3:7). 
[] 20D :1.0 (CHCl3, c 1.0);  
1H-NMR (CDCl3): 0.87 (t, 3H, J=7.0 Hz, CH3), 1.20-1.35 (m, 12H, 6 CH2), 1.61 (m, 2H, 
CH2), 2.00 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 2.04 (s, 3H, COCH3), 2.09 (s, 3H, COCH3), 
2.30 (t, 2H, J=7.6 Hz, CH2), 3.57-3.69 (m, 2H, H-3a and H-3b), 3.76 (ddd, 1H, J5’,6’a=5.6 
Hz, J5’,6’b=2.3 Hz, J4’,5’=9.8 Hz, H-5’), 3.88 (m, 1H, H-2), 4.05-4.12 (m, 2H, H-1a and H-1b), 
4.16 (dd, 1H, J6’a,6’b=12.3 Hz, H-6’a), 4.20 (dd, 1H, H-6’b), 4.61 (d, 1H, J1’,2’=8.0 Hz, H-1’), 
5.00 (dd, 1H, J2’,3’=9.8 Hz, H-2’), 5.04 (dd, 1H, J3’,4’=9.8 Hz, H-4’), 5.21 (dd, 1H, H-3’);  
13C-NMR (CDCl3): 14.1 (CH3), 20.5-20.7 (4 COCH3), 22.7 (CH2), 24.9 (CH2), 29.0-29.5 
(4 CH2),  31.8 (CH2), 34.1 (CH2), 61.9 (C6’), 62.8 (C3), 63.1 (C1), 68.4 (C4’), 71.2 (C2’), 
72.0 (C5’), 72.5 (C3’), 81.5 (C2), 101.2 (C1’), 169.2, 169.4, 170.2, 170.6 and 173.4 (5 
CO); 
ESI-MS (CH3OH, positive-ion mode): m/z 599.3 [M+Na]
+, calcd for C27H44O13, m/z 
576.28 [M]. 
General procedure to prepare trytil derivatives 41a or b 
Compound 40 was dissolved in dry pyridine (0.1 M) and trityl chloride (2 eq.) was added. 
The reaction mixture was heated at 100 °C and stirred under argon for 3h (TLC, hexane: 
EtOAc 6:4). Then, the solvent was evaporated under reduced pressure and the obtained 
crude compound was submitted to flash chromatography (Hexane/AcOEt 75:25 + 1% TEA) 
to yield compound 41a or b. 
Application of the general procedure to 
compound 40a (470 mg, 0.682 mmol) with trityl 
chloride (380 mg, 1.364 mmol) afforded 
compound 1-O-octadecanoyl-3-O-trityl-2-O-
(2’,3’,4’,6’-tetra-O-acetyl--D-glucopyranosyl)-
sn-glycerol 41a as an oil (610 mg, 0.655 mmol, 
96% yield).  
[] 20D :3.3 (CHCl3, c 1.0);  
1H-NMR (Pyd5): 0.85 (t, 3H, J=6.5 Hz, CH3), 1.16-1.33 (m, 28H, 14 CH2), 1.64 (m, 2H, 
CH2), 1.96 (s, 3H, COCH3), 1.99 (s, 3H, COCH3), 2.01 (s, 3H, COCH3), 2.15 (s, 3H, COCH3), 
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2.35 (t, 2H, J=7.5 Hz, CH2), 3.44 (dd, 1H, J3a,2=6.0 Hz, J3a,3b=9.4 Hz, H-3a), 3.57 (dd, 1H, 
J3b,2=5.1 Hz, H-3b), 4.13 (ddd, 1H, J5’,6’a=2.0 Hz, J5’,6’b=4.3 Hz, J4’,5’=9.6 Hz, H-5’), 4.33 
(dd, 1H, J6’a,6’b=12.1 Hz, H-6’a), 4.38 (m, 1H, H-2), 4.49 (dd, 1H, J1a,2=5.8 Hz, J1a,1b=11.6 
Hz, H-1a), 4.56 (dd, 1H, H-6’a), 4.58 (dd, 1H, J1b,2=3.5 Hz, H-1b), 5.19 (d, 1H, J1’,2’=8.0 
Hz, H-1’), 5.48 (dd, 1H, J2’,3’=9.6 Hz, H-2’), 5.50 (dd, 1H, J3’,4’=9.6 Hz, H-4’), 5.77 (dd, 1H, 
H-3’), 7.26 (dd, 3H, J=7.3 Hz, Ph), 7.35 (dd, 6H, J=7.4 Hz, Ph), 7.65 (d, 6H, J=7.8 Hz, Ph);  
13C-NMR (Pyd5): 13.8 (CH3), 19.7-20.3 (4 COCH3), 22.4 (CH2), 24.7 (CH2), 28.6-28.8 
(12 CH2), 31.6 (CH2), 33.8 (CH2), 62.1 (C6’), 63.4 (C3), 63.5 (C1), 68.7 (C4’), 71.6 (C2’), 
71.7 (C5’), 72.9 (C3’), 77.0 (C2), 86.7 (OCPh3), 100.6 (C1’), 127.0 (3 CH, Ph), 127.8 (6 
CH, Ph), 128.7 (6 CH, Ph), 144.0 (3 C, Ph), 169.1, 169.3, 169.8, 170.0 and 172.8 (5 CO);  
ESI-MS (CH3OH, positive-ion mode): m/z 953.5 [M+Na]
+, calcd for C54H74O13, m/z 
930.51 [M].  
Application of the general procedure to 
compound 40b (508 mg, 0.881 mmol) with trityl 
chloride (491 mg, 1.762 mmol) afforded 
compound 1-O-decanoyl-3-O-trityl-2-O-
(2’,3’,4’,6’-tetra-O-acetyl--D-glucopyranosyl)-sn-
glycerol 41b as an oil (510 mg, 0.623 mmol, 70% 
yield).  
[] 20D :3.4 (CHCl3, c 1.0);  
1H-NMR (Pyd5): 0.85 (t, 3H, J=7.0 Hz, CH3), 1.14-1.30 (m, 12H, 6 CH2), 1.63 (m, 2H, 
CH2), 1.96 (s, 3H, COCH3), 2.00 (s, 3H, COCH3), 2.01 (s, 3H, COCH3), 2.14 (s, 3H, COCH3), 
2.34 (t, 2H, J=7.5 Hz, CH2), 3.43 (dd, 1H, J3a,2=6.0 Hz, J3a,3b=9.6 Hz, H-3a), 3.57 (dd, 1H, 
J3b,2=5.2 Hz, H-3b), 4.13 (ddd, 1H, J5’,6’a=2.5 Hz, J5’,6’b=4.4 Hz, J4’,5’=9.5 Hz, H-5’), 4.33 
(dd, 1H, J6’a,6’b=12.2 Hz, H-6’a), 4.38 (m, 1H, H-2), 4.49 (dd, 1H, J1a,2=6.0 Hz, J1a,1b=11.6 
Hz, H-1a), 4.55 (dd, 1H, H-6’a), 4.58 (dd, 1H, J1b,2=3.6 Hz, H-1b), 5.19 (d, 1H, J1’,2’=8.0 
Hz, H-1’), 5.48 (dd, 1H, J2’,3’=9.5 Hz, H-2’), 5.51 (dd, 1H, J3’,4’=9.5 Hz, H-4’), 5.77 (dd, 1H, 
H-3’), 7.26 (dd, 3H, J=7.3 Hz, Ph), 7.35 (dd, 6H, J=7.4 Hz, Ph), 7.64 (d, 6H, J=7.8 Hz, Ph);  
13C-NMR (Pyd5):13.8 (CH3), 19.6-20.4 (4 COCH3), 22.4 (CH2), 24.7 (CH2), 28.4-29.6 (4 
CH2), 31.6 (CH2), 33.8 (CH2),  62.0 (C6’), 63.4 (C3), 63.5 (C1), 68.7 (C4’), 71.6 (C2’), 71.7 
(C5’), 72.9 (C3’), 77.0 (C2), 86.6 (OCPh3), 100.6 (C1’), 127.0 (3 CH, Ph), 127.8 (6 CH, Ph), 
128.7 (6 CH, Ph), 144.0 (3 C, Ph), 169.1, 169.3, 169.8, 170.0 and 172.8 (5 CO);  
ESI-MS (CH3OH, positive-ion mode): m/z 841.3 [M+Na]
+, calcd for C46H58O13, m/z  
818.39 [M]. 
General procedure of hydrazinolisys to give compounds 42a or b  
Compound 41 was dissolved in EtOH 85% (0.1 M) and hydrazine hydrate (10 eq.) was 
added drop by drop. The reaction mixture was left stirring overnight at 45 °C. The 
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solvent was evaporated under pressure and the crude was purified by flash 
chromatography (CH2Cl2/CH3OH 95:5) to yield title compounds. 
Application of the general procedure to 
compound 41a (596 mg, 0.640 mmol) with 
hydrazine hydrate (300 L, 6.40 mmol) afforded 
compound 1-O-octadecanoyl-3-O-trityl-2-O--D-
glucopyranosyl-sn-glycerol 42a as an oil (223 mg, 
292 mmol, 45% yield). 
[] 20D :+6.3 (CHCl3, c 1.0);  
1H-NMR (Pyd5): 0.85 (t, 3H, J=7.0 Hz, CH3), 1.15-1.31 (m, 28H, 14 CH2), 1.61 (m, 2H, 
CH2), 2.32 (m, 2H, CH2), 3.54 (dd, 1H, J3a,2=6.6 Hz, J3a,3b=9.4 Hz, H-3a), 3.66 (dd, 1H, 
J3b,2=4.7 Hz, H-3b), 3.92 (m, 1H, H-5’), 3.99 (m, 1H, H-2’), 4.19-4.27 (m, 2H, H-3’and H-
4’), 4.34 (m, 1H, H-6’a), 4.46 (m, 1H, H-6’b), 4.49 (m, 1H, H-2), 4.66-4.72 (m, 2H, H-1a 
and H-1b), 5.04 (d, 1H, J1’,2’=7.7 Hz, H-1’), 7.23 (dd, 3H, J=7.3 Hz, Ph), 7.32 (dd, 6H, 
J=7.4 Hz, Ph), 7.64 (d, 6H, J=7.8 Hz, Ph);  
13C-NMR (Pyd5): 13.8 (CH3), 22.4 (CH2), 24.7 (CH2), 28.8-29.7 (12 CH2),  31.6 (CH2), 
33.9 (CH2), 62.4 (C6’), 63.7 (C3), 63.8 (C1), 71.2 (C3’ or C4’), 74.7 (C2’), 76.0 (C2), 77.9 
(C3’ or C4’ and C5’), 86.6 (OCPh3), 104.3 (C1’), 126.9 (3 CH, Ph), 127.8 (6 CH, Ph), 128.7 
(6 CH, Ph), 144.2 (3 C, Ph), 173.0 (CO);  
ESI-MS (CH3OH, positive-ion mode): m/z 785.3 [M+Na]
+, calcd for C46H66O9, m/z 762.47 
[M]. 
Application of the general procedure to compound 
41b (475 mg, 0.580 mmol) with hydrazine hydrate 
(270 L, 5.80 mmol) afforded compound 1-O-
decanoyl-3-O-trityl-2-O--D-glucopyranosyl-sn-
glycerol 42b as an oil (210 mg, 322 mmol, 56% 
yield). 
[] 20D :+7.8 (CHCl3, c 1.0);  
1H-NMR (Pyd5): 0.83 (t, 3H, J=7.0 Hz, CH3), 1.07-1.28 (m, 12H, 6 CH2), 1.60 (m, 2H, 
CH2), 2.31 (m, 2H, CH2), 3.54 (dd, 1H, J3a,2=6.5 Hz, J3a,3b=9.4 Hz, H-3a), 3.66 (dd, 1H, 
J3b,2=4.7 Hz, H-3b), 3.92 (m, 1H, H-5’), 3.98 (m, 1H, H-2’), 4.18-4.26 (m, 2H, H-3’and H-
4’), 4.33 (dd, 1H, J5’,6’a=4.9 Hz, J6’a,6’b=11.5 Hz, H-6’a), 4.45 (dd, 1H, J5’,6’ab=2.2 Hz, H-6’b), 
4.49 (m, 1H, H-2), 4.65-4.71 (m, 2H, H-1a and H-1b), 5.03 (d, 1H, J1’,2’=7.7 Hz, H-1’), 
7.23 (dd, 3H, J=7.3 Hz, Ph), 7.32 (dd, 6H, J=7.4 Hz, Ph), 7.63 (d, 6H, J=7.8 Hz, Ph);  
13C-NMR (Pyd5): 13.8 (CH3), 22.4 (CH2), 24.7 (CH2), 28.7-29.3 (4 CH2),  31.5 (CH2), 
33.8 (CH2), 62.4 (C6’), 63.7 (C3), 63.8 (C1), 71.2 (C3’ or C4’), 74.7 (C2’), 76.0 (C2), 77.9 
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(C3’ or C4’ and C5’), 86.6 (OCPh3), 104.3 (C1’), 126.9 (3 CH, Ph), 127.8 (6 CH, Ph), 128.7 
(6 CH, Ph), 144.2 (3 C, Ph), 173.0 (CO);  
ESI-MS (CH3OH, positive-ion mode): m/z 673.2 [M+Na]
+, calcd for C38H50O9, m/z 650.35 
[M]. 
General procedure of oxidation to obtain products 43a,b  
Compound 42a or 42b was suspended in a 55:45 mixture of CH3CN and 0.67M 
phosphate sodium buffer at pH 6.7 (0.1 M). TEMPO (0.21 eq.), NaClO2 (20% aqueous 
solution, 3 eq.) and NaClO (15% aqueous solution, 0.15 eq.) were added. After stirring 
for 3 hours at room temperature (TLC, CH2Cl2/CH3OH 9:1), acetonitrile was removed 
under reduced pressure and the aqueous phase was extracted with Et2O. The organic 
layers were assembled, dried over anhydrous Na2SO4, filtered and evaporated to give 
the compound 43a or b as an amorphous solid, which were used without further 
purification in the next step. 
Application of the general procedure to 
compound 42a (223 mg, 0.292 mmol) with 
TEMPO (10 mg, 0.061 mmol), NaClO2 (400 l of 
20% aqueous solution, 0.876 mmol) and NaClO 
(25l of 15% aqueous solution, 0.044 mmol) 
afforded 1-O-octadecanoyl-3-O-trityl-2-O--D-glucuronopyranosyl-sn-glycerol 43a (220 
mg, 0.283 mmol, 97% yield) as an amorphous solid.  
Mp: 98-99 °C;  
[] 20D :11.1 (CHCl3:CH3OH 65:35, c 1.0);  
1H-NMR (Pyd5): 0.85 (t, 3H, J=7.0 Hz, CH3), 1.13-1.35 (m, 28H, 14 CH2), 1.59 (m, 2H, 
CH2), 2.28 (m, 2H, CH2), 3.56 (dd, 1H, J3a,2=6.6 Hz, J3a,3b=9.2 Hz, H-3a), 3.68 (dd, 1H, 
J3b,2=4.4 Hz, H-3b), 4.03 (dd, J1’,2’=7.6 Hz, J2’,3’=8.0 Hz, 1H, H-2’), 4.25 (m, 1H, H-3’), 4.32-
4.42 (m, 2H, H-4’ and H-5’), 4.54 (m, 1H, H-2), 4.60-4.71 (m, 2H, H-1a and H-1b), 5.06 
(d, 1H, H-1’), 7.19 (dd, 3H, J=7.4 Hz, Ph), 7.31 (dd, 6H, J=7.4 Hz, Ph), 7.63 (d, 6H, J=7.8 
Hz, Ph);  
13C-NMR (Pyd5): 13.8 (CH3), 22.4 (CH2), 24.7 (CH2), 28.8-29.7 (12 CH2), 31.6 (CH2), 
33.8 (CH2), 63.5 (C1 and C3), 73.1 (C4’ or C5’), 74.4 (C2’), 75.5 (C2), 76.5 (C4’ or C5’), 
77.6 (C3’), 86.6 (OCPh3), 103.7 (C1’), 126.8 (3 CH, Ph), 127.8 (6 CH, Ph), 128.7 (6 CH, 
Ph), 144.1 (3 C, Ph), 173.0 (CO), 174.3 (CO);  
ESI-MS (CH3OH, negative-ion mode): m/z 775.5 [M-1]
-, calcd for C46H64O10, m/z 776.45 
[M]. 
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Application of the general procedure to 
compound 42b (210 mg, 0.323 mmol) with 
TEMPO (10 mg, 0.061 mmol), NaClO2 (440 l of 
20% aqueous solution, 0.969 mmol) and NaClO 
(25l of 15% aqueous solution, 0.048 mmol) 
afforded 1-O-decanoyl-3-O-trityl-2-O--D-
glucuronopyranosyl-sn-glycerol 43b (211 mg, 0.317 mmol, 98% yield) as an amorphous 
solid.  
Mp: 154-155 °C;  
[] 20D :11.3 (CHCl3:CH3OH 65:35, c 1.0);  
1H-NMR (Pyd5): 0.84 (t, 3H, J=7.0 Hz, CH3), 1.07-1.28 (m, 12H, 6 CH2), 1.57 (m, 2H, 
CH2), 2.26 (m, 2H, CH2), 3.56 (dd, 1H, J3a,2=6.6 Hz, J3a,3b = 9.0 Hz, H-3a), 3.64 (dd, 1H, 
J3b,2=4.2 Hz, H-3b), 3.99 (dd, J1’,2’=7.8 Hz, J2’,3’=8.5 Hz, 1H, H-2’), 4.16-4.27 (m, 3H, H-3’, 
H-4’ and H-5’), 4.57 (m, 1H, H-2), 4.65 (dd, 2H, J1’a,2=4.8 Hz, J1’a, 1’b=11.5 Hz, H-1a), 4.70 
(dd, 2H, J1’b,2=4.0 Hz, H-1b), 5.00 (d, 1H, H-1’), 7.20 (dd, 3H, J=7.4 Hz, Ph), 7.31 (dd, 6H, 
J=7.4 Hz, Ph), 7.62 (d, 6H, J=7.8 Hz, Ph);  
13C-NMR (Pyd5): 13.8 (CH3), 22.4 (CH2), 24.6 (CH2), 28.7-29.3 (4 CH2), 31.5 (CH2), 
33.8 (CH2), 63.2 (C1), 63.4 (C3), 73.2 (C4’ or C5’), 74.3 (C2’), 74.9 (C2), 76.0 (C4’ or C5’), 
77.7 (C3’), 86.6 (OCPh3), 103.1 (C1’), 126.8 (3 CH, Ph), 127.8 (6 CH, Ph), 128.7 (6 CH, 
Ph), 144.1 (3 C, Ph), 173.0 (CO), 175.6 (CO);  
ESI-MS (CH3OH, negative-ion mode): m/z = 663.2 [M-1]
-, calcd for C38H48O10, m/z 
664.32 [M]. 
General procedure to obtain final products 27a,b  
Compound 43 was dissolved in CH2Cl2 (0.1 M) and the same amount on weight of 
starting material of Dowex® Marathon™ C, H+ form was added. The reaction was stirred 
at room temperature under nitrogen atmosphere until TLC analysis (CH2Cl2:CH3OH 9:1) 
showed disappearance of the starting material and formation of a new product. The 
white suspension obtained was filtered and the residue washed with CH2Cl2 was 
eliminated, while the remaining solid was then washed with AcOEt and iPrOH and 
evaporated under reduced pressure yielding the desired pure product. 
Application of the general procedure to 
compound 43a (50 mg, 0.064 mmol) with 
Dowex® Marathon™ C, H+ form (50 mg) afforded 
1-O-octadecanoyl-2-O--D-glucuronopyranosyl-
sn-glycerol 27a (60 mg, 0.112 mmol, 76% yield) 
as a white solid. 
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Mp: 127-128 °C;  
[] 20D :29.3 (CHCl3:CH3OH 65:35, c 0.5);  
1H-NMR (Pyd5): 0.85 (t, 3H, J=7.0 Hz, CH3), 1.13-1.31 (m, 28H, 14 CH2), 1.64 (m, 2H, 
CH2), 2.37 (m, 2H, CH2), 4.10 (dd, J1’,2’=7.8 Hz, J2’,3’=8.9 Hz, 1H, H-2’), 4.16 (dd, 1H, 
J3a,2=5.5 Hz, J3a,3b=11.5 Hz, H-3a), 4.23 (dd, 1H, J3b,2=4.9 Hz, H-3b), 4.33 (dd, 1H, J3’,4’=8.9 
Hz, H-3’), 4.52 (m, 1H, H-2), 4.60 (dd, 1H, J4’,5’=8.9 Hz, H-4’), 4.66 (d, 1H, H-5’), 4.69-
4.77 (m, 2H, H-1a and H-1b), 5.22 (d, 1H, H-1’);  
13C-NMR (Pyd5): 13.8 (CH3), 22.4 (CH2), 24.7 (CH2), 28.8-29.5 (12 CH2), 31.6 (CH2), 
33.9 (CH2), 62.2 (C3), 63.9 (C1), 72.9 (C4’), 74.3 (C2’), 77.3 (C3’ and C5’), 78.7 (C2), 
104.5 (C1’), 172.1 (CO), 173.1 (CO);  
ESI-MS (CH3OH, negative-ion mode): m/z 533.3 [M-1]
-, calcd for C27H50O10, m/z 534.34 
[M].  
Application of the general procedure to 
compound 43b (140 mg, 0.210 mmol) with 
Dowex® Marathon™ C, H+ form (140 mg) afforded 
1-O-decanoyl-2-O--D-glucuronopyranosyl-sn-
glycerol 27a (72 mg, 0.170 mmol, 81% yield) as a 
white sticky solid. 
[] 20D :31.6 (CHCl3:CH3OH 65:35, c 1.0);  
1H-NMR (Pyd5): 0.82 (t, 3H, J=7.0 Hz, CH3), 1.09-1.27 (m, 12H, 6 CH2), 1.62 (m, 2H, 
CH2), 2.36 (m, 2H, CH2), 4.09 (dd, J1’,2’=7.8 Hz, J2’,3’=8.4 Hz, 1H, H-2’), 4.15 (dd, 1H, 
J3a,2=5.5 Hz, J3a,3b=11.4 Hz, H-3a), 4.21 (dd, 1H, J3b,2=4.8 Hz, H-3b), 4.32 (dd, 1H, J3’,4’=8.9 
Hz, H-3’), 4.51 (m, 1H, H-2), 4.58 (dd, 1H, J4’,5’=8.9 Hz, H-4’), 4.64 (d, 1H, H-5’), 4.68-
4.76 (m, 2H, H-1a and H-1b), 5.20 (d, 1H, H-1’);  
13C-NMR (Pyd5): 13.7 (CH3), 22.4 (CH2), 24.7 (CH2), 28.7-29.2 (4 CH2), 31.5 (CH2), 
33.8 (CH2), 62.2 (C3), 63.8 (C1), 72.8 (C4’), 74.3 (C2’), 77.2 (C5’), 77.3 (C3’), 78.7 (C2), 
104.5 (C1’), 172.1 (CO), 173.1 (CO);  
 ESI-MS (CH3OH, negative-ion mode): m/z 421.5 [M-1]
-, Calcd for C19H34O10, m/z 422.22 
[M].  
Configuration assignment of compound 40a  
Compound 40a (27 mg, 0.038 mmol) was 
dissolved in dry pyridine (1 mL) and acetic 
anhydride (500 l, Py/Ac2O 2:1 v/v) was added. 
The reaction was stirred at room temperature 
and stopped after 3 hours (TLC, hexane/AcOEt 
6:4). Then the solvent was evaporated under 
reduced pressure and the crude purified by 
flash chromatography (hexane/AcOEt 7:3) and the obtained pure compound (oil, 24 
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mg, 0.033 mmol, 82% yield) resulted identical to the known 1-O-octadecanoyl-3-O-
acetyl-2-O-(2’,3’,4’,6’-tetra-O-acetyl--D-glucopyranosyl)-sn-glycerol 44.60 
[] 20D :-8.7 (CHCl3, c 1);  
1H NMR (CDCl3):  = 0.86 (t, 3H, J=7.0 Hz, CH3), 1.19-1.33 (m, 28H, 14 CH2), 1.59 (m, 
2H, CH2), 1.98 (s, 3H, COCH3), 2.00 (s, 3H, COCH3), 2.01 (s, 3H, COCH3), 2.04 (s, 3H, 
COCH3), 2.06 (s, 3H, COCH3), 2.29 (t, 2H, J=7.6 Hz, CH2), 3.67 (ddd, 1H, J5’,6’a=2.4 Hz, 
J5’,6’b=5.1 Hz, J4’,5’=10.0 Hz, H-5’), 4.04 (m, 1H, H-2), 4.06-4.20 (m, 5H, H-1a, H-1b, H-3a, 
H-3b and H-6’a), 4.22 (dd, 1H, J6’a,6’b=12.3 Hz, H-6’b), 4.61 (d, 1H, J1’,2’=7.9 Hz, H-1’), 
4.96 (dd, 1H, J2’,3’=9.6 Hz, H-2’), 5.04 (dd, 1H, J3’,4’=9.6 Hz, H-4’), 5.17 (dd, 1H, H-3’);  
13C-NMR (CDCl3): =14.1 (CH3), 20.4-20.08 (5 COCH3), 22.7 (CH2), 24.8 (CH2), 28.9-29.9 
(12 CH2), 31.9 (CH2), 34.1 (CH2), 62.0 (C6’), 63.1 (C1), 63.3 (C3), 68.4 (C4’), 71.3 (C2’), 
71.9 (C5’), 72.7 (C3’), 75.6 (C2), 100.8 (C1’), 169.1, 169.3, 170.2, 170.5, 170.6 and 
173.3 (6 CO); 
ESI-MS (CH3OH, positive-ion mode): m/z 753.5 [M+Na]
+, calcd for C37H62O14, m/z 
730.41 [M]. 
2.7.4 Synthesis of glucuronosyl derivatives 28a,b 
Synthesis of 2’,3’,4’,6’-tetra-O-acetyl-n-decyl-D-glucopyranosyl 47 
To a solution of glucose pentaacetate 45 in dry CH2Cl2 (0.1 
M) in Ar atmosphere, decanoyl alcohol (3 eq., 4.5 ml) was 
added and after cooling to -10 °C also BF3·Et2O (3.25 eq., 
3.0 ml) was added dropwise. The reaction mixture was 
left stirring at room for 4 hours, then diluted with 50 ml 
of CH2Cl2 and washed with saturated aqueous NaHCO3 (50 
ml), H2O (50 ml) and brine (50 ml). The organic layers were dried (Na2SO4), filtered and 
concentrated under vacuum. 1H NMR analysis of the crude mixture showed the 
formation of two diasteroisomers. Purification of the crude product using silica gel 
gradient flash chromatography (hexane/AcOEt from 8:2 to 1:1) afforded 1.34 g (2.74 
mmol, 36%) of the major diastereoisomer 47, as a white solid.  
For characterization see Ref.67  
Synthesis of n-decyl-D-glucopyranosyl 48a 
To a solution of 47 (1.30 g, 2.66 mmol) in CH3OH (5 mL) 
CH3ONa 0.7 M in CH3OH (3 eq., 11.5 ml) was added. The 
reaction was stirred for 5 hours at room temperature and 
quenched with Dowex H+ washing with CH3OH. After 
removal of the solvent under vacuum, the resulting white 
solid product 48a (802 mg, 2.503 mmol, 94%) was used 
without further purification in the next step.  
For characterization see Ref. 67  
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Synthesis of n-decyl-D-glucopyranosiduronic acid 28a 
Compound 48a (100 mg, 0.312 mmol) 
was suspended in a 55:45 mixture of 
CH3CN and 0.67M phosphate sodium 
buffer at pH 6.7 (0.1 M, 3 ml). TEMPO 
(0.21 eq., 10 mg, 0.065 mmol), NaClO2 
(20% aqueous solution, 3 eq., 0.936 mmol, 430 l) and NaClO (15% aqueous solution, 
0.15 eq., 0.047 mmol, 25 l) were added. After stirring 4 hours at room temperature 
(TLC, CH2Cl2/CH3OH 85:15), 10 ml of Na2S2O3 0.5 M and a few drops of HCl 12 M were 
added. The aqueous phase was extracted with Et2O (3×10 ml) and the organic layers 
were assembled, dried over anhydrous Na2SO4, filtered and evaporated under reduced 
pressure. The crude was purified by silica gel flash chromatography (CH2Cl2/CH3OH 
from 8:2 to 7:3) to give 28a (55 mg, 0.164 mmol, 53%) as a white solid.  
For characterization see Ref.62  
Synthesis of n-octyl-D-glucopyranosiduronic acid 28b 
The commercial octyl-D-glucopyranosyl 
(100 mg, 0.342 mmol) was suspended in a 
55:45 mixture of CH3CN and 0.67M phosphate 
sodium buffer at pH 6.7 (0.1 M, 3.5 ml). 
TEMPO (0.21 eq., 11 mg, 0.072 mmol), NaClO2 
(20% aqueous solution, 3 eq., 1.026 mmol, 460 l) and NaClO (15% aqueous solution, 
0.15 eq., 0.051 mmol, 25 l) were added. After stirring 4 hours at room temperature 
(TLC, CH2Cl2/CH3OH 85:15), 10 ml of Na2S2O3 0.5 M and  a few drops of HCl 12 M were 
added.  The aqueous phase was extracted with Et2O (10 ml ×3) and the organic layers 
were assembled, dried over anhydrous Na2SO4, filtered and evaporated under reduced 
pressure. The crude was purified by silica gel flash chromatography (CH2Cl2/CH3OH 
from 8:2) to give 28b (65 mg, 0.212 mmol, 62%) as a white solid.  
For characterization see Ref.62  
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2.7.5 Akt Inhibition Assays 
Akt1 ELISA activity assay. The inhibitory activity of compounds 26a,b, 27a,b and 28a,b 
Miltefosine, Perifosine and Sodium Dodecyl Sulfate SDS was tested employing the 
CycLex AKT/PKB kinase Assay/Inhibitor Screening Kit. Plates were pre-coated with 
“AKTide-2T” which can be efficiently phosphorylated by Akt1. The detector antibody 
specifically detects the phosphorylated “AKTide-2T”. Particularly, to perform the test, 
the samples 26b, 27a,b, 28a,b and SDS were dissolved in DMSO (note that 26a was 
insoluble in this solvent), and Miltefosine and Perifosine in water. The prepared 
solutions were diluted in Kinase Buffer to a final concentration of 500, 100, 50, 10 and  
1µM. Compounds were added together with constitutive active form of human Akt1 
(25 m units/well), and allowed to phosphorylate the bound substrate following the 
addiction of Mg2+ and ATP. The amount of phosphorylated substrate was measured by 
binding it with horseradish peroxidase conjugate of an anti -phpspho-AKTide-2T 
monoclonal antibody, which then catalyzes the conversion of the chromogenic 
substrate tetra-methylbenzidine from the colourless reduced form to the yellow 
oxidized product, after the addition of the stopping reagent. The absorbance of the 
resulting solution is determined spectrophotometrically at = 450 nm, and it is related 
to Akt1 activity in the tested solution. Staurosporine at the final concentration of 1µM 
was employed as “inhibitor control” as indicated in the assay protocol.   
Each experiment was performed in triplicate.  
2.7.6 Cellular studies 
Compounds preparation. All tested compounds were easily dissolved in 100% DMSO at 
50 mM, while Perifosine was dissolved in H2O at 20 mM. 
Cell culture and cell growth assay. The human ovarian carcinoma IGROV-1 cell line68 
was grown in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C 
in 5% CO2 atmosphere. For cell growth inhibition assays, cells were plated in 12 well -
plates at 10000 cells/cm2 in complete medium. The day after seeding, cells were 
exposed to solvent (DMSO) or to different concentration of the novel compounds for 
72 h. For tests in serum-free medium, the day after seeding complete medium was 
substituted with serum-free medium and the cells were exposed to the compounds. 
Twenty four hours later drug-containing medium was replaced with complete medium. 
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Cells were harvested using trypsin and counted 96 h after seeding by a Coulter 
Counter.  
Each experiment was performed three times. The percentages of inhibition in drug-
treated versus untreated samples are reported in dose-response curves. IC50 




Fluorescent probes to study Akt inhibitor distribution 
3.1 Introduction 
The application of fluorescent probes in biochemistry is of considerable interest 
because it can enable the study of several biological pathways and explain cascades of 
activation/inhibition. With their use, advantages in understanding the protein activity 
in their natural environment, in real-time and in non-invasive fashion, can also be 
reached. This gives insight into the protein physiological behavior allowing to gain 
information about their alterations in pathological contexts, which can be exploited to 
develop therapeutic strategies. 
The phenomenon of fluorescence, first described by Herschel in 1845 for the quinine,69 
starts when a molecule in a singlet electronic ground state (S0) absorbs energy which 
promotes the transition of an electron to an higher energy state (S1). This excited 
electron quickly returns to the previous level through more excited state with 
intermediate energy, as illustrated in the Jabloński diagram (Figure 3.1).  
 
Figure 3.1: Jabloński diagram. 
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If the decay takes place with photon emission produces the fluorescent effect which 
manifests itself with the emission of light having a longer wavelength and lower energy 
than the absorbed radiation. The most striking examples of fluorescence occur when 
the absorbed radiation is in the ultraviolet region of the spectrum, invisible to the 
human eye, and the emitted light is in the visible region. 
In Figure 3.2 a generic absorption/emission spectrum is reported. The maximal 
absorption (max) is related to the energy between the ground state S0 and the higher 
energy level reached by the electron S1. The maximal emission wavelength (em) is 
longer than max, and their difference, demonstrated by Stokes,
70 is therefore called 
“Stokes shift”. This parameter is an index of the applicability of the fluorophores. Small 
Stokes shifts reveal susceptibility to self-quenching via energy transfer, limiting their 
use.71 Other characteristics of the fluorophores are the lifetime of the excited state (), 
that generally have a range from 0.1 to 100 ns and influence the time-resolved 
measurement72 and fluorescence polarization applications,73 the quantum efficiency 
(), which is the ratio of photons fluoresced and absorbed, and the extinction 
coefficient (. 
Fluorophores can be used in many ways, including as labels for biomolecules, enzyme 
substrates or environmental indicators. The choice between a fluorophore or another 
is based on their specific chemical properties, such as reactivity, stability or 
lipophilicity, and photophysical properties, e.g. max, em, and  
 
Figure 3.2: Generic absorption and emission spectra. max, em and Stokes shift are shown. 
 Chapter 3 
59 
As touched on before, Herschel found that the quinine, a natural compound relevant 
for both medicinal and organic chemistry, had fluorescent properties. To date, more 
classes of fluorescent dyes74 have been developed and gathered on the basis of their 
origins and chemical characteristics. The main fluorophores, reported in function of 
their brightness vs the wavelength, are shown in Figure 3.3.  
 
Figure 3.3: Plot of fluorophore brightness ( × ) vs the wavelength of maximum absorption (max) for 
the major classes of fluorophores. The color of the structure indicates its wavelength of maximum 
emission (em). For clarity, only the fluorophoric moiety of some molecules is shown. In evidence quinine 
and NBD, used as fluorophore in this PhD thesis (see below). Taken from Ref.74  
Apart from the quinine, the Nature offers a lot of others fluorophores. Among these, 
aromatic amino acids as phenylalanine, tyrosine and tryptophan have fluorescence 
properties, first described by Weber.75 The latter is the most fluorescent amino acid 
used as index for a variety of processes like protein folding and ligand binding.76 
Also polycyclic aromatics compounds are largely used as fluorescent dyes, as 
naphthalene and pyrene derivatives. In particular, pyrene exhibits a long-lived excited 
state with >100 ns which allows to study protein conformation.77 A small heterocyclic 
fluorophore is the 4-chloro-7-nitro-1,2,3-benzoxadiazole (NBD-Cl).78 When it binds to a 
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primary amine its fluorescent properties are disclosed. This fluorophore can be easily 
conjugated to small molecules, such as sugars79 and exploited in the preparation of 
lipid probes80 and novel kinase substrates.81  
These are just some examples of the main fluorophores known, but there are many 
others. Therefore, elaboration of these core structures could provide numerous others 
probes for assaying biological systems since biochemical and biological pathways 
require ever more sophisticated and tailored probes. 
3.2 Aim of the work 
The possibility of studying with fluorescent probes the intracellular distribution of our 
synthetic inhibitors of the Akt is at the basis of this PhD chapter. This would allow us to 
better understand if the glucuronosyl derivatives enter the cells and, eventually, 
inhibitory properties are applied on the Akt in the cytosol or in the nucleus. 
Fluorescent compounds constitute interesting and powerful tools for drug discovery 
programs and also, as in our case, could be used to explain the action mechanism. 
To this end, the 1-O-octadecanoyl-2-O--D-glucuronopyranosyl-sn-glycerol 27a, which 
resulted the most active Akt inhibitor among the synthesized analogues reported in 
Chapter 2, was selected and functionalized with a fluorescent dye to the free hydroxyl 
group on the glycerol moiety. We decided to use the 7-nitro-1,2,3-benzoxadiazole 
(NBD) fluorescent group since in literature a similar example is reported. Indeed 
Sakaguchi82 used the NBD probe to demonstrate the localization of 
sulfoquinovosylmonoacylglycerols SQMG. 
So, the purpose of this part of PhD project was to synthesize two compounds, 49a and 
49b showed in Figure 3.4, carrying the same fluorophore but attached to the hydroxyl 
group of the glycerol moiety with chains of different length. In this way, we obtained 
two compounds with different polarity related to the compound of interest 27a to 
study its localization. 
 Chapter 3 
61 
 
Figure 3.4: Compound 27a, which resulted the most active Akt inhibitor among the synthesized 
analogues reported in Chapter 2, and derivatives 49a and b with fluorescent probe. 
3.3 Results and discussion  
3.3.1 Synthesis of fluorescent compounds 49a,b 
To prepare the desired products 49a and 49b, the same synthetic scheme was 
planned, which foresees to start from 1-O-octadecanoyl-2-O-(2’,3’,4’,6’-tetra-O-
acetyl-D-glucopyranosyl)-sn-glycerol 40a (Scheme 3.1). To introduce the spacer with 
the amino group, necessary for the following reaction with the NBD-Cl, Boc-amino-
aliphatic acid with two different length were chosen. Specifically, the 6-(Boc-
amino)hexanoic acid 50a or the 11-(Boc-amino)undecanoic acid 50b, were inserted on 
the glycerol moiety of the compound 40a by means of a condensation reaction with 2 
equivalents of N-(3-dimethylaminopropyl)-N’-ethylcarbonimide hydrochloride EDCI 
and 4 eq. of 4-(dimethylamino)pyridine DMAP in dichloromethane 0.1M. Under this 
condition, the reaction proceeded to completion in an hour at room temperature 
under magnetic stirring, affording compound 51a or b with high yield. 
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Scheme 3.1: a) EDCI, DMAP, CH2Cl2 dry, rt, 97-85%; b) Hydrazine hydrate, EtOH aq. 85%, 45°C, 40-46%; c) 
TEMPO, NaClO/NaClO2, CH3CN, 0.67M phosphate buffer (pH 6.7), rt, quantit.; d) TFA, CH2Cl2, rt, quantit.; 
e) NBD-Cl, NaHCO3, CH3CN, H2O, 55°C, 35-43%. 
The following reaction was the hydrazinolysis performed using 5 eq. of hydrazine 
hydrate, which proved to be the best amount of reagent to use obtained from several 
previous attempts, as already discussed in Chapter 2 section 2.3.2, in aqueous ethanol 
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at 45°C, to give 52. The switch from primary hydroxyl group in position 6 of the sugar 
to carboxyl group was accomplished by oxidation performed with TEMPO in 
acetonitrile and buffer sodium phosphate mixture and NaClO/NaClO2 system. The 
product 53 was recovered as pure compound with Et2O extraction and subsequently 
the Boc protection on the nitrogen was easily removed after 30 minutes under 
magnetic stirring with trifluoroacetic acid (10 eq.) in dichloromethane. Finally, the free 
amine 54 was reacted with the NBD chloride reagent to achieve the two fluorescent 
compounds 49a or b. This last reaction was carried out in acetonitrile 0.1M with the 
adding dropwise of the reactive dissolved in acetonitrile (1 eq., 18 mL/mmol) and an 
aqueous NaHCO3 solution (3 eq., 6 mL/mmol), since basic condition is necessary for the 
formation of the product. The reaction mixture was stirring for 1 hour and half at 55°C. 
Afterwards TLC analysis (CH2Cl2/MeOH 85:15) showed the formation of a fluorescent 
spot corresponding to the desired product.  
The fluorescent properties of the two synthesized compounds 49a and b were also 
estimated. The spectra reported in Figure 3.5 show for both the compounds a 
maximum peak of emission at 520 nm with excitation at 432 nm, as expected from the 
literature.74 
 
Figure 3.5: Spectra of emission of compounds 49a and b. With excitation at 432 nm a maximum peak at 
520 nm for both compounds is evident. 
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3.4 Conclusions 
A straightforward synthetic strategy for the achievement of functionalized compounds 
49a and b as derivatives of the glucuronosylacylglicerol inhibitor 27a is presented in 
this chapter. The applied procedure employs the insertion of an amino spacer on the 
glycerol moiety and the following attachment of a fluorescent group. 
The biological evaluation of these two compounds aimed to study their cell localization 
is now underway. The knowledge gained from this work might shed light on their 
action mechanism and eventually suggest some modifications to their structural 
features in order to obtain more ative compounds.  
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3.5 Experimental section 
3.5.1 General methods 
Chemical: All chemicals and solvents were purchased as reagent grade from Sigma–
Aldrich and were used as received, except for CH2Cl2 which was distilled from calcium 
hydride prior to use. Air- and moisture sensitive liquids and solutions were transferred 
via oven-dried syringe. 
All reactions were monitored by TLC analysis carried out on silica gel plate (Merck 
60F254). Flash column chromatography (FCC) was performed on silica gel high-purity 
grade, pore size 60Å, 230-400 mesh particle size (Sigma-Aldrich) or by a Biotage 
IsoleraTM Prime flash purification system (Biotage-Uppsala, Sweden). Evaporation 
under reduced pressure was effected with a bath temperature at 40°C or under strem 
of nitrogen.  
The structures of all the new synthesized compounds were confirmed through full 1H 
and 13C NMR characterization and mass spectroscopy, which confirmed purity and 
identity of all synthesized compounds. 
1H NMR analysis were performed at 500 MHz with a Bruker FT-NMR AVANCE™ DRX500 
spectrometer using a 5 mm z-PFG (pulsed field gradient) broadband reverse probe at 
298 K unless otherwise stated, and 13C NMR spectra at 125.76 MHz were done for all 
the new compounds. Chemical shifts are reported as  (ppm) relative to residual CHCl3 
or CH3OD fixed respectively at 7.26 and 3.30 ppm (higher field signal) for 
1H NMR 
spectra and relative to CDCl3 fixed at 77.0 ppm (central line) and CD3OD at 49.0 ppm 
(central line) for 13C NMR spectra. Integrals are in accordance with assignments and 
coupling constants (J) are given in hertz (Hz). For detailed peak assignments 2D spectra 
were measured (COSY and HSQC). Splitting patterns are described by using the 
following abbreviations: br, broad; s, singlet; d, doublet; t, triplet; m, multiplet; dd, 
doublet of doublet; ddd, doublet of doublet of doublet; td, triplet of doblet; dt, doblet 
of triplet. 
Mass spectra were recorded in negative or positive-ion electrospray (ESI) mode on a 
Thermo Quest Finnigan LCQ DECA™ ion trap mass spectrometer. The mass 
spectrometer was equipped with a Finningan ESI interface. Sample solutions were 
injected with a ionization spray voltage of 4.5 kV or 5.0 kV (positive and negative -ion 
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mode, respectively), a capillary voltage of 32 V or -15 V (positive and negative-ion 
mode, respectively), and capillary temperature of 250 °C. Data were processed by 
Finnigan Xcalibur software system. 
Optical rotations were determined on a Perkin–Elmer 241 polarimeter at 20°C, in a 1 
dm or 1 cm cell. Melting points were recorded on a Büchi 510 capillary melting point 
apparatus and were uncorrected.  
Fluorimeter of final compounds was measured with Luminiscence Spectrometer LS 50B 
(Perkin-Elmer). 
3.5.2 Synthesis of fluorescent compounds 49a,b 
General procedure of the condensation reaction with Boc-amino-aliphatic acid 
1-O-octadecanoyl-2-O-(2’,3’,4’,6’-tetra-O-acetyl-D-glucopyranosyl)-sn-glycerol 40 
was dissolved in dry CH2Cl2 (0.1M). The proper Boc-amino-aliphatic acid (2 eq.), EDCI (4 
eq.) and DMAP (2 eq.) were added and the mixture stirred under Ar atmosphere for 1 
hour (TLC check Hexane/AcOEt 6:4). The reaction was poured into brine solution 
(30ml) and extracted with CH2Cl2 (3×30ml). The organic phase was dried over 
anhydrous Na2SO4, filtered and the solvent was removed in vacuum to afford the crude 
product which was purified by automatic flash chromatography (Hexane/AcOEt 65:35 
to 30:70) giving 51a or b. 
Application of the general procedure to 
40a (787 mg, 1.14 mmol) with 6-(Boc-
amino)hexanoic acid (576 mg, 2.28 
mmol), EDCI (874 mg, 4.56 mmol) and 
DMAP (278 mg, 2.28 mmol) afforded 
compound 1-O-octadecanoyl-3-O-(6-
terbutoxycarbonylamino-hexanoyl)-2-O-(2’,3’,4’,6’-tetra-O-acetyl-D-glucopyranosyl)-
sn-glycerol 51a as a white solid (997 mg, 1.105 mmol, 97% yield).  
Mp: 59.4-61.8°C; 
[] 20D :8.2 (CHCl3, c 1.0); 
1H-NMR (CDCl3): 0.87 (t, 3H, J=7.0 Hz, CH3), 1.22-1.37 (m, 30H, 15 CH2), 1.46 (s, 9H, 
3 CH3), 1.48 (m, 2H, CH2), 1.58-1.67 (m, 4H, 2 CH2), 2.00 (s, 3H, COCH3), 2.02 (s, 3H, 
COCH3), 2.03 (s, 3H, COCH3), 2.08 (s, 3H, COCH3), 2.28-2.35 (m, 4H, 2 CH2), 3.10 (br t, 
2H, CH2N), 3.69 (ddd, 1H, J5’,6’a=2.5 Hz, J5’,6’b=5.0 Hz, J4’,5’=10.0 Hz, H-5’), 4.05 (m, 1H, H-
2), 4.05-4.27 (m, 6H, H-1a, H-1b, H-3a, H-3b, H-6’a and H-6’b), 4.59 (br s, 1H, NH), 4.63 
 Chapter 3 
67 
(d, 1H, J1’,2’=8.0 Hz, H-1’), 4.98 (dd, 1H, J2’,3’=9.6 Hz, H-2’), 5.06 (dd, 1H, J3’,4’=9.6 Hz, H-
4’), 5.19 (dd, 1H, H-3’); 
13C-NMR (CDCl3): 14.1 (CH3), 20.4-21.0 (4 COCH3), 22.7 (CH2), 24.4 (CH2), 24.8 (CH2), 
26.3 (CH2), 28.4 (3 CH3), 29.2-29.7 (13 CH2), 31.9 (CH2), 33.8 (CH2), 34.1 (CH2), 40.0 
(CH2N), 60.4 (C6’), 61.9 (C1), 63.1 (C3), 68.3 (C4’), 71.2 (C2’), 71.9 (C5’), 72.7 (C3’), 75.6 
(C2), 79.0 (C(CH3)3), 100.8 (C1’), 156.0 (COBoc), 169.2, 169.4, 170.2 and 170.6, (4 
COCH3), 173.1 and 173.4 (2 CO);  
ESI-MS (CH3OH, positive-ion mode): m/z 924.5 [M+Na]
+, calcd for C46H79NO16, m/z 
901,54 [M]. 
Application of the general procedure to 
40a (805 mg, 1.168 mmol) with 11-
(Boc-amino)undecanoic acid (704 mg, 
2.336 mmol), EDCI (895 mg, 4.672 
mmol) and DMAP (285 mg, 2.336 
mmol) afforded compound 1-O-
octadecanoyl-3-O-(11-terbutoxycarbonylamino-undecanoyl)-2-O-(2’,3’,4’,6’-tetra-O-
acetyl-D-glucopyranosyl)-sn-glycerol 51b as a white solid (1090 mg, 1.121 mmol, 
96% yield).  
Mp: 83.6-84.2°C; 
[] 20D :5.8 (CHCl3, c 0.6);  
1H-NMR (CDCl3): 0.88 (t, 3H, J=7.0 Hz, CH3), 1.25 (br s, 40H, 20 CH2), 1.44 (s, 9H, 3 
CH3), 1.48 (m, 2H, CH2), 1.54-1.65 (m, 4H, 2 CH2), 2.00 (s, 3H, COCH3), 2.02 (s, 3H, 
COCH3), 2.03 (s, 3H, COCH3), 2.08 (s, 3H, COCH3), 2.31 (td, 4H, J=2.6 Hz, J =7.6, 2 CH2), 
3.09 (br t, 2H, CH2N), 3.69 (ddd, 1H, J5’,6’a=2.5 Hz, J5’,6’b=5.0 Hz, J4’,5’=10.0 Hz, H-5’), 4.05 
(m, 1H, H-2), 4.05-4.27 (m, 6H, H-1a, H-1b, H-3a, H-3b, H-6’a and H-6’b), 4.50 (br s, 1H, 
NH), 4.63 (d, 1H, J1’,2’ = 8.0 Hz, H-1’), 4.98 (dd, 1H, J2’,3’ = 9.6 Hz, H-2’), 5.06 (dd, 1H, J3’,4’ 
= 9.6 Hz, H-4’), 5.19 (dd, 1H, H-3’); 
13C-NMR (CDCl3): 14.1 (CH3), 20.6-20.9 (4 COCH3), 22.7 (CH2), 24.7 (CH2), 24.8 (CH2), 
26.8 (CH2), 28.4 (3 CH3), 29.1-30.0 (18 CH2), 31.9 (CH2), 34.0 (CH2), 34.1 (CH2), 40.6 
(CH2N), 61.9 (C1), 63.0 (C3), 63.1 (C6’), 68.3 (C4’), 71.2 (C2’), 71.9 (C5’), 72.7 (C3’), 75.7 
(C2), 79.0 (C(CH3)3), 100.8 (C1’), 156.0 (COBoc), 169.1 169.4, 170.2 and 170.6, (4 
COCH3), 173.3 (2 CO);  
ESI-MS (CH3OH, positive-ion mode): m/z 999.4 [M+Na]
+, calcd for C51H89NO16, m/z 
971,62 [M]. 
General procedure of hydrazinolisys to give compounds 52a or b 
Compound 51 was dissolved in EtOH 85% (0.1 M) and hydrazine hydrate (5 eq.) was 
added drop by drop. The reaction mixture was left stirring 6 hours at 45°C. Then, the 
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solvent was evaporated under stream of nitrogen and the crude was purified by flash 
chromatography (CH2Cl2/CH3OH 95:5) to yield title compounds. 
Application of the general procedure to 
51a (458 mg, 0.507 mmol) with 




as an oil (171 mg, 0.233 mmol, 46% yield). 
[] 20D :5.9 (CH3OH, c 1.0); 
1H-NMR (CD3OD): 0.89 (t, 3H, J=7.0 Hz, CH3), 1.23-1.36 (m, 30H, 15 CH2), 1.42 (s, 
9H, 3 CH3), 1.47 (m, 2H, CH2), 1.57-1.65 (m, 4H, 2 CH2), 2.35 (td, 4H, J=2.8 Hz, J=7.5 Hz, 
2 CH2), 3.02 (dd, 2H, J=6.9 Hz, J=12.8 Hz, CH2N), 3.16 (dd, 1H, J1’,2’ =8.0 Hz, J2’,3’=9.0 Hz, 
H-2’), 3.26-3.36 (m, 3H, H-3’, H-4’ and H-5’), 3.65 (dd, 1H, J5’,6’a=5.2 Hz, J6’a,6’b=12.0 Hz, 
H-6’a), 3.85 (d, 1H, J6’a,6’b=12.0 Hz, H-6’b), 4.17 (dd, 1H, J1b/3b,2=5.0 Hz, J=10.0 Hz, H-2), 
4.23 (d, 3H, J1b/3b,2=5.0 Hz, H-1a, H-1b, H-3a or H-3b,), 4.28 (dd, 1H, J3a/3b,2=5.0 Hz, 
J3a/3b,1a/1b=11.4 Hz, H-3a or H-3b), 4.41 (d, 1H, J1’,2’=8.0 Hz, H-1’); 
13C-NMR (CD3OD): 14.4 (CH3), 23.7 (CH2), 25.9 (CH2), 26.0 (CH2), 27.3 (CH2), 28.8 (3 
CH3), 30.2-30.8 (13 CH2), 33.1 (CH2), 34.8 (CH2), 34.9 (CH2), 41.2 (CH2N), 62.9 (C6’), 64.3 
(C1), 64.8 (C3), 71.4 (C4’), 75.6 (C2’), 76.1 (C2), 77.5 (C5’), 78.0 (C3’), 79.8 (C(CH3)3), 
104.4 (C1’), 158.5 (COBoc), 175.1 and 175.4 (2 CO); 
ESI-MS (CH3OH, positive-ion mode): m/z 756.4 [M+Na]
+, calcd for C38H71NO12, m/z 
733.49 [M]. 
Application of the general procedure to 
51b (558 mg, 0.576 mmol) with 




glycerol 52b as an oil (185 mg, 0.230 mmol, 40% yield). 
[]
20
D :-8.0 (CH3OH, c 1.0); 
1H-NMR (CD3OD): =0.89 (t, 3H, J=7.0 Hz, CH3), 1.22-1.36 (m, 40H, 20 CH2), 1.42 (s, 9H, 
3 CH3), 1.47 (m, 2H, CH2), 1.56-1.65 (m, 4H, 2 CH2), 2.34 (td, 4H, J=4.4 Hz, J=7.4 Hz, 2 
CH2), 3.01 (t, 2H, J=7.0 Hz, CH2N), 3.17 (dd, 1H, J1’,2’=8.0 Hz, J2’,3’=9.1 Hz, H-2’), 3.25-
3.36 (m, 3H, H-3’, H-4’ and H-5’), 3.65 (dd, 1H, J5’,6’a=4.7 Hz, J6’a,6’b=12.5 Hz, H-6’a), 3.85 
(d, 1H, J6’a,6’b=12.5 Hz, H-6’b), 4.15-4.26 (m, 4H, H-2, H-1a, H-1b, H-3a or H-3b,), 4.29 
(dd, 1H, J3a/3b,2=4.6 Hz, J3a/3b,1a/1b=11.3 Hz, H-3a or H-3b), 4.42 (d, 1H, J1’,2’=8.0 Hz, H-1’); 
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13C-NMR (CD3OD): 14.4 (CH3), 23.7 (CH2), 26.0 (CH2), 27.9 (CH2), 28.8 (3 CH3), 30.2-
30.8 (13 CH2), 33.1 (CH2), 34.9 (CH2), 41.4 (CH2N), 62.9 (C6’), 64.1 (C1), 64.7 (C3), 71.6 
(C4’), 75.0 (C2’), 76.0 (C2), 78.0 (C5’), 78.1 (C3’), 79.7 (C(CH3)3), 104.4 (C1’), 158.5 
(COBoc), 175.2 and 175.3 (2 CO); 
ESI-MS (CH3OH, positive-ion mode): m/z 826.47 [M+Na]
+, calcd for C43H81NO12, m/z 
803.57 [M]. 
General procedure of oxidation to obtain compounds 53a,b  
Compound 52a or b was suspended in a 55:45 mixture of CH3CN and 0.67M phosphate 
sodium buffer at pH 6.7 (0.1 M). TEMPO (0.21 eq.), NaClO2 (20% aqueous solution, 3 
eq.) and NaClO (15% aqueous solution, 0.15 eq.) were added. After stirring overnight 
at room temperature (TLC, CH2Cl2/CH3OH 9:1), the reaction mixture was diluted with 
diethyl ether (10 mL). The organic layer was separated and the aqueous layer was 
extracted again with diethyl ether (2x10 mL). The combined organic extracts were 
dried over Na2SO4, filtered, and the solvent was eliminated under reduced pressure to 
afford the crude product 53a or b with quantitative yield, which were employed in the 
following step without further purification. 
Application of the general procedure to 
52a (155 mg, 0.211 mmol) with TEMPO 
(7 mg, 0.044 mmol), NaClO2 (290 l of 
20% aqueous solution, 0.633 mmol) and 
NaClO (16l of 15% aqueous solution, 
0.032 mmol) afforded compound 1-O-
octadecanoyl-3-O-(6-terbutoxycarbonylamino-hexanoyl)-2-O--D-glucuronopyranosyl-
sn-glycerol 53a as a glass (158 mg, 0.211 mmol, quantitative yield).  
[] 20D :8.9 (CHCl3, c 1.2); 
1H-NMR (CDCl3:CD3OD 9:1): = 0.79 (t, 3H, J=7.0 Hz, CH3), 1.13-1.29 (m, 30H, 15 CH2), 
1.35 (s, 9H, 3 CH3), 1.38-1.41 (m, 2H, CH2), 1.49-1.57 (m, 4H, 2 CH2), 2.26 (m, 4H, 2 
CH2), 2.98 (t, 2H, J=6.9 Hz, CH2N), 3.26 (dd, 1H, J1’,2’=7.9 Hz, J2’,3’=9.0 Hz, H-2’), 3.40 (dd, 
1H, J3’,4’=9.0 Hz, H-3’), 3.56 (dd, 1H, J4’,5’=9.7 Hz, H-4’), 3.71 (1H, d, H-5’), 4.04 (dd, 1H, 
J1b/3b,2=5.0 Hz, J=10.0 Hz, H-2), 4.11 (dd, 1H, J3a/3b,2=5.0 Hz, J3a/3b,1a/1b=11.8 Hz, H-3a or 
H-3b), 4.13-4.18 (m, 2H, H-1a, H1b), 4.19 (dd, 1H, J3a/3b,2=5.0 Hz, J3a/3b,1a/1b=11.8 Hz, H-
3a or H-3b), 4.34 (d, 1H, H-1’); 
13C-NMR (CD3OD): 13.9 (CH3), 20.1 (CH2), 22.5 (CH2), 24.2 (CH2), 24.6 (CH2), 26.0 
(CH2), 28.2 (3 CH3), 29.0-30.1 (12 CH2), 31.7 (CH2), 33.7 (CH2), 33.9 (CH2), 40.1 (CH2N), 
62.8 (C1), 63.4 (C3), 71.1 (C4’), 72.7 (C2’), 74.3 (C2), 77.5 (C5’), 75.7 (C3’), 79.3 
(C(CH3)3), 103.0 (C1’), 156.5 (COBoc), 170.8 (COOH), 173.7 and 174.0 (2 CO); 
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ESI-MS (CH3OH, negative-ion mode): m/z 746.4 [M-1]
-, calcd for C38H69NO13, m/z 
747.47 [M]. 
Application of the general procedure to 
52b (75 mg, 0.093 mmol) with TEMPO (3 
mg, 0.019 mmol), NaClO2 (126 l of 20% 
aqueous solution, 0.279 mmol) and 
NaClO (7l of 15% aqueous solution, 
0.014 mmol) afforded compound 1-O-
octadecanoyl-3-O-(11-terbutoxycarbonylamino-undecanoyl)-2-O--D-
glucuronopyranosyl-sn-glycerol 53b as a glass (76 mg, 0.093 mmol, quantitative yield).  
 [] 20D :8.2 (CHCl3, c 1.8); 
1H-NMR (CD3OD: CDCl3: 6:3): = 0.85 (t, 3H, J=7.0 Hz, CH3), 1.20-1.32 (m, 40H, 20 CH2), 
1.40 (s, 9H, 3 CH3), 1.43-1.48 (m, 2H, CH2), 1.53-1.62 (m, 4H, 2 CH2), 2.31 (m, 4H, 2 
CH2), 3.00 (t, 2H, J=7.0 Hz, CH2N), 3.23 (t, 1H, J1’,2’=7.9 Hz, H-2’), 3.40 (t, 1H, J3’,4’=9.0 
Hz, H-3’), 3.44 (t, 1H, J4’,5’=9.0 Hz, H-4’), 3.55 (1H, d, H-5’), 4.19-4.27 (m, 4H, H-2, H1a, 
H1b, H-3a or H-3b), 4.32 (m, 1H, H-3a or H-3b), 4.42 (d, 1H, H-1’); 
13C-NMR (CD3OD): 14.3 (CH3), 23.3 (CH2), 25.5 (CH2), 27.5 (CH2), 28.7 (3 CH3), 29.8-
30.6 (20 CH2), 32.6 (CH2), 34.7 (CH2), 41.1 (CH2N), 63.6 (C1), 64.3 (C3), 72.9 (C4’), 74.4 
(C2’), 74.6 (C2), 77.1 (C3’), 77.5 (C5’), 79.6 (C(CH3)3), 103.6 (C1’), 157.9 (CONBoc), 
174.9 and 175.0 (2 CO), 175.9 (COOH); 
ESI-MS (CH3OH, negative ion mode): m/z 816.8 [M-1]
-, calcd for C43H79NO13, m/z 817.55 
[M]. 
General procedure of Boc deprotection  
To a solution of compound 53a or b in CH2Cl2 (0.1 M) TFA (10 eq.) was added drop by 
drop. The reaction mixture turn yellow and after 30 minutes the TLC check 
(CH2Cl2/CH3OH 8:2) showed disappearance of the starting material and formation of 
the product. The solvent was evaporated and the crude product 54a or b, which did 
not need further purification, was recovered with quantitative yield. 
Application of the general procedure to 53a (150 
mg, 0.200 mmol) with TFA (154 L, 2.00 mmol) 
afforded compound 1-O-octadecanoyl-3-O-(6-
amino-hexanoyl)-2-O--D-glucuronopyranosyl-sn-
glycerol 54a as a white vax (129 mg, 0.200 mmol, 
quantitative yield).  
[] 20D :1.20 (CH3OH, c 2.8); 
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1H-NMR (CD3OD): =0.88 (t, 3H, J=6.7 Hz, CH3), 1.27 (s, 30H, 15 CH2), 1.37-1.44 (m, 2H, 
CH2), 1.54-1.70 (m, 4H, 2 CH2), 2.36 (dt, 4H, J=7.3 Hz, J=14.7 Hz ,2 CH2), 2.93 (t, 2H, 
J=7.4 Hz, CH2N), 3.22 (t, 1H, J1’,2’=8Hz, H-2’), 3.40 (t, 1H, J3’,4’=9.0 Hz, H-3’), 3.52 (t, 1H, 
J4’,5’=9.0 H-4’), 3.81 (1H, d, H-5’), 4.15 (dd, 1H, J=4.8 Hz, J=9.7 Hz, H-2), 4.18-4.26 (m, 
4H, H-1a, H1b, H-3a and H-3b), 4.50 (d, 1H, H-1’); 
13C-NMR (CD3OD): 14.4 (CH3), 17.8 (CH2), 21.0 (CH2), 23.7 (CH2), 25.2 (CH2), 26.8 
(CH2), 28.1 (CH2), 30.2-30.7 (10 CH2), 33.0 (CH2), 34.5 (CH2), 34.9 (CH2), 40.5 (CH2N), 
64.1 (C1), 63.8 (C3), 64.8 (C2), 73.0 (C4’), 74.6 (C2’), 76.7 (C3’), 77.3 (C5’), 104.5 (C1’), 
172.4 (COOH), 174.9 and 175.3 (2 CO);  
ESI-MS (CH3OH, positive-ion mode): m/z 665.5 [M+18]
+, calcd for C33H61NO11, m/z 
647.42 [M]. 
Application of the general procedure to 53b (70 
mg, 0.085 mmol) with TFA (65 L, 0.85 mmol) 
afforded compound 1-O-octadecanoyl-3-O-(11-
amino-undecanoyl)-2-O--D-
glucuronopyranosyl-sn-glycerol 54b as an oil (61 
mg, 0.085 mmol, quantitative yield).  
[] 20D :1.1 (CH3OH, c 2.0); 
1H-NMR (CD3OD): =0.89 (t, 3H, J=6.9 Hz, CH3), 1.24-1.35 (m, 40H, 20 CH2), 1.54-1.69 
(m, 6H, 3 CH2), 2.34 (q, 4H, J=7.4 Hz, 2 CH2), 2.91 (t, 2H, J=7.6 Hz, CH2N), 3.22 (dd, 1H, 
J1’,2’=7.9 Hz, J2’,3’=9.0 Hz, H-2’), 3.39 (t, 1H, J3’,4’=9.0 Hz, H-3’), 3.50 (t, 1H, J4’,5’=9.0 H-4’), 
3.73 (1H, d, H-5’), 4.17-4.28 (m, 5H, H-1a, H1b, H-3a, H-3b and H-2), 4.47 (d, 1H, H-1’);  
13C-NMR (CD3OD): 14.4 (CH3), 23.7 (CH2), 25.9 (CH2), 26.0 (CH2), 27.4 (CH2), 28.5 
(CH2), 30.1-30.7 (17 CH2), 33.0 (CH2), 34.9 (2CH2), 40.8 (CH2N), 64.1 (C1), 64.7 (C3), 73.2 
(C4’), 74.7 (C2’), 76.4(C2), 76.7(C5’), 77.5 (C3’), 104.4 (C1’), 173.6 (COOH), 175.2 and 
175.3 (2 CO); 
ESI-MS (CH3OH, positive-ion mode): m/z 740.50 [M+23]
+, calcd for C38H71NO11, m/z 
717.50 [M]. 
Synthesis of final compounds 49a and b 
Compound 54a or b was dissolved in acetonitrile (0.1 M) and a solution of NBD-Cl (1.0 
eq.) in acetonitrile (18 mL/mmol) and sodium bicarbonate (3.0 equiv) in water (6 
mL/mmol), were added dropwise. The reaction mixture was stirred at 55 °C for 1 hour 
away from the light. Then acetonitrile was concentrated under reduced pressure, the 
pH was adjusted to ∼2.0 with 10 ml of HCl 0.1 N and the mixture was extracted with 
CH2Cl2 (3x15 mL) The combined organic layers were washed with H 2O, dried over 
Na2SO4 and the solvent was evaporated under vacuum. The crude obtained was 
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purified by flash column cromatography (CH2Cl2/CH3OH 85:15) to afford the final 
compound 49a or b. 
Application of the general procedure to 54a 
(120 mg, 0.185 mmol) with NBD-Cl (37 mg, 
0.185 mmol) and NaHCO3 (47 mg, 0.565 
mmol) afforded compound 1-O-
octadecanoyl-3-O-(6-[(7-nitro-2,1,3-
benzoxadiol-4-yl)amino]-hexanoyl)-2-O--D-
glucuronopyranosyl-sn-glycerol 49a as a 
brown solid (52 mg, 0.065 mmol, 35% yield).  
[] 20D :not measurable; 
1H-NMR (CD3OD): =0.88 (t, 3H, J=7.0 Hz, CH3), 1.23-1.34 (m, 30H, 15 CH2), 1.45-1.53 
(m, 2H, CH2), 1.54-1.64 (m, 2H, CH2), 1.66-1.72 (m, 2H, CH2), 1.76-1.82 (m, 2H, CH2), 
2.33 (t, 2H, J=7.3 Hz, CH2), 2.39 (t, 2H, J=7.3 Hz, CH2N), 3.21 (dd, 1H, J1’,2’=7.8 Hz, 
J2’,3’=9.0 Hz, H-2’), 3.39 (t, 1H, J3’,4’=9.0 Hz, H-3’), 3.45 (t, 1H, J4’,5’=9.0 H-4’), 3.58 (d, 1H, 
H-5’), 4.20-4.26 (m, 4H, H-1a, H1b, H-3a and H-3b), 4.28-4.37 (m, 1H, H-2), 4.45 (d, 1H, 
H-1’), 6.33 (br d, 1H, Ar), 8.53 (br d, 1H, Ar); 
13C-NMR (CD3OD): 14.4 (CH3), 23.7 (CH2), 25.6 (CH2), 25.9 (CH2), 27.5 (CH2), 30.2-
30.8 (10 CH2), 33.1 (CH2), 34.7 (CH2), 34.9 (CH2), 40.6 (CH2N), 64.0 (C1), 64.8 (C3), 73.6 
(C4’), 74.9 (C2’), 75.8 (C2), 76.4 (C5’), 77.7 (C3’), 104.2 (C1’), 174.9 and 175.3 (2 CO);  
ESI-MS (CH3OH, negative-ion mode): m/z 809.6 [M-1]-, calcd for C39H62N4O14, m/z 
810.42 [M]. 
Application of the general procedure to 
54b (50 mg, 0.069 mmol) with NBD-Cl (14 
mg, 0.069 mmol) and NaHCO3 (18 mg, 
0.207 mmol) afforded compound 1-O-
octadecanoyl-3-O-(11-[(7-nitro-2,1,3-
benzoxadiol-4-yl)amino]-undecanoyl)-2-O-
-D-glucuronopyranosyl-sn-glycerol 49b as 
a brown solid (43 mg, 0.049 mmol, 43% 
yield).  
[] 20D :not measurable; 
1H-NMR (CD3OD+20% CDCl3): =0.89 (t, 3H, J=7.0 Hz, CH3), 1.24-1.37 (m, 40H, 20 CH2), 
1.57-1.65 (m, 6H, 3 CH2), 1.79 (dt, 2H, J=7.5 Hz, J=14.9 Hz, CH2), 1.95-2.11 (m, 2H, CH2), 
2.35 (dt, 2H, J=4.7 Hz, J=7.5 Hz, CH2N), 3.26 (t, 1H, J1’,2’=8.0 Hz, H-2’), 3.44 (t, 1H, 
J3’,4’=9.0 Hz, H-3’), 3.48-3.55 (m, 1H, H-4’), 3.63 (t, 1H, J4’,5’=9.0, H-5’), 4.21-4.29 (m, 4H, 
H-1a, H1b, H-3a and H-3b), 4.31-4.38 (m, 1H, H-2), 4.47 (d, 1H, H-1’), 6.32 (d, 1H, J=8.8 
Hz, Ar), 8.53 (d, 1H, J=8.8 Hz, Ar); 
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13C-NMR (CD3OD+20% CDCl3): 14.4 (CH3), 23.5 (CH2), 25.7 (2 CH2), 27.9 (CH2), 28.8 
(CH2), 29.9-30.5 (17 CH2), 32.8 (CH2), 34.8 (2 CH2), 40.6 (CH2N), 63.7 (C1), 64.5 (C3), 
73.2 (C4’), 74.4 (C2’), 75.5 (C2), 75.8 (C5’), 77.3 (C3’), 103.9 (C1’), 174.9 and 175.1 (2 
CO);  
ESI-MS (CH3OH, negative-ion mode): m/z 879.5 [M-1]-, calcd for C44H72N4O14, m/z 















Gold nanoparticles as carriers for fully synthetic 
carbohydrate vaccine candidates against Streptococcus 
pneumoniae  
4.1 Introduction 
Vaccination is a key strategy for the control of many infectious diseases. Although the 
introduction of antibiotics in therapy 50 years ago has slowed down the research in 
this field, today multidrug-resistance and adverse effects have pushed towards new 
strategies to improve the vaccines in use.  
Carbohydrates expressed at pathogen surface, such as capsular polysaccharides of 
many bacteria or the dense array of oligosaccharides of HIV virus, are involved in 
interactions with host cells and play a pivotal role in the immune response, usually 
masking the highly immunogenic protein material and avoiding an effective production 
of specific and functional antibodies. Because polysaccharides are typical T -
independent antigens,83 they are poor immunogens and unable to establish long-term 
immunological memory. In 1931, Avery and Goedel84 have demonstrated that the 
conjugation of the polysaccharide of Streptococcus pneumoniae serotype 3 bacteria to 
an immunogenic protein carrier enhances the immunogenicity of the carbohydrate by 
inducing a T-dependent switch, with the formation of a long-lasting memory response. 
This evidence has opened the way to the concept of conjugate vaccines, which have 
been highly successful in preventing infectious diseases. 85,86 
However, many others features need to be improved. One bottleneck is the natural 
source of the carbohydrate antigens currently used in vaccine preparations. Not all 
bacterial strains can be cultured on sufficient scale and the process of isolation and 
purification from bacterial cultures can be complicated, besides the fact that these 
processes require many checks at different stages raising the cost of the vaccine. 87 In 
the last years, much effort has been devoted to the individuation of the smallest 
saccharide structures able to evoke an immunological response. In this way, thank also 
to the improvements in the synthetic carbohydrate chemistry field, the possibility to 
use synthetic carbohydrate fragments of the corresponding natural antigens have been 
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exploited and well-defined chemical structures lacking of impurities and with less or 
no batch-to-batch variability can be produced.88 Another upside to take into account 
about the use of synthetic oligosaccharides is also the possibility to functionalize their 
reducing end, during the synthesis, with a spacer amenable for the following 
chemoselective conjugation. Consequently, synthetic oligosaccharide-protein 
conjugates vaccines have emerged as an attractive option. In 2004, the first large -scale 
synthesis of the polysaccharide capsular antigen of Haemophilus influenzae type b 
(Hib) was reported by Bencomo et al.89 and the first semi-synthetic carbohydrate 
conjugate vaccine was introduced in Cuba’s national vaccination program. The 
minimum portion of antigen necessary to evoke an immunological response has been 
also found for glycosylphosphatidylinositol (GPI), an important toxin in malaria 
disease. Seeberger90 has proposed the synthesis of GPI glycan fractions, and in 
particular, suggested that a pentasaccharide residue likely represents the minimal 
epitope for naturally elicited anti-GPI antibodies. The synthesis of the minimum 
fraction with immunological activity was reported also for many other human 
pathogens, such as Shigella flexeri 2a,91 Neisseria meningitides A,92,93 Streptococcus 
pneumoniae 6C94 and 14.95 
Many of these natural saccharide antigens are characterized by the presence of labile 
portions in the original structure that can be easily subjected to hydrolysis, e.g. 
phosphate bridges. These capsular polysaccharide require transporting and storing in 
cold conditions due to their limited shelf-life at room temperature. This inconvenient 
has addressed the research toward the generation of new molecular entities related to 
natural structures to be used in the development of glycoconjugates vaccines. 
Examples of synthetic analogues of natural antigen, in which chemical modifications 
improve the chemical stability maintaining the immunological properties unaltered or 
close to corresponding original structure, are reported in the literature for many 
pathogen bacteria, such as Streptococcus pneumoniae 19F96 and Neisseria 
meningitides A.97,98 
Although the use of synthetic glycan antigens may improve many of the discussed 
aspects, no-specific methods are used for the conjugation of the antigens to the 
protein carrier introducing heterogeneity in the resulting glycoconjugates, which can 
show diverse pharmacokinetic and immunological properties due to different 
glycan/protein ratios and glycosylation sites.85 Another main concern to solve about 
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glycoconjugate vaccines is the risk of carrier-induced epitope suppression. For this 
reason, the search for new carriers that may overcome the hurdles encountered with 
the use of proteins is object of intense research.  
Among the different strategies, nanoparticulate systems have attracted very interest 
because they could offer advantages over proteins as vaccine carriers. 99 One of the 
most important aspects is their small size, which allows administration through several 
routes and influences the uptake by antigen presenting cells (APCs), but above all what 
is important is the possibility to insert, in the same nanostructure, different antigenic 
components which may increase the efficacy of the vaccine candidate. Thus, 
nanostructures can be used to more effectively manipulate or deliver immunologically 
active components and successful applications of nanotechnology in the field of 
immunology could enable the generations of new vaccines.100 In addition, the 
assembly of more units of carbohydrate antigens in the same scaffold leads to the 
generation of glycoclusters with high-avidity interactions for the receptor involved in 
the immunological response.101 In fact, it is well-known that carbohydrate-
carbohydrate102 and carbohydrate-protein interactions,103,104 are weakly and of low 
affinity. To overcome these drawbacks, carbohydrates are generally aggregated in 
nature into higher-order oligomeric structures. This so-called "cluster glycoside effect" 
noted by Lee and co-workers in 1995,103 has inspired the design of different 
multivalent systems, in which, as effect of the phenomenon of multivalency, the 
overall binding can be much stronger than the combination of the individual binding 
events.105  
In the last years, various strategies have been used to translate this knowledge to the 
preparation and design of synthetic multivalent systems that could be used as delivery 
systems in the vaccinology field. This is reflected in the development of different 
structures, such as glycoliposomes,106 glycopolymers,107 glycopeptides and 
glycoproteins,108 glycocalixarene,109 glycodentrimers,110 glycocyclodextrines,111 
glycofullerenes112 and glyconanoparticles.113 These multivalent model systems, thanks 
to their ability to mimic the natural presentation of biomolecules, are starting to 
emerge as potential vaccines able to evoke an immune response higher than the one 
of the polysaccharide antigens used in classical vaccination. Also, it has been observ ed 
that the degree of carbohydrates loading influence the immunogenicity of the 
vaccine.114  
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Several examples of conjugation of synthetic repeating units of natural polysaccharide 
antigens to nanoplatforms have been developed with the aim to conceive fully 
synthetic carbohydrate vaccines. For instance, a liposome-based vaccine exposing 
carbohydrate epitopes has been developed against Shigella flexneri serotype 2a 
(SF2a).115 In particular, glycoliposomes carrying at their surface a T cell epitope peptide 
and synthetic repeating units of O-specific polysaccharide moiety of Shigella flexneri 
have been prepared, and the synthetic system has induced a specific, long lasting and 
protective immune response against SF2a in mice. Recently, a liposome-based 
oligosaccharide system has been developed as vaccine against Streptococcus 
pneumoniae serotype 14.116 Liposomes carrying a single repeating unit of the antigen 
and a glycosylceramide as a stimulator of Natural Killer T cells (NKT), essential for class 
switching and affinity maturation, have shown ability to generate high titers of IgG 
antibodies and memory responses against S. pneumoniae. 
Many studies are underway to develop anti-cancer vaccine using Tumor-Associate 
Carbohydrate Antigens (TACAs), expressed in abnormal amounts and with unique 
structural modifications on the surface of cancer cells. TACAs have been extensively 
used as markers for cancer detection and disease progression.  Boons117 has developed 
a three components vaccine, able to elicit in mice high titers of IgG antibody in which 
Tn antigen (Gal-NAc-O-Ser/Thr, TACAs) is carried by liposomes together with a TLR2 
agonist and a T-helper epitope. Another system used as carrier for synthetic 
carbohydrate anti-cancer antigens is based on bacteriophage Q.118 Alo in this case the 
high local density of the Tn antigen on the carrier was found to be crucial for induction 
of Tn-specific IgG titers.  
Also the envelope glycoprotein gp120 of HIV virus was targeted in a study on the 
research of a vaccine against the virus. The high mannose-type oligosaccharides have 
been individuated as a target to develop carbohydrate-based vaccines against the HIV 
virus due to their ability to bind the broadly neutralizing 2G12 antibody. Synthetic 
analogues of the natural undecasaccharide were synthesized and conjugated to 
different carriers in order to explore the possibility to prepare synthetic multivalent 
HIV vaccines that may elicit a 2G12-like antibody response. The group of Wang 
assembled oligomannose clusters on a cholic acid119 and on a D-galactose120 scaffold, 
whereas Danishefsky’s group constructed oligomannose motifs on cyclic peptide 
scaffolds.121 Others nanostructures as a dendrons122 or icosahedral virus capsides123 
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were evaluated as potential carriers for a fully synthetic vaccine anti-HIV. However, 
although these systems were able to induce a carbohydrate-specific immune response 
in animals, the IgG antibodies were unable to bind to gp120 or to neutralize the virus. 
All these examples are a clear demonstration of how nanotechonology-based 
approaches can be used as an alternative to conventional protein carrier vaccine. 
In the context of nanotechnology, gold nanoparticles represent a useful carrier for 
synthetic vaccines. Gold nanoparticles coated with carbohydrate molecules have been 
extensively evaluated as potential multivalents systems for carbohydrate antigens.113 
The first synthesis of gold nanoparticles coated with suitably functionalized 
carbohydrates, named glyconanoparticles (GNPs), was developed in 2001 by Penadés 
and co-workers124 to study carbohydrate-mediated interactions (Figure 4.1).  
 
Figure 4.1: General scheme of gold glyconanoparticles (GNPs). GNPs consist of an inorganic core of 
nanometric size which is functionalized with suitably-derivatized carbohydrates together with othesr 
different ligands. 
The in situ reduction of chloroauric acid (HAuCl4) in the presence of carbohydrate 
ligands bearing a thiol-ending group allows the formation of stable and water soluble 
gold GNPs. An advantage of this synthetic procedure is that the organic 
materials/Au(III) ratio allows to control the growth of the gold nanoclusters to give an 
average gold diameter ranging from 1 to 10 nm. In comparison with other multivalent 
systems above cited, gold glyconanoparticles offer some benefits. Chemically defined 
composition and globular shape with an exceptionally small core size are their main 
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characteristics.124, 125 They are known for their inertness and for their ease preparation 
and purification. The carbohydrate coating provides stability and dispersibility in 
biological media, biocompatibility and non-cytotoxicity.113 As multivalent systems, they 
can display large number of molecules on a reduced surface. Furthermore the 
insertion on the gold surface of several ligands in a controlled way,126, 127 and their 
presentation can be modulated by the proper choice of linkers with a different degree 
of rigidity and flexibility.128 
Thus, gold glyconanoparticles have been designed and evaluated as carriers to improve 
classical vaccination, with the attempt to develop fully synthetic carbohydrate-based 
vaccine. The first example of GNPs used as carriers for tumoral antigens (Tumor 
Associate Carbohydrate Antigens, TACA) was reported by Penadés.126 Gold 
nanoparticles bearing various proportions of the mucine-associated sTn antigen 
(Neu5Ac2-6GalNAc-O-Ser/Thr) expressed on a variety of epithelial cancer cells, the 
Lewisy antigen, able to elicit antibodies against some types of carcinomas, a peptide 
from tetanus toxoid as T cell helper, and glucose as inert component to control the 
density of the other components were designed and prepared as a platform for 
potential anticancer vaccines.  
Another potential anticancer vaccine based on glyconanotechnology, containing a 
TACA supported on Au-NPs, has been designed by Barchi and co-workers.129,130 They 
have reported the preparation of a three-component vaccine related to Thomsen 
Friedenreich disaccharide TF (Gal1-3GalNAc-O-Ser/Thr) as potential antigen, that is 
present in about 90% of carcinomas but is rarely expressed in normal tissue. A 28-
residue peptide from the complement derived protein C3d as molecular adjuvant to 
induce B-cells activation and a thiol-ending spacer to modulate the ratio of the ligands 
to the gold surface were also attached on the nanoparticles. Biological tests have 
shown that these GNPs have been able to induce an immunological response in mice.  
Gold nanoparticles coated with analogues of the capsular polysaccharide of Neisseria 
meningitidis type A (MenA) were proposed by Scrimin131 ELISA test of these 
nanoparticles showed a very strong binding to polyclonal human antibodies against 
MenA. Factors that affect the T cell response, such as the numbers of repeating units 
of antigen arranged on the gold surface or the size of glyconanoparticles, are also 
reported.132 
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Recently, the group of Penadés developed gold nanoparticles bearing selected 
fragments of capsular polysaccharide antigens which have been evaluated as potential 
carriers for fully synthetic carbohydrate-based vaccines against S. pneumoniae 
serotype 14 (Figure 4.2).133 
Specifically, GNPs carrying the synthetic branched tetrasaccharide repeating unit of 
serotype 14, [Pn14, β-D-galactopyranosyl-(1→4)-β-D-glucopyranosyl-(1→6)-[β-D-
glucopyranosyl-(1→4)]-2-acetamido-2-deoxy-D-glucopyranoside, Figure 4.2b], 
identified as the smallest structure necessary to evoke an immunological response, 95 
were studied. Gold glyconanoparticles with tetrasaccharide Pn14 together with D-
glucose, used to aid water solubility and to modify the antigen density and the T-
helper ovalbumin 323-339 peptide (OVA323-339), prerequisite for the induction of IgG 
against the tetrasaccharide, in a 45:50:5 molar ratio were prepared. They resulted able 
to induce specific IgG antibodies against native capsular polysaccharide  Pn14 and sera 
obtained from mice immunized with this GNP were able to opsonize S. pneumoniae 
type 14 bacteria in an opsonophagocytosis assay.  
 
Figure 4.2: (a) Streptoccocus pneumoniae capsular polysaccharide serotype 14 β-D-galactopyranosyl-
(1→4)-β-D-glucopyranosyl-(1→6)-[β-D-glucopyranosyl-(1→4)]-2-acetamido-2-deoxy-D-glucopyranoside; 
(b) synthetic branched tetrasaccharide repeating unit resulted able to elicit IgG in vivo; (c) 
glyconanoparticle bearing the Streptoccocus pneumoniae serotype 14, glucose and OVA peptide in a 
45:50:5 molar ratio able to invoke an immunological response.133 
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Infections from Streptococcus pneumoniae are still a global health concern, and for 
this reason they are target of many studies. Even though there are vaccines against 
this bacterium, it is estimated that 1.6 million people die from this infection every 
year, of whom one million are children.134,135 So, nowadays the research towards a 
better vaccine is still open.  
S. pneumoniae belongs to the class of encapsulated bacteria that present coats of 
saccharides involved in the interaction with cell and protein, including antibodies. It is 
the causative agent of a variety of diseases, as bacterial sepsis, pneumonia, meningitis 
and otitis particularly affecting the elderly and the children.  To date, 93 capsular 
serotypes have been identified, with different structures and immunogenicity, 136 
whereof 23 are components of the first polysaccharide vaccine against S. pneumoniae 
currently available, the PneumoVax, launched in 1983. Unfortunately, PneumoVax 
resulted poorly immunogenic in children, elderly and immunocompromised people and 
in adults gives only a partial protection without the generation of immunological 
memory. This clinical limitation is attributed to the nature of carbohydrates, typically 
known as T-independent antigens. Following the introduction of the concept of 
“glycoconjugate vaccine”, Prevnar, a new vaccine containing seven of the most 
virulence polysaccharides capsular antigens, conjugated to the non-toxic cross reactive 
material from diphtheria toxic CRM197 protein, has been licensed in 2000. Today, 
Prevnar 13, with more antigens, is in use against this bacterium, and other  
formulations are in development.  
However, Prevenar 13 is expensive,137 poorly thermostable,138 with limited 
immunogenicity and it shows a variable level of protection in different individuals and 
ethnic groups. These limitations and the promising results reported by the group of 
Penadés on the use of gold nanoparticles as carrier for saccharide antigens related to 
Streptococcus pneumoniae serotype 14, prompted us to further explore this 
construction also with other serotype of saccharide antigens of the bacterium, in order 
to verify if this strategy could protect against a wider range of S. pneumoniae 
serotypes. 
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4.2 Aim of the work 
This part of PhD project was directed to the preparation of a new type of gold 
nanoparticles covered with the antigenic determinant of Streptococcus pneumoniae 
serotype 19F, which is another among the most virulence factor of the bacterium, 
alone or together with the one of serotype 14. This strategy will allow an additional 
validation of gold nanoparticles as carriers for saccharide antigens and the 
development of new multiantigenic system, mimicking the commercial multiantigenic 
conjugate vaccines. 
Thus, inspired by the results reported in a previous investigation of Penadés group, 
new gold nanoparticles have been prepared (Figure 4.3). Firstly, GNPs carrying the 
trisaccharide repeating unit of the Streptococcus pneumoniae serotype 19F antigen 
[Pn19F PS, 2-acetamido-2-deoxy β-D-mannopyranosyl-(1→4)-α-D-glucopyranosyl-
(1→2)-α-L-rhamnopyranoside] were prepared in order to demonstrate that the activity 
of this kind of constructions can be generalized and it is not limited to serotype 14. 
Beyond this first aim, we also investigated on the necessity of the presence of glucose 
on the glyconanoparticles, generally used to aid water solubility and modify antigen 
density. In other words, if the absence of this sugar does not modify the stability and 
dispersibility of the system, it would be possible to remove glucose and increase the 
amount of antigen carried by the gold nanoparticles for achieving a better immune 
response together with the possibility of administrating a lower amount of vaccine. To 
test this, we prepared GNPs coated only with trisaccharide Pn19F and OVA peptide.  
Finally, we prepared a third type of GNPs coated with both saccharide antigen 
serotypes 19F and 14 to develop new “multiantigenic” gold nanoparticles  displaying 
different carbohydrate antigens on a single nanoparticle. In this way, we can 
investigate if gold nanoparticles with capsular polysaccharide antigen fragments of 
different serotypes of a single bacterium have the potential to mimick the effect of 
commercial multiantigenic conjugate vaccines. 
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Figure 4.3: Schematic representation of gold glyconanoparticles (GNPs) carrying saccharide antigens 
related to Streptococcus pneumoniae proposed in this thesis. The trisaccharide related to serotype 19F 
55 alone or together with tetrasaccharide related to serotype 14 56, functionalized with long thiol linker, 
as active component in combination with glucose 57, functionalized with a short thiol linker used as inner 
component, and OVA peptide 58 used as T-helper, in various molar ratio, were linked on the gold 
surface. 
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4.3 Results and discussion 
During the six months period of my PhD spent in the Laboratory of 
GlycoNanotechnology of Prof. Penadés, I have prepared different gold 
glyconanoparticles with the aim to develop fully synthetic carbohydrate-based vaccine 
against Streptococcus pneumoniae. In particular, the objective has been to assess the 
possibility to employ GNPs as carriers of multivalent antigenic systems able to evoke 
an immune response.  
To prepare the GNPs, the first step has been the synthesis of the thiol ending ligands 
that have to be linked on the gold nanocluster surface, exploiting the well-known 
affinity of sulfur for gold,139 i.e. the saccharide antigen, glucose and OVA peptide.  
The choice of the linker used to attach the neoglycoconjugates to the gold 
nanoparticles is very important. In fact, the nature, the length and the flexibility of the 
spacers are key factors in controlling the presentation of ligands and their behavior in 
the molecular recognition process.113,128 As for the tetrasaccharide related to Pn14, the 
trisaccharide repeating unit of serotype 19F antigen was conveniently functionalized 
with a long thiol linker, the 23-mercapto-3,6,9,12-tetraoxatricosyl isothiocyanate, 
characterized by an aliphatic portion of eleven carbon atoms, that confers rigidity to 
the inner organic shell to protect the gold core, and a hydrophilic portion of 
tetraethylenglycol, which provides flexibility to the glycans on the GNPs.  
On the other hand, -D-glucose, used to confer solubility to the gold nanoparticles and 
to modify the concentration of the active components, was functionalized with a short 
linker of five carbon atoms. This allows the saccharide antigens, the Pn19F and Pn14, 
to protrude above the gold surface with respect to the glucose.  
Finally, the T-helper ovalbumin 323-339 peptide (OVA323-339), was inserted on the 
GNPs, since it was already demonstrated that its presence, in the minimum quantity of 
5%, is essential to induce the generation of IgG against the native polysaccharide of S. 
pneumoniae.133 To allow the binding of OVA peptide to the gold surface of the 
glyconanoparticles, an additional glycine and mercapto-propionic acid linker at the N-
terminus were added. 
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4.3.1 Synthesis of Thiol-Ending Ligands  
Thiol-ending Pn19F Trisaccharide: 
Regarding the Streptococcus pneumoniae 19F antigen used in the preparation on the 
GNPs, we have decided to use the trisaccharide repeating unit 59 with an aminopropyl 
linker at the reducing end necessary for the functionalization with the long thiol -
ending linker (Figure 4.4). Indeed, it was demonstrated that the single trisaccharide 59 
and the natural repeating unit 60 have comparable inhibitory activity in a classical 
competitive ELISA assay in the binding between the 19F polysaccharide and the ant i-
19F human polyclonal antibody (Ref.96 and unpublished data).  
These data justify our idea to use the single repeating unit 59, synthesized starting 
from the protected repeating unit 61 which was obtained following a well-established 
and reproducible synthetic route developed in our research group (Scheme 4.1).140 
 
Figure 4.4: Trisaccharide related to Pn19F PS with amino-linker 59 and natural trisaccharide related to 
Pn19F PS, 2-acetamido-2-deoxy β-D-mannopyranosyl-(1→4)-α-D-glucopyranosyl-(1→2)-α-L-
rhamnopyranoside-(1-OPO4H
-) 60. 
Briefly, a glycosylation reaction was performed between the acceptor disaccharide 62 
and the glucose donor 63, with the neighbouring group partecipation of the acetate in 
position 2 chosen to obtain only the beta anomer of the trisaccharide 64. With a 
Zemplén reaction, the acetate protecting group was easily removed and replaced with 
the imidazolyl sulfate to give 66. The following substitution with an azido nucleophile 
invert the configuration from glucose to mannose and the reduction and in situ 
acetylation of compound 67 gave the desired fully protected repeating unit of S. 
pneumoniae serotype 19F 61. 
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Scheme 4.1: a) TESOTf, CH2Cl2 dry, -20°C, 75%; b) CH3ONa, CH3OH, rt, 95%; c) NaH, sulfonyldiimidazole, 
DMF, -40°C, 85%; d) NaN3, DMF, 80°C, 70%; e) Zn, THF/Ac2O/AcOH, rt, 70%. 
Then, the protected repeating unit 61 was submitted to further derivatization and 
specifically allyl protective group was removed to obtain 68, while the following 
functionalization of the free hydroxyl group with the trichloroacetimidate,  an excellent 
leaving group, gave donor 69 for the next step (Scheme 4.2). 
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Scheme 4.2: a).I step Ir catalyst, THF dry; II step I2, THF/H2O 4:1, rt, 90%; b) Cl3CCN, CH2Cl2 dry, rt, 90%. 
The repeating unit of Pn19F was then coupled with N-(benzyloxycarbonyl)-3-
amminopropyl-carbamate as the acceptor N-protected spacer 70 (Scheme 4.3). 
Starting from donor 69 the glycosidation reaction was carried out in dry 
dichloromethane at 0°C using trimethylsilyl triflate (TMSOTf) as acid promoter and 
molecular sieves. The reaction was not selective and the glycosidation product 71 was 
obtained as a alpha/beta mixture. Initially, we decided to go on in the work using the 
alpha/beta mixture, because previous investigations (unpublished data), showed that 
the two diasteroisomers have a comparable activity in an ELISA test. Later, we decided 
to separate the mixture to prepare also GNPs coated only with the natural alpha 
anomer. The separation of the anomeric mixture was performed at this stage through 
a preparative TLC using the system hexane/ethyl acetate 1:1 as eluent. Then, the 
following reactions have been carried out both on the alpha/beta mixture and only on 
the alpha anomer.  
Compound 71 was submitted to hydrogenolysis with palladium hydroxide on activated 
charcoal using as solvent a mixture of ethyl acetate/methanol/water with an 
additional amount (1 eq.) of HCl 0,1M in water. All the benzyl groups were removed 
and product 72, isolated as the chloride salt, was used to perform the coupling 
reaction with 23-mercapto-3,6,9,12-tetraoxatricosyl isothiocyanate 73. Also in this 
case a mixture of solvents, in particular water/isopropanol/acetonitrile 1:1:1, was 
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necessary to dissolve both the saccharide and the linker, and the pH was set to basic 
by addition of triethylamine. Evaporation of the solvents and trituration of the crude 
product with diethyl ether until complete removal of the unreacted linker gave the 
pure thioacetyl derivatives 74. Finally, Zémplen transesterification, with sodium 
methoxide in methanol and purification on Sephadex LH-20 provided the suitably 
functionalized trisaccharide conjugate 55 (Scheme 4.3).  
 
 
Scheme 4.3: a) TMSOTf, m.s. 4Å, CH2Cl2 dry, 0°C, 90%; b) Pd(OH)2, H2, AcOEt/CH3OH/H2O 1:1:1. HCl 0.1M, 
rt, quant.; c) H2O/iPrOH/CH3CN 1:1:1, TEA 0.05M, rt, 75%; d) CH3ONa, CH3OH, rt, 90%. 
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Glucose thiol-ending 
The 5-(Thio)pentyl β-D-glucopyranoside, chosen to assist the water dispersibility and 
biocompatibility of the GNPs, was synthesized following a reported procedure. 127 
Briefly, the commercially available glucose pentacetate 75, was glycosidated with 4-
penten-1-ol 76 under Fisher conditions to give 77, followed by free radical mediated 
tioacetilation with thioacetic acid. Compound 78 was finally converted with a Zémplen 
reaction in the desired derivative 57 in good overall yields (Scheme 4.4). 
 
Scheme 4.4: a) BF3·Et2O, CH2Cl2 dry, rt; b) CH3COSH, AIBN, THF, reflux, c) CH3ONa, CH3OH, Ar, rt. 
OVA323-339 peptide T-helper 
The presence of the OVA323-339 peptide, as a T-helper, has been shown to be essential 
for the induction of an antibody response to the antigen. So, it has been used in the 
minimal amount required (5%) also in the preparation of GNPs with the Pn19F as 
antigen. The OVA323-339 peptide 58 (Figure 4.5) with an additional glycine and 
mercapto-propionic acid linker at the N-terminus HS(CH2)2C(O)GISQAVHAAHAEINEAGR 
was obtained from GenScript Corp (Piscataway, NJ, USA).  
 
Figure 4.5: T-helper OVA323-339 peptide structure with an additional glycine and mercapto-propionic acid 
linker at the N-terminus 58. 
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4.3.2 Preparation of glyconanoparticles  
Having in hand all the components with the thiol-ending function, the next step has 
been the GNPs preparation. In this PhD thesis, the so-called direct in situ formation of 
glyconanoparticles based on a modification of Brust’s method141 and developed by the 
group of Penadés127 was used (Figure 4.6). The protocol consists in treating a water 
solution of a Au(III) salt with sodium borohydride as reductive agent in the presence of 
an excess of the thiol-ending glycoconjugates in order to assure full coverage of the 
GNP surface. The reducing agent was used with the double role to reduce the gold to 
Au(0) and keep the thiols in their reduced state for binding to the gold. Moreover, the 
use of direct method allows to obtain nanoparticles incorporating different ligands in 
various proportions on the gold surface.  
 
Figure 4.6: Schematic representation of the GNPs formation with the direct method. 
In detail, the first step required for the preparation of the GNPs is to make a mixture of 
the thiol-ending compounds that have to be linked on the gold surface of the nascent 
GNP in the desired proportion. To confirm the ligands ratio, 1H NMR spectrum was 
registered before performing the reaction. Then, to a methanolic solution of the 
mixture of thiol-ending conjugates (5 equiv.), was added an aqueous solution of 
tetrachloroauric acid (HAuCl4, 1 equiv.). The resulting mixture was reduced with 
sodium borohydride (NaBH4, 27 equiv.) and the suspension was vigorously shaken for 2 
hours. GNPs achieved in this way were purified for centrifugal filtering using a mixture 
of water/methanol and then by dialysis. Freeze-drying gave GNPs as a dark solid which 
can be stored at 4°C for months and redissolved in water prior to use.  By this 
methodology, GNPs bearing different amounts of the trisaccharide repeating unit 
related to 19F Streptococcus pneumoniae, alone or together with the tetrasaccharide 
of the serotype 14, were prepared and described in detail below. 
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The starting aim of this work has been to prepare and test new GNPs, analogue to the 
ones with 45:50:5 molar ratio of Pn14, glucose and OVAp, which gave the best 
immunogenic response in a previous work,133 but bearing a different saccharide 
antigen, i.e. the trisaccharide repeating thiol ending unit 55 related to 19F 
Streptococcus pneumoniae. In this way, we could compare the two systems and extend 
the knowledge on the properties of GNPs as potential carriers of different antigens.  
So, GNPs 79, showed in Figure 4.7, were prepared by mixing trisaccharide 55, glucose 






Figure 4.7: Preparation of GNPs 79 composed of Pn19F 55, glucose 57 and OVAp 58 in 45:50:5 molar 
ratio. The percentage is referred to the ligand ratio in the starting mixture, which is maintained in the 
mixture after the nanoparticle formation. 
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The second purpose of this work has been to investigate the role of glucose in the 
behavior of gold nanoparticles. If the absence of this sugar does not modify the 
stability and dispersibility of the resulting system, the glucose can be removed and this 
can allow to increase the amount of the active component, the trisaccharide, carried 
by the GNPs. So, this prompted the preparation of glyconanoparticle 80 coated only by 
the repeating unit related to Pn19F 55 and OVA peptide 58 T-helper in 95:5 molar ratio 




Figure 4.8: Preparation of GNPs 80 composed of Pn19F 55 and OVAp 58 in 95:5 molar ratio. The 
percentage is referred to the ligand ratio in the starting mixture, which is maintained in the mixture a fter 
the nanoparticle formation. 
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Another idea in the last part of this work was to develop new "multiantigenic GNPs", 
coated with serotype 14 and serotype 19F of S. pneumoniae antigens both arranged in 
the same Au-nanoparticles. The GNPs 81 with a 40:40:15:5 molar ratio of the thiol-
ending trisaccaride 19F 55, the thiol-ending tetrasaccharide 14 56, the -D-glucose 57 
and OVA peptide 58 were prepared according to the standard methodology (Figure 
4.9). This molar ratio maintains the percentage of each active component, e.g. the two 
carbohydrate antigens Pn14 and Pn19F, close to the one used in the GNP loaded with 
only one antigen. To do this, the quantity of D-glucose has been reduced from 50% to 
15%, approximately. Indeed, an advantage of the direct method used to prepare all the 
GNPs of this work, is the possibility to modify the density of derivatives attached on 
the gold surface in a controlled way. To decrease the percentage of one component, in 
this case glucose, another component can be introduced, the tetrasaccharide. 125 
 
 
Figure 4.9: Preparation of GNPs 81 composed of Pn19F 55, Pn14 56, glucose 57 and OVAp 58 with the 
molar ratio of 40:40:15:5. The percentage is referred to the ligand ratio in the starting mixture, which is 
maintained in the mixture after the nanoparticle formation. 
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Finally, glyconanoparticle 82 with a molar ratio of ligands of 45:50:5 were also 
prepared using only the alpha anomer of the trisaccharide repeating unit 55 of Pn19F,  




Figure 4.10: Preparation of GNPs 82 composed of alfa anomer Pn19F 55a, glucose 57 and OVAp 58 in 
45:50:5 molar ratio. The percentage is referred to the ligand ratio in the starting mixture, which is 
maintained in the mixture after the nanoparticle formation. 
 
The amount, the molar ratio of ligands and the structure of the GNPs prepared are 
summarised in Table 4.1. 








Thiol-ending ligands Structure 
79 992 Pn19F/Glc/OVAp 
45:50:5 
 
80 808 Pn19F/OVAp 
95:5 
 
81 1130 Pn19F/Pn14/Glc/OVAp 
40:40:15:5 
 




Table 4.1: Gold GNPs prepared in this PhD project functionalized with thiol-ending repeating units of 
Streptococcus pneumoniae Pn19F 55 and Pn14 56, -D-glucose 57 and OVA peptide T helper 58. 
*The total amount of GNP produced and summarized in this table, has been achieved repeating more 
times the reaction procedure reported in the experimental. 
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4.3.3 Characterization of of glyconanoparticles 
In order to characterize the prepared glyconanoparticles different techniques were 
used, such as Transmission Electron Microscopy (TEM), Ultraviolet-Visible (UV/Vis), 
Circular Dichroism (CD), and Nuclear Magnetic Resonance (NMR).  
All GNPs were found to be water-soluble and stable under physiological conditions 
without flocculation. They showed an exceptionally small core with an average 
diameter of 1.2 nm, as demonstrated by Transmission Electron Microscopy (TEM) 
examination. In addition, TEM micrographs showed uniform dispersion of the GNPs 
and no aggregation was evident. Based on the gold core size (determined by TEM 
analysis) and Murray’s table,142 an average molecular formula and the corresponding 
molecular weights were estimated.  
 
Figure 4.11: As example, the characterization of glyconanoparticles 79 (Pn19F/Glc/OVAp 45:50:5) was 
herein reported. a) TEM micrograph in H2O; b) size-distribution histogram obtained by measuring around 
400 nanoparticles; c) UV/Vis spectrum obtained with concentration 0.10 mg/ml in H2O; d) CD spectrum 
obtained with concentration 0.25 mg/ml in H2O. 
For the characterization of the others GNPs see experimental section. 
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Also the Ultraviolet-visible (UV/Vis) spectra can give an indication of the GNPs 
dimensions. Small GNPs with a diameter below 2 nm do not show the plasmon 
absorption band around at 520 nm.143 In our case, the registered UV/Vis spectra never 
showed a surface plasmon band, which is a further confirmation of the small size of 
the GNPs. 
The Circular Dichroism (CD) spectroscopy measures differences in the absorption of 
the polarized light and it is routinely used to study chiral molecules. Generally, metallic 
nanoparticles are achiral, but the conjugation with biomolecules can impart chirality 
and create a plasmon-induced CD signal in the visible spectral region.144 The absence 
of regular structure results in zero CD intensity, while an ordered structure gives a 
spectrum which could contain both positive and negative signals. All the GNPs 
prepared were analyzed by CD but none of them showed a signal in the spectrum 
despite the presence of the sugar on the gold surface (Figure 4.11). 
The 1H NMR spectra of GNPs generally features broader peaks compared to those of 
the corresponding free ligands. Furthermore, the comparison of the 1H NMR spectrum 
of the starting mixture with the unreacted collected fractions after cluster formation 
can give a good qualitative indication about the ratio of the different ligands attached 
on the GNPs. This is usefull to confirm that the ratio of the ligands covering 
nanoparticles is the same as in the initial mixture used to prepare GNPs. All the 
prepared GNPs were controlled with NMR analyses, which confirmed the expected 
molar ratio of the ligands (Figure 4.12). 
Additionally, the active component loaded on GNPs was also evaluated by quantitative 
NMR (1H qNMR): 20 L of D2O containing 0.05 wt. % of 3-(trimethylsilyl) propionic-
2,2,3,3-d4 acid, sodium salt (TSP-d4) as an internal standard was added to a known 
quantity of GNPs dissolved in 180 L of D2O. The amount of saccharide attached to 
nanoparticles was determined by comparison of the integral of the broad signal of 
selected regions of the spectrum with the singlet of the internal standard.145 After the 
analysis, the TSP can be removed by dialysis, so this no-destructive approach can be 
easily used to know the moles of ligands per mg of GNP.  
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Figure 4.12: a) 1H NMR (500 MHz, D2O) of GNP 79 (c) 
1H NMR (500 MHz, CD3OD:D2O 5:1) of the mixture 
used to prepare GNP 79 and (b) 
1
H NMR of the mixture after the preparation of the GNP. Integration of 
selected signals shows that the ratio between trisaccharide 55, glucose conjugate 57, and OVA peptide 
58 is about 45:50:5. Furthermore, comparison of the integration of selected signals in the 1H NMR 
spectrum of the mixture before (c) and after (b) the preparation of the GNP, with the exception of the 
OVAp signal which is overestimated, confirms the correct molar ratio of ligands attached on the Au 
nanoparticles.  
For the spectra related to the others GNPs see experimental section. 
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Calculation of the amount of antigen loaded on the GNPs 
The amount of antigen related to S. pneumoniae arranged on the GNPs prepared in 
this thesis was determined in two different ways:  
1) By calculation of the GNP molecular formula therough TEM measurements of the 
gold core and estimation of the number of attached ligand using the statistic 
calculation of the Murray’s table  
2) By qNMR of the GNPs with TSP as internal standard, as described before (section 
4.3.3) 
For example, the calculation of the amount of trisaccharide ligand arranged on the 
GNP 79 with Pn19F/Glc/OVA 45:50:5 molar ratio is hereafter reported. 
By TEM micrographs, the average diameter found is 1.2±0.3 nm which corresponds to 
nanoparticles of 79 gold atoms with 60 surface atoms and 38 minimal ligands, 
according to Murray’s table142 (Figure 4.13). 
 
Figure 4.13: Murray’s table shows for gold nanoparticles having a diameter of 1.2 nm (RCORE ~0.65 nm) 79 
atoms of Au with 60 surface atoms and 38 chains. 
The 1H NMR analysis of the mixture of the three components before and after the 79 
GNP formation confirmed a ratio of 45:50:5 (Figure 4.12). 
By the combination of these results, the average molecular formula estimated was: 
Au79(Pn19F)17(Glc)19(OVAp)2 
that gave an average molecular weight of  41.8 KDa 
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In this way, 160 g of GNP 79, which was the amount of gold nanoparticles exactly 
weighted, correspond to 3.8 nmol of GNPs, that multiplied for the number of ligands of 
the trisaccaride conjugate 55 (i.e. seventeen) give 64.6 nmol and, consequently, 65.1 
g of trisaccharide arranged on the gold surface.  
On the other hand, qNMR analysis (Figure 4.14) performed on the same amount of 
GNPs gave 13.6 nmol of trisaccharide which corresponding only to 13.7 g of 
trisaccharide 55 . 
 
Figure 4.14: 1H qNMR (500MHz, D2O): 160 g of GNP 79 were dissolved in 180 L of D2O and 20 L of 
D2O containing 0.05 wt.% TPS were added; 13.65 nmol of trisaccharide 55 were found which 
corresponding to 13.7 g of trisaccharide conjugate antigen. 
In Table 4.2, the quantity of the trisaccharide Pn19F and tetrasaccharide Pn14, which 
cover the gold surface of the GNPs prepared, calculated with the two methods are 
resumed.  
As demonstrated, the amount of active component arranged on the GNP calculated 
with these two ways is very different. Apparently, the qNMR is not the most 
appropriate method to estimate the amount of organic compounds bound on the gold 
surface most probably because of the greater difficulty of integration in the GNP 
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spectra and to the different proton relaxation times of organic compound coupled to 
gold atoms. Moreover, the valuation based on the TEM analysis and Murray’s table 
could not be enough precise due to the manual measurement of the diameter of gold 
core. However, we decided to use this last application to determinate the antigen  
carried by the GNPs for the immunization assays in order to avoid differences with 
previous investigation and to have comparable values. 133 
To verify our hypothesis on the limitation of qNMR analysis, the same experiment was 
performed using free glucose. A quantity of glucose, equal to the quantity attached to 
the GNP 79 calculated by TEM analysis, was dissolved in D2O and the same volume of 
TSP used in GNP 79 analysis was added. In this case, the amount of glucose obtained 
by qNMR was the one expected, but in this experiment glucose was not attached on 
the gold surface and consequently the signal of the anomeric proton of glucose and 
the singlet of the TSP were easily integrated. This experiment can confirm that the 
presence of the inorganic portion, i.e. the Au, influences the proton relaxation time, 
with effects on the signal integration ratio. 
In the literature is also reported a similar problem when the amount of compound 
loaded on the gold surface was calculated with quantitative NMR and 
thermogravimetric analysis. Also in this case, the comparison of the data indicated 
reproducibility within 15%.131 










79 160 65.5 13.7 
 
Pn19F/Glc/OVAp 45:50:5 
















Table 4.2: Amount of antigen carried by the different the GNPs sent for the immunizazzion assays.  
(a) Value obtained by average molecular formula based on the average size of GNPs after TEM analysis; 
(b) Value obtained by quantitative NMR using TSP as internal standard. 
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4.4 Immunological evaluation  
All the gold glyconanoparticles described in this PhD thesis have been tested in vivo in 
mice, after ethical approval. Inbred 6-week-old female BALB/c mice have been 
immunized intracutaneously with GNPs in mixture with Quillaja purified saponin (Quil -
A) as adjuvant.  
As a first step, an ELISA assay was performed on sera to measure the antibodies 
against native polysaccharide related to serotype 14 and 19F of Streptococcus 
pneumoniae. When polysaccharide serotype 14 was used as coating material in the 
ELISA plate, specific anti-type 14 polysaccharide IgG antibodies (anti-Pn14 PS IgG) were 
found in the sera of mice immunized with GNP 81, carrying both serotype 14 and 19F, 
and 83 with only Pn14. On the contrary, in the ELISA with polysaccharide serotype 19F 
(Pn19F PS) as coating material, IgG antibodies were not detected in the sera of mice 
immunized with the GNPs. In this case, antibodies were only found in the sera of mice 
immunized with vaccine PVC13, the 13-valent pneumococcal conjugate vaccine, used 
as positive control, even if with a lower amount with respect to the Pn14PS ELISA, but 
in according with the literature146 (Figure 4.15).  
The inactivity of sera collected from mice immunized with GNPs 79, 80 and 82 towards 
the native 19F polysaccharide could be due to the inability of the single trisaccharide 
repeating unit on the GNPs to function as epitope in vivo, although our previous data 
demonstrated in vitro inhibitory activity in a classical competitive ELISA assay. This 
would suggest that a longer saccharide fragment (more than one repeating unit) is 
necessary to induce the activation of the immune system. Another explanation of the 
inability to elicit antibody could be ascribed to the absence of the phosphate group. 
The aminopropyl linker is in fact directly attached to the sugar instead of having a 
phosphate bridge at the reducing end.  
On the other hand, the high activity showed by GNP 81 even higher than the activity of 
83, could be explained by an adjuvant effect of the trisaccharide antigen Pn19F, which 
is charged on the GNPs together with tetrasaccharide antigen Pn14. Several 
carbohydrate-based compounds, as polysaccharides derived from bacteria,147 are 
known to have immunostimulating properties, acting as adjuvants, which enhance the 
immune response increasing also the production of antibodies. 148 For instance, 
galactosylceramide has been largely evaluated as immunostimulant over the years, as 
well as mannosamine. It may be possible that the mannosaminic portion of the 
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trisaccharide repeating unit related to Pn19F used in the preparation of the GNPs, 
exhibits its immunostimulant properties enhancing the activity of the tetrasaccharide 
repeating unit related to Pn14 since the immune response of GNP 81 is higher than the 
one of GNPs 83 carrying only the tetrasaccharide related to Pn 14. 
 
 
Figure 4.15: Specific anti-S. pneumoniae type 14 polysaccharide (Pn14 PS) and anti-S. pneumoniae type 
19F polysaccharide (Pn19F PS) IgG antibodies determined by ELISA. ELISA were performed using Pn14 PS 
and Pn19F PS as coating material. The level of antibodies is expressed as the log10 of the dilution giving 
twice the OD obtained for control mice. PVC13 and saline buffer immunization served as positive and 
negative control respectively.  
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Further investigation to clarify this preliminary result obtained with Pn19F and Pn14 
polysaccharide as coating materials was carried out using the gold nanoparticles to 
cover the ELISA plate (Figure 4.16), following a procedure already reported.149  
With this assay, we could verify if the GNPs, used as coating material, are recognized 
by the sera of immunized mice. When GNP 83 carrying the branched tetrasaccharide 
antigen related to Pn14 of S. pneumoniae was used as coating material in the ELISA 
plate, we found high level of IgG antibodies in sera of mice immunized with GNPs 
covered with the saccharide Pn14, i.e. 83 and 81 and PVC13 positive control. Also, 
lower IgG binding in mice sera from 79, 80, 82 immunization was observed, but this 
can be due to interaction from other part of GNPs such as peptide and linker, as 
previously reported.133  
The same ELISA was performed with GNP 79 carrying the trisaccharide repeating unit 
of serotype 19F as coating material. In this case, IgG antibodies against 79 were found 
in sera of mice immunized with 81, carrying both Pn19F and Pn14, 79, 80 and 82, even 
if in a lower titer with respect to ELISA with GNP 83 as coating material.  
It is worth noting that there is no difference in the activity of GNPs 79 carrying 
trisaccharide Pn19F in alpha/beta mixture together with glucose and OVAp 45:50:5 
molar ratio and 82 with the same molar ratio of the three components, but with only 
alpha anomer of trisaccharide Pn19F, conferming our previous results (unpublished 
data). Furthermore, the higher amount of trisaccharide Pn19F carried by GNP 80 
respect with 79 does not reflect a greater activity.  
These last results are very interesting because they indicate that the trisaccharide 
repeating unit is antigenic, despite it is not able to induce the production of antibodies 
IgG that recognize the native polysaccharide 19F. However, other experiments are 
currently underway to find the correct epitope fragment and to get more information 
on the applicability of these GNPs as carrier for saccharide antigens of S. pneumoniae.  




Figure 4.16: IgG antibodies against GNP 83 and 79 detected in sera of mice immunized. ELISA was 
performed using these GNPs as coating materials.  The level of antibodies is expressed as the log10 of the 
IgG titer. 
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4.5 Conclusions  
In this chapter, the preparation and immunological evaluation of gold  nanoparticles 
bearing saccharide antigens related to serotypes Pn19F and Pn14 of Streptococcus 
pneumoniae have been reported. Different percentages of thiol-ending antigens as 
active component, glucose as inner component, and OVA323-339 peptide as T-helper, 
were used to obtain the glyconanoparticles through a direct method. The GNPs were 
purified by dialysis and characterized by different techniques, such as Ultraviolet-
visible (UV/Vis), Circular Dichroism (CD), Transmission Electron Microscopy (TEM) and 
Nuclear Magnetic Resonance (1H NMR and qNMR). GNPs resulted well-soluble and 
stable in water and, as solid they can be stored at 4°C in the dark. 
All the GNPs prepared has been evaluated for their immunological activity. The most 
promising result has been achieved with the multiantigenic system 81, in which the 
presence of the trisaccharide antigen related to serotype 19F enanches the 
immunological activity in vivo of the GNP carrying the tetrasaccharide serotype 14.  
Encouraging results have been also obtained using GNP as coating materials in ELISA 
assay. In this case, IgG were found in sera of mice immunized with all the gold 
glyconanoparticles under examination, thus demonstrating the antigenicity of the 
system. 
 Chapter 4 
109 
4.6 Experimental section 
4.6.1 General methods 
Chemical: All chemicals were purchased as reagent grade from Sigma–Aldrich, except 
chloroauric acid (Strem Chemicals), and were used without further purification.  
Dichloromethane (CH2Cl2) and tryethyamine (TEA) used in the synthesis of  74 were 
distilled from calcium hydride. Methanol (CH3OH) was degassed with Argon before to 
use to avoid oxidation of compound 55. Air- and moisture sensitive liquids and 
solutions were transferred via oven-dried syringe or stainless steel cannula through 
septa. Reactions were monitored by thin-layer chromatography (TLC) on silica gel 60 
F254 aluminium-backed sheets (Merck) with visualization under UV (254 nm) and/or by 
staining with p-anisaldehyde solution [anisaldehyde (25 mL), H2SO4 (25 mL), EtOH (450 
mL), and CH3COOH (1 mL)], followed by heating at over 200 °C. Size-exclusion column 
chromatography was performed on Sephadex LH-20 (GE Healthcare). Flash column 
chromatography (FCC) was performed on silica gel high-purity grade, pore size 60Å, 
230-400 mesh particle size. Preparative TLC was performed on TLC plate 20×20 cm 
Silica gel 60 F254 glass-backed sheets (Merck). Organic solvents were removed by rotary 
evaporation under reduced pressure at approximately 40°C (water bath). Purified 
water was obtained from a Simplicity Ultrapure Water System (Millipore). Nanopure 
water (18.2 MΩ-cm) was obtained by a Thermo Scientific Barnstead NANOpure 
DIamond Water System. 
All the GNPs prepared were purified by centrifugal filtering with AMICON (10.000 
MWCO) and dialyses carried out using Slide–A-Lyzer dialysis cassette (3500 MWCO). 
UV/Vis spectra were measured with Beckman Coulter DU 800 UV/Vis 
Spectrophotometer. To perform the measurement a solution of GNPs 0,10mg/ml in 
HPLC gradient grade water has been prepared and plastic cuvettes with an internal 
width of 45mm were used. All UV/Vis spectra were subtracted from blank.  
Circular Dichroism spectra were performed on a Jasco 720 Spectrophotometer. A 
solution of GNPs 0,25mg/ml in HPLC gradient grade water and quartz cuvette with a 1 
mm path length was used to carry out the measurement. All CD spectra were 
subtracted from blank. 
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TEM analysis was performed with a Philips JEOL JEM-2100F microscope, working at 
200 kV. A single drop (~2 µL) of an aqueous solution 0.05 mg/mL in HPLC gradient 
grade water of GNPs was placed on a copper grid coated with a carbon film (Electron 
Microscopy Sciences) that was left to dry in air for several hours at room temperature 
in order to carry out the experiment. Statistical determination of gold dimension was 
performed using Image J programme and the average diameter of gold core can be 
correlated to the number of ligands present on GNP. 142 
1H and 13C NMR spectra were recorded on Bruker 500 MHz (high resolution) 
spectrometer. Chemical shifts (δ) are given in ppm relative to the residual signal of the 
solvent used. Specifically 7.26 ppm for CDCl3, 3.31 ppm for CD3OH and 4.79 ppm for 
D2O in 
1H NMR spectra and 77.0 ppm (central line) for CDCl3 and 49.0 ppm (central 
line) for CD3OD in 
13C NMR spectra Coupling constants (J) are reported in Hz. Splitting 
patterns are described by using the following abbreviations: br, broad; s, singlet; d, 
doublet; t, triplet; m, multiplet; dd, doublet of doublet; dt, doublet of triplet. 
Mass spectra were measured with an Esquire 6000 ESI-Ion Trap spectrometer from 
Bruker Daltonics. High-resolution mass spectra (HRMS) were obtained using the MALDI 
technique with a 4700 Proteomics Analyzer (Applied Biosystems) operated in MALDI -
TOF-TOF configuration. 
Biochemical: For the immunization assays inbred 6-week-old female BALB/c mice were 
employed. Quil-A® saponin used as adjuvant and co-administered with GNPs was a gift 
from Dr. Erik B. Lindblad and Brenntag Biosector, Denmark.  
ELISA plates were coated with purified Pn14PS or Pn19F PS purchased from Statens 
Serum Institut, Denmark, while Nunc MaxiSorp plates were employed for the GNP-
ELISA.  
Goat anti-mouse IgG and IgG horseradish peroxidase were purchased from Silenus, 
Amrad Operations PTY LTD, Australia. 
Bovine Serum Albumin, BSA, was purchased from Sigma-Aldrich. 
TMB substrate (3,3′,5,5′-Tetramethylbenzidine) was achieved by Life technologies 
Optical density (OD) values were obtained with a micro-titer plate spectrophotometer 
at 450 nm (Tecan Infinite F200). 
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4.6.2 Synthesis of thiol-ending trisaccharide related to serotype Pn19F. 
Synthesis of N-(benzyloxycarbonyl)-3-amminopropyl (2-acetamido-3-O-benzyl-4,6-O-
benzylidene -2-deoxy--D-mannopyranosyl-(14)-(2,3,6-tri-O-benzyl--D-
glucopyranosyl)-(12)-3,4-di-O-benzyl-a,-L-rhamnopyranoside 71 






rhamnopyranoside 69 (90 mg, 0.07 mmol, 1 eq.) and N-(benzyloxycarbonyl)-3-
amminopropyl 70 (58 mg, 0.28 mmol, 4 eq.) were dissolved in dry CH2Cl2 (1.5 ml, 
0.05M) containing molecular sieves 4 Å (50 mg). The suspension was left stirring under 
Ar atmosphere at room temperature for 15 minutes, then it was cooled at 0°C and 
TMSOTf 0.1 M in CH2Cl2 (140 l, 0.014 mmol, 0.2 eq.) was added. After 15 minutes, the 
reaction mixture was neutralized with TEA, filtrated over a Celite pad and the solvent 
evaporated under reduced pressure. Purification through flash chromatography 
(Hexane/Ethyl Acetate 6:4) of the crude afforded compound 71 (85 mg, 0.063 mmol, 
90% yield), in mixture  as white foam.  
In order to prepare GNPs coated only with the natural alpha anomer, 40 mg of mixture 
of the product was submitted to a preparative TLC (Hexane/Ethyl Acetate 1:1), and the 
alpha anomer was also separately characterized.  
Alpha/beta mixture:  
1H-NMR (CDCl3): δ=1.38 (d, 1.2H, J6r,5r=6.2 Hz, CH3), 1.42 (d, 1.8H, J6r,5r=6.2 Hz, CH3), 
1.62-1.69 (m, 2H, CH2), 1.76 (br s, 1.2H, CH3CO), 1.77 (br s, 1.8H, CH3CO), 3.03-3.09 
(m, 0.4H, H-5m), 3.12-3.19 (m, 0.6H, H-5m), 3.21-5.15 (m, 35.4H, OCH2CH2CH2N, 
OCH2CH2CH2N, 0.4H-1g, H-2g, H-3g, H-4g, H-5g, 2H-6g, H-1r, H-2r, H-3r, H-4r, H-5r, H-
1m, H-2m, H-3m, H-4m, 2H-6m, 7CH2Ph), 5.48 (s, 1H, CHPh), 5.53 (br d, 1H, J=10.9 Hz, 
NH), 5.61 (d, 0.6H, J=3.6 Hz, H-1g), 7.19-7.52 (m, 40H, 8Ph); 
13C-NMR (CD3Cl): δ=17.9 (CH3), 18.0 (CH3), 23.1 (CH3CO), 23.3 (CH3CO), 29.6 
(CH2), 29.8 (CH2), 38.0 (CH2N), 38.8 (CH2N), 50.5 (C2m), 65.4 (OCH2), 66.5 (CH2Ph-
cbz), 66.7 (CH2Ph-cbz), 67.1 (C5m), 67.4 (C5m), 67.9 (C6g), 68.2 (C6g), 68.4 
(C5r), 68.6 (C5r), 69.2 (C5g), 69.8 (C5g), 70.9 (CH2Ph), 71.2 (CH2Ph), 71.9 (CH2Ph), 
72.1 (CH2Ph), 72.7 (CH2Ph), 73.4 (CH2Ph), 74.2 (CH2Ph), 74.7 (CH2Ph), 75.0 (C2r), 75.3 
(CH2Ph), 75.5 (C4g), 75.7 (C4g), 75.9 (C3m), 78.5 (C4m), 79.0 (C3r), 79.2 (C3r), 
79.7 (C2g), 79.8 (C2g), 80.0 (C4r), 80.1 (C4r), 80.3 (C3g), 80.4 (C3g), 96.8 
(C1g), 96.9 (C1g), 97.5 (C1r), 99.6 (C1m), 101.6 (CHPh benzilidene), 126.1, 126.3, 
126.4, 126.5, 126.6, 127.2-127.9 (16C), 128.0-128.6 (18C), 128.9, 129.0, 129.7, 134.4, 
136.6 (2C Cbz  and ), 134.3, 137.4, 137.6 (3C), 137.7 (2C), 137.8, 138.1 (3C), 138.2, 
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138.3 (2C), 138.4 (3C), 138.5 (3C), 138.7 (2C), 139.5, 139.6 (2C), 139.7, 156.3 (OCONH 
linker), 170.4 (CONHAc). 
ESI-MS (CH3OH, positive-ion mode): m/z 1371.5 (100%) [M+Na]
+, 1372.5 (90%) 
[M+Na+1]+, Calcd for C80H88N2O17, m/z 1348.61 [M]. 
Alpha anomer: 
1H-NMR (CDCl3): δ=1.38 (d, 3H, J6r,5r=6.2 Hz, CH3), 1.60-1.69 (m, 2H, CH2), 1.74 (s, 3H, 
CH3CO), 3.07 (dt, 1H, J5,6=4.9 Hz, J5,6’=10.0 Hz, H-5m), 3.18 (d, 1H, J5,6’=10.0 Hz, H-6’g), 
3.22-3.34 (m, 4H, CH2N, H-6g, H-3m), 3.35-3.41 (m, 1H, CH2’O), 3.47-3.64 (m, 5H, H-2g, 
H-4r, H-5r, H-4m, H-6m), 3.65-3.75 (m, 1H, -OCH2), 3.82-3.90 (m, 2H, H-3g, H-3r), 4.01-
4.13 (m, 4H, H-4g, H-5g, H-2r, H-6’m), 4.24 (d, 1H, J=12.0, CHPh), 4.45 (br s, 1H, H-1m), 
4.48 (d, 1H, J=12.0, CHPh), 4.54-4.75 (m, 9H, H-1r, H-2m, 7 CHPh), 4.80 (d, 1H, J=12.0, 
CHPh), 4.91 (d, 1H, J1,2=3.4 Hz, H-1g), 4.95-4.98 (m, 3H, 2 CHPh, NH), 5.08 (dd, 2H, 
J=14.2, CH2Ph), 5.50 (m, 2H, CHPh benzylidene, NHAc), 7.19-7.52 (m, 40H, 8 Ph); 
13C-NMR (CD3Cl): δ=18.0 (CH3), 23.3 (CH3CO), 29.6 (CH2), 38.8 (CH2N), 50.5 (C2m), 65.5 
(OCH2), 66.7 (CH2Ph-cbz), 67.1 (C5m), 67.9 (C6g), 68.4 (C5r), 68.7 (C6m), 69.8 (C5g), 
71.2 (CH2Ph), 72.1 (CH2Ph), 72.7 (CH2Ph), 73.4 (CH2Ph), 74.7 (CH2Ph), 75.0 (C2r), 75.3 
(CH2Ph), 75.5 (C4g), 75.9 (C3m), 78.5 (C4m), 79.0 (C3r), 79.7 (C2g), 80.1 (C4r), 80.4 
(C3g), 96.9 (C1g), 97.5 (C1r), 99.6 (C1m), 101.6 (CHPh benzylidene), 126.1, 126.4, 
127.3, 127.4 (2C), 127.6 (2C), 127.7 (2C), 127.9, 128.0, 128.1 (2C), 128.2 (2C), 128.3 
(2C), 128.4 (2C), 128.5 (2C), 128.6 (2C), 129.0, 136.6 (C Cbz), 137.4, 137.7, 138.2, 
138.4, 138.6, 139.6, 156.3 (OCONH linker), 170.4 (CONHAc); 
ESI-MS (CH3OH, positive-ion mode): m/z 1371.8 (100%) [M+Na]
+, Calcd for C80H88N2O17, 
m/z 1348.61 [M]. 
Synthesis of amino-hydroxypropyl 2-acetamido-2-deoxy β-D-mannopyranosyl-(14)-α-D-
glucopyranosyl-(12)--L-rhamnopyranoside 72 
The protected trisaccharide 71 (39 mg, 0.029 
mmol, 1 eq.) was dissolved in a mixture of 
AcOEt/CH3OH/HCl 0.1M in H2O 1:1:1 (1 ml, 
0.03M) and hydrogenolyzed at atmospheric 
pressure with palladium hydroxide on 
activated charcoal (39 mg) for 48 hours. The 
mixture was filtrated to remove the catalized. The filtrate was concentrated under 
reduced pressure and then freeze dried to give the product 72 isolated as the chloride 
salt (17 mg, quant.) as a white solid.  
The same procedure above described was used to obtain also the alpha anomer.  
Alpha/beta mixture: 
1H-NMR (D2O): δ=1.32 (d, 1.2H, J6r,5r=6.2 Hz, CH3), 1.34 (d, 1.8H, J6r,5r=5.8 Hz, CH3), 
1.97-2.03 (m, 2H, CH2), 2.09 (s, 3H, CH3CO), 3.15 (t, 2H, J=7.2 Hz, CH2N), 3.40-4.05 (m, 
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15.4H, H-2g, H-3g, H-4g, 2H-6g, 0.4H-2r, H-3r, H-4r, H-5r, H-3m, H-4m, H-5m, 2H-6m, 
OCH2), 4.06-4.08 (m, 0.4H, H-5g), 4.10 (d, 0.6H, J2,3=3.1 Hz, H-2r), 4.18 (dt, 0.6H, 
J5,6=2.7 Hz, J5,6’=10.2 Hz, H-5g), 4.57 (br d, 1H, J2,3=4.4 Hz, H-2m), 4.74 (s, 0.6H, H-1r), 
4.91 (br s, H-1m), 4.93 (d, 0.4H, J1,2=1.2 Hz, H-1r), 5.01 (d, 0.4H, J1,2=3.8 Hz, H-1g); 
5.15 (d, 0.6H, J=3.8 Hz, H-1g); 
13C-NMR (D2O): δ=16.5 (CH3), 16.6 (CH3), 22.0 (CH3CO), 26.6 (CH2), 26.8 (CH2), 
37.5 (CH2N), 37.6 (CH2N), 53.3 (C2m), 59.6 (C6g), 59.8 (C6g), 60.4 (C3m), 65.1 
(OCH2), 66.6 (C4m), 67.3 (OCH2), 68.9, 69.6, 70.2 (C5g), 70.3 (C5g), 71.1, 71.2, 
71.5 (C2g), 71.8 (C2g), 71.9 (C5r and C5r, 72.0 (C3r and C3r, 72.5 (C4r), 76.3 
(C5m), 76.5 (C6m), 77.9 (C2r), 78.6 (C4g and C4g), 97.2 (C1r), 97.5 (C1g), 99.3 
(C1m), 99.4 (C1m), 99.8 (C1g), 100.4 (C1r), 175.4 (CONHAc);  
ESI-MS (CH3OH, positive-ion mode): m/z 587.1 (95%) [M+1]
+, 609.5 (50%) [M+23]+, 
Calcd for C23H42N2O15, m/z 586.58 [M]. 
Alpha anomer:  
1H-NMR (D2O): δ=1.32 (d, 3H, J6r,5r=6.2 Hz, CH3), 1.97-2.03 (m, 2H, CH2), 2.08 (s, 3H, 
CH3CO), 3.08-3.19 (m, 2H, CH2N), 3.44-3.49 (m, 1H, H-5m), 3.49-3.64 (m, 4H, H-4m, H-
4r, H-2g, OCH2), 3.67-3.72 (m, 2H, H-5r, H-4g), 3.75-3.79 (m, 2H, 2H-6g), 3.80-3.99 (7H, 
H-3m, 2H-6m, H-2r, H-3r, H-3g, OCH’2), 4.06-4.10 (m, 1H, H-5g), 4.56 (dd, 1H, J1,2=1.3 
Hz, J2,3=4.3Hz, H-2m), 4.90 (d, 1H, J1,2=1.3 Hz, H-1m), 4.93 (d, 1H, J1,2=1.2 Hz, H-1r), 
5.01 (d, 1H, J1,2=3.8 Hz, H-1g); 
13C-NMR (D2O): δ=16.5 (CH3), 22.0 (CH3CO), 26.6 (CH2), 37.5 (CH2N), 53.3 (C2m), 59.6 
(C6g), 60.4 (C3m), 65.1 (OCH2), 66.6 (C4m), 68.9, 69.6, 70.3 (C5g), 71.1, 71.2 (C2g), 71.8 
(C5r), 72.0 (C3r), 76.3 (C5m), 76.5 (C6m), 78.7 (C4g), 97.2 (C1r), 97.5 (C1g), 99.3 (C1m), 
175.4 (CONHAc); 
ESI-MS (CH3OH, positive-ion mode): m/z 609.27 (100%) [M+Na]
+, 587.29 (95%) [M+1]+, 
Calcd for C23H42N2O15, m/z 586.58 [M]. 
Synthesis of 3-[2-acetamido-2-deoxy β-D-mannopyranosyl-(14)-α-D-glucopyranosyl-
(12)--L-rhamnopyranosyloxy]-1-propyl 3-(23-S-Acetyl-mercapto-3,6,9,12-
tetraoxatricosyl) thiourea 74 
To a solution of 3-
aminopropyl trisaccharide 
72 (3.91 mg, 6.27 μmol, 1.0 
equiv.) in H2O:iPrOH:CH3CN 
(1:1:1, v/v/v, 0.6 mL) a 
solution of 23-mercapto-
3,6,9,12-tetraoxatricosyl isothiocyanate linker 73 (5.82 mg, 12.55 μmol, 2.0 equiv.) in 
H2O:iPrOH:CH3CN (1:1:1, v/v/v, 0.6 mL) was added and the pH was set to basic by 
addition of triethylamine 0.05 M in H2O:iPrOH:CH3CN (188 μL, 9.41 μmol, 1.5 equiv.). 
The mixture was stirred at room temperature for 24 h and then the solvent was 
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evaporated. The crude material was kept in high vacuum to remove the residual 
triethylamine and then triturated with Et2O (3 × 2ml) in order to get rid of the excess 
of the linker. Then, the crude was further purified by Sephadex LH-20 chromatography 
using as eluent CH3OH/H2O 9:1 to afford the trisaccharide conjugate 74 as a white solid 
(4.95 mg, 4.71 μmol, 75%).  
Alpha/beta mixture:  
1H-NMR (CD3OD): δ=1.27-1.38 (m, 17H, CH3, 7CH2), 1.53-1.60 (m, 4H, CH2CH2SAc, 
OCH2CH2(CH2)9SAc), 1.81-1.91 (m, 2H, OCH2CH2CH2N), 2.02 (s, 3H, NHAc), 2.30 (s, 3H, 
SAc), 2.86 (t, 2H, J=7.3 Hz, CH2SAc), 3.27-3.93 (m, 35.4H, H-2g, H-3g, H-4g, 2H-6g, 0.4H-
2r, H-3r, H-4r, H-5r, H-3m, H-4m, H-5m, 2H-6m, 9CH2O, 2CH2N), 4.00 (d, 0.6H, J1,2=3.8 
Hz, H-2r), 4.04-4.07 (m, 0.4H, H-5g), 4.13-4.17 (m, 0.6H, H-5g), 4.50 (br d, 1H, J=4.1 
Hz, H-2m),4.61 (s, 0.6H, H-1r), 4.78 (s, 1H, H-1m), 4.83 (d,0.4H, J1,2=0.9 Hz, H-1r), 
4.92 (d, 0.4H, J1,2=3.8 Hz, H-1g), 5.11 (d, 0.6H, J1,2=3.8 Hz, H-1g); 
13C-NMR (CD3OD): δ=18.0 (2CH3) 22.7 (2CH3CO), 27.1 (CH2), 29.8, 29.9 (CH3CO), 30.2 
(SAc), 30.5 (2CH2), 30.6 (2CH2), 30.7 (2CH2), 37.5 (CH2N), 47.8, 54.9 (C2m and C2m), 
61.3, 61.4, 61.9, 66.3, 68.2 (2C), 70.2, 70.7, 70.8, 71.1, 71.3, 71.5, 71.6, 71.7, 71.8, 
71.9, 72.4, 73.2, 73.5, 73.7, 73.8, 74.0 (2C), 74.1, 74.2, 74.5 (2C), 78.6, 78.7, 79.9, 80.1, 
80.3, 99.2 (C1r), 99.6 (C1g), 100.9 (C1m), 101.8 (C1g), 102.1(C1r), 174.7 
(NCOCH3), 190.9 (S=C) 197.6 (SCOCH3); 
TOF MS ESI (CH3OH, positive-ion mode): m/z 1072.7 (100%) [M+Na]
+, Calcd for 
C45H83N3O20S2, m/z 1049.50 [M]. 
Alpha anomer:  
1H-NMR (CD3OD): δ=1.27-1.39 (m, 17H, CH3, 7CH2), 1.53-1.59 (m, 3.7H, 1.7 CH2CH2SAc, 
OCH2CH2(CH2)9SAc), 1.63-1.71 (m, 0.3H, CH2CH2SS), 1.72-1.79 (m, 1H, OCH2CH2CH2N), 
1.83-1.90 (m, 1H, OCH2CH2’CH2N), 2.02 (s, 3H, NHAc), 2.30 (s, 3H, SAc), 2.69 (t, 0.3H, 
J=7.8 Hz, CH2SS), 2.86 (t, 1.7 H, J=7.3 Hz, CH2SAc), 3.15-3.92 (m, 36H, H-2g, H-3g, H-4g, 
2H-6g, H-2r, H-3r, H-4r, H-5r, H-3m, H-4m, H-5m, 2H-6m, 9CH2O ,2CH2N), 4.05 (br d, 
1H, J=8.7 Hz, H-5g), 4.50 (d, 1H, J1,2=3.0 Hz, H-2m), 4.78 (s, 1H, H-1m), 4.81 (s, 1H, H-
1r), 4.92 (1H, H-1g);  
13C-NMR (CD3OD) Characteristic signals: δ=17.7 (CH3), 22.4 (CH3CON), 26.0 (CH2SS), 
29.3 (CH2SAc), 30.2 (CH3COS), 37.6 (CH2N), 54.2 (C2m), 71.8 (C5g), 98.9 (C1r), 99.4 
(C1g), 100.6 (C1m), 175.42 (CONHAc);  
TOF MS ESI (CH3OH, positive-ion mode): m/z= 1072.49 (100%) [M+Na]
+, Calcd for 
C45H83N3O20S2, m/z 1049.50 [M]. 
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Synthesis of 3-[2-acetamido-2-deoxy β-D-mannopyranosyl-(14)-α-D-glucopyranosyl-
(12)--L-rhamnopyranosyloxy]-propyl 1-(23-mercapto-3,6,9,12-tetraoxatricosyl) 
thiourea 55 
To a solution of S-protected 
trisaccharide 74 (4.95 mg, 
4.71 μmol, 1.0 equiv.) in 
CH3OH (500 L, 0.01M) solid 
CH3ONa (0.500 mg, 9.42 
mol, 2.0 eq.) was added. 
The mixture was stirred at room temperature for 4 hours under Ar atmosphere until 1H 
NMR check analysis attested the complete disappearance of starting material. The 
solvent was evaporated and the crude material was purified by Sephadex LH-20 
chromatography using as eluent CH3OH/H2O 9:1 to afford the trisaccharide conjugate 
product 55 as a white solid after lyophilization (4.32 mg, 4.28 μmol, 90%).  
Alpha/beta mixture:  
1H-NMR (CD3OD): δ=1.26-1.44 (m, 17H, CH3, 7CH2), 1.53-1.62 (m, 3.10H, 1.10 
CH2CH2SH, 2 OCH2CH2), 1.65-1.71 (m, 0.90H, CH2CH2SS), 1.72-1.82 (m, 2H, 
OCH2CH2CH2N), 2.03 (s, 3H, NHAc), 2.49 (t, 0.6H, J=7.3 Hz, CH2SH) 2.69 (t, 1.4H, J=7.3 
Hz, CH2SS), 3.25-4.17 (m, 37H, H-2g, H-3g, H-4g, H-5g, 2H-6g, H-2r, H-3r, H-4r, H-5r, H-
3m, H-4m, H-5m, 2H-6m, 9CH2O, 2CH2N), 4.50 (d, 1H, J = 3.7 Hz, H-2m), 4.78 (s, 1H, H-
1m), 4.81 (s, 1H, H-1r), 4.91 (H-1g), 5.11 (d, 0.6H, J=3.8 Hz, H-1g); 
13C-NMR (CD3OD): δ=18.0 (CH3) 22.7 (CH3CON), 27.2 (CH2), 29.4, 30.3, 30.6, 30.7, 31.3, 
39.8, 40.9, 54.9 (C2m), 61.4, 61.9, 66.3, 68.2, 71.1, 71.2, 71.6, 71.9, 72.0, 72.4, 74.1, 
74.5, 78.6, 79.8, 80.1, 80.2, 99.2 (C1r), 99.5 (C1g), 100.6 (C1m), 101.4 (C1g), 101.9 
(C1r), 174.7 (NCOCH3); 
TOF MS ESI (CH3OH, positive-ion mode): m/z=1030.48 (100%) [M+Na
+], Calcd for 
C43H81N3O19S2, m/z=1007.49 [M]. 
Alpha anomer:  
1H-NMR (CD3OD): δ=1.24-1.39 (m, 17H, CH3, 7CH2), 1.51-1.61 (m, 2.9H, 0.9 CH2CH2SH, 2 
OCH2CH2), 1.64-1.70 (m, 1.1H, CH2CH2SS), 1.72-1.79 (m, 2H, OCH2CH2CH2N), 2.03 (s, 3H, 
NHAc), 2.46 (t, 0.9H, J=7.3 Hz, CH2SH) 2.69 (t, 1.1H, J=7.3 Hz, CH2SS), 3.19-3.92 (m, 
36H, H-2g, H-3g, H-4g, 2H-6g, H-2r, H-3r, H-4r, H-5r, H-3m, H-4m, H-5m, 2H-6m, 
9CH2O, 2CH2N), 4.02-4.08 (m, 1H, H-5g), 4.51 (d, 1H, J=4.5 Hz, H-2m), 4.78 (d, 1H, J=1.2 
Hz, H-1m), 4.81 (s, 1H, H-1r), 4.91 (H-1g); 
13C-NMR (CD3OD): characteristic signals δ=18.0 (CH3) 22.7 (CH3CON), 54.9 (C2m), 99.2 
(C1r), 99.5 (C1g), 100.6 (C1m), 174.7 (NCOCH3); 
TOF MS ESI (CH3OH, positive-ion mode): m/z=1030.48 (100%) [M+Na
+], Calcd for 
C43H81N3O19S2, m/z=1007.49 [M]. 
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4.6.3 Synthesis and characterization of the glyconanoparticles  
General protocol for the preparation of the GNPs 
To a 0.012M solution in CH3OH of the mixture of the thiol-ending ligands, e.g. the 
trisaccharide related to Pn19F 55, the tetrasaccharide related to Pn14 56, the -D-
glucose 57 and OVA peptide 58 (5 eq.), were added tetrachloroauric acid HAuCl4 
(0.025M in H2O, 1 eq.) and sodium borohydride NaBH4 (1M in H2O, 27 eq.) in four 
portions under vigorous shaking. The black suspension formed was shaken for 2 hours 
at room temperature. After that, the reaction mixture was diluted with a mixture of 
HPLC gradient grade H2O and CH3OH 75/25 v/v and subjected to centrifugal filtering 
with AMICON 10.000 MWCO (5 min, 10.000 rpm,10 times). The filtrate phase, which is 
the volume that pass through the filter containing unreacted ligands, were collected 
and analyzed by 1H NMR to verify the conservation of the molar ratio of ligands 
attached on the gold surface, and eventually use them again to prepare another batch 
of the same GNP after their purification with Sephadex LH-20 using as eluent 
CH3OH/H2O 9:1. On the other hand, the dark concentrated solute, the fraction that 
does not pass through the membrane containing the GNPs, was purified by dialysis 
with Slide-A-Lyzer 3.500 MWCO Dialisys Cassette placed in a 2 L beaker full of 
NANOPURE water under gentle stirring. After changing the water for nine times in 
three days, the dark solution was freeze-dried to give the GNPs as a dark solid, which 
can be stored at 4°C for months and redissolved in water prior to use.  
For the ligands analysis, proton nuclear magnetic resonance (1H NMR) spectra of the 
initial mixture and of the filtrate phase after GNP formation were recorded and their 
comparison confirms the expected molar ratio of the components attached on the gold 
surface of the GNPs prepared. The ratio of the ligands in the GNP was evaluated by 
integrating the signals of the anomeric protons of the glucopyranosyl unit or the H -2 
proton of the mannopyranosyl unit of the trisaccharide 55, the 4 anomeric protons of 
tetrasaccharide 56 which collapse in an unique signal, the anomeric proton of 
glucoside 57 and the methyl groups of isoleucine and valine of OVA 323–339 peptide 
conjugate 58.  
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Pn19F/Glc/OVA (45:50:5) GNP 79 
A mixture of thiol-ending trisaccharide 
19F 55 (0.960 mg, 0.952 mol, 9 eq.), 
-D-glucose conjugate 57 (0.299 mg, 
1.050 mol, 10 eq.), and OVA peptide 
58 (0.203 mg, 0.105 mol, 1 eq.) in 
MeOH (175 l, 0.012M) was prepared. 
HAuCl4 (16.80 l, 0.421 mol, 0.025M 
in H2O, 1eq.) and sodium borohydride NaBH4 (11.40 l, 11.378 mol, 1M in H2O, 27 
eq.) were added to afford 378 g of GNP 79. 
TEM (average diameter): 1.2±0.3 nm; 
Average molecular formula estimated based on the size of the cluster obtained from 
TEM micrographs: Au79(C43H80N3O19S2)17(C11H21O6S)19(C79H126N27O27S)2 ~41.8 KDa; 
UV/Vis (H2O, c=0.10 mg/mL): surface plasmon band not observed; 
CD (H2O, c=0.25 mg/mL): circular dichroism not observed;  
1H qNMR (500MHz, D2O): 160 g of GNP were dissolved in 180 L of D2O and 20 L of 
D2O containing 0.05 wt.% TPS were added. 13.65 nmol of trisaccharide conjugate were 
found.  
 




Figure 4.17: (a) TEM micrographs and (b) histograms of size distribution, (c) UV/Vis adsorption and (d) 
circular dichroism spectra of gold GNPs 79. (e) 1H NMR spectrum (500MHz, CD3OD:D2O 5:1) of the 
mixture used to prepare GNP and (f) 1H NMR spectrum (500MHz, D2O) of GNP 79 obtained. Integration of 
selected signals shows that the ratio between trisaccharide 55, glucose conjugate 57 and OVAp 58 is 
about 45:50:5. 
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Pn19F/OVA (95:5) GNP 80 
A mixture of thiol-ending trisaccharide 
19F 55 (1.400 mg, 1.390 mol, 19 eq.) 
and OVA peptide 58 (0.140 mg, 0.073 
mol, 1 eq.) in MeOH (122 l, 0.012M) 
was prepared. HAuCl4 (11.70 l, 0292 
mol, 0.025M in H2O, 1eq.) and sodium 
borohydride NaBH4 (7.90 l, 7.90 mol, 
1M in H2O, 27 eq.) were added to afford 336 g of GNP 80. 
TEM (average diameter): 1.2±0.3 nm; 
Average molecular formula estimated based on the size of the cluster obtained from 
TEM micrographs: Au79(C43H80N3O19S2)36(C79H126N27O27S)2 ~55.6 KDa; 
UV/Vis (H2O, c=0.10 mg/mL): surface plasmon band not observed; 
CD (H2O, c=0.25 mg/mL): circular dichroism not observed; 
1H qNMR (500MHz, D2O): 160 g of GNP were dissolved in 180 L of D2O and 20 L of 
D2O containing 0.05 wt.% TPS were added. 10.40 nmol of trisaccharide conjugate were 
found.  
 




Figure 4.18: (a) TEM micrographs and (b) histograms of size distribution, (c) UV/Vis adsorption and (d) 
circular dichroism spectra of gold GNPs 80. (e) 1H NMR spectrum (500MHz, CD3OD:D2O 5:1) of the 
mixture used to prepare GNP and (f) 1H NMR spectrum (500MHz, D2O) of GNP 80 obtained. Integration of 
selected signals shows that the ratio between trisaccharide 55 and OVAp 58 is about 95:5.  
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Pn19F/Pn14/Glc/OVA (40:40:15:5) GNP 81 
A mixture of thiol-ending trisaccharide 
19F 55 (1.300 mg, 1.290 mol, 8 eq.), 
tetrasaccharide thiol-ending 
tetrasaccharide 14 56* (1.530 mg, 
1.290 mol, 8 eq.), -D-glucose 
conjugate 57 (0.147 mg, 0.520 vmol, 3 
eq.), and OVA peptide 58 (0.334 mg, 
0.174 mol, 1 eq.) in MeOH (273 l, 
0.012M) was prepared. HAuCl4 (26.20 l, 0.655 mol, 0.025M in H2O, 1 eq.) and 
sodium borohydride NaBH4 (17.7 l, 17.7 mol, 1M in H2O, 27 eq.) were added to 
afford 770 g of GNP 81.  
*Tetrasaccharide amino-hydroxypropyl β-D-galactopyranosyl-(1→4)-β-D-glucopyranosyl-
(1→6)-[β-D-glucopyranosyl-(1→4)]-2-acetamido-2-deoxy-D-glucopyranoside was provided 
by Dr. Martina Lahmann, School of Chemistry, Bangor University, Bangor, UK. The thiol-
ending derivative was synthesized following synthetic procedure reported.133 
TEM (average diameter): 1.2±0.3 nm;  
Average molecular formula estimated based on the size of the cluster obtained from 
TEM micrographs:  
Au79 (C43H80N3O19S2)15(C49H90N3O25S2)15(C11H21O6S)6 (C79H126N27O27S)2 ~53.9 Kda; 
UV/Vis (H2O, c=0.10 mg/mL): surface plasmon band not observed; 
CD (H2O, c=0.25 mg/mL): circular dichroism not observed; 
1H qNMR (500MHz, D2O): 372 g of GNP were dissolved in 180 L of D2O and 20 L of 
D2O containing 0.05 wt.% TPS were added. 37.70 nmol of trisaccharide conjugate and 
38.35 nmol of tetrasaccharide conjugate were found.  
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Figure 4.19: (a) TEM micrographs and (b) histograms of size distribution, (c) UV/Vis adsorption and (d) 
circular dichroism spectra of gold GNPs 81. (e) 
1
H NMR spectrum (500MHz, CD3OD:D2O 5:1) of the 
mixture used to prepare GNP and (f) 1H NMR spectrum (500MHz, D2O) of GNP 81 obtained. Integration of 
selected signals shows that the ratio between trisaccharide 55, tetrasaccaride 56, glucose conjugate 57 
and OVAp 58 is 40:40:15:5.  
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Pn19F/Glc/OVA (45:50:5) GNP 82 
A mixture of thiol-ending 
trisaccharide 19F 55a (0.732 mg, 
0.726 mol, 9 eq.), -D-glucose 
conjugate 57 (0.228 mg, 0.807 mol, 
10 eq.) and OVA peptide 58 (0.155 
mg, 0.0807 mol, 1 eq.) in MeOH 
(135 l, 0.012M) was prepared. 
HAuCl4 (12.90 l, 0.323 mol, 0.025M 
in H2O, 1 eq.) and sodium borohydride NaBH4 (8.80 l, 8.713 mol, 1M in H2O, 27 eq.) 
were added to afford 504 g of GNP 82. 
TEM (average diameter): 1.2±0.3 nm; 
Average molecular formula estimated based on the size of the cluster obtained from 
TEM micrographs: Au79(C43H80N3O19S2)17(C11H21O6S)19(C79H126N27O27S)2 ~41.8 KDa; 
UV/Vis (H2O, c=0.10 mg/mL): surface plasmon band not observed; 
CD (H2O, c=0.25 mg/mL): only a small signal is evident; 
 




Figure 4.20: (a) TEM micrographs and (b) histograms of size distribution, (c) UV/Vis adsorption and (d9 
circular dichroism spectra  gold GNPs 82. (e) 1H NMR spectrum (500MHz, CD3OD:D2O 5:1) of the mixture 
used to prepare GNP and (f) 1H NMR spectrum (500MHz, D2O) of GNP 82 obtained. Integration of 
selected signals shows that the ratio between trisaccharide 55, glucose conjugate 57 and OVAp 58 is 
45:50:5. 
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4.6.4 Immunization studies 
The mouse immunization study was approved by the Animal Care and Use Committee 
of PT. Bimana Indomedical, Bogor, Indonesia. Inbred 6-week-old female BALB/c mice 
were maintained at the Animal Laboratory of PT. Bimana Indomedical, Bogor, 
Indonesia.  
Five mice per group were immunized intradermal with 6.0 µg of GNPs  containing 
approximately 2.4 g of antigen per dose in mixture with 20 µg of Quil-A® saponin 
adjuvant (A gift from Dr. Erik B. Lindblad and Brenntag Biosector, Denmark). 133,95 
PCV13 vaccines (13-valent pneumococcal conjugate vaccine, Pfizer, Inc.) were 
commercially acquired and were diluted in saline 1:10 (100 µl per mouse) 150 and saline 
(0.9% [wt/vol] NaCl in water) were used as positive and negative control respectively . 
A booster of 6 µg of GNPs antigen was given on day 35 without adjuvant. Blood 
samples were taken one week after the booster immunization. 
4.6.5 Enzyme-linked immunosorbent assay 
The enzyme-linked immunosorbent assay (ELISA) was performed to measure the 
antibodies to native Pn14 PS and to Pn19F PS at the Eijkman Institute for Molecular 
Biology, Jakarta, Indonesia as described previously.133 
Briefly, serially diluted sera were incubated for 1 h at 37 °C  in flat-bottom plates, 
coated with 100 µl of purified Pn14 PS or Pn19F PS (5 μg/mL). 
After coating the plates were blocked with 3% gelatin, then washed and horseradish 
peroxidase-conjugated goat anti-mouse IgG was added and incubated for 1 h at 37°C. 
A ready-to-use TMB substrate was added to visualize the amount of bound peroxidase. 
The reaction was stopped by the addition of 0.5 M H 2SO4. Optical density (OD) values 
were obtained with a micro-titer plate spectrophotometer at 450 nm. Antibody titers 
were expressed as the log10 of the dilution giving twice the OD obtained for control 
mice. 
4.6.6 GNP-ELISA 
GNP-ELISA was performed to measure the antibodies towards gold nanoparticles in 
sera of mice immunized at the Eijkman Institute for Molecular Biology, Jakarta, 
Indonesia following a reported procedure.149  
50 µL of a 25µg/mL in sodium buffer solution (50 mM, pH 9.7) of GNPs 83 or 78, were 
used to coat the Nunc MaxiSorp plate. After discarding the GNPs solutions and 
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washing 2 times with 200 L of PBS (Phosphate buffered saline) solution (10mM, 
pH=7.4), the wells were blocked with 200µL of 1% BSA in PBS at room temperature for 
30 min. The blocking solution was discarded and 100µL of mice pool serum at different 
dilution in assay buffer (0.5% BSA) were added to the plate. After shaking for 1 h at 
500rpm, the wells were washed with PBS (3x200µL) and then 100 µL of anti-mouse IgG 
horseradish peroxidase was added for mice serum IgG detection. After 30 min of 
shaking at 500 rpm, the wells were washed with PBS (3x200µL) and, f inally, a ready-to-
use TMB substrate was added to visualize the amount of bound peroxidase. The 
reaction was stopped by the addition of 0.5 M H2SO4. The optical density was 
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